Çàðåãèñòðèðîâàòüñÿ

Ïîõîæèå òåìû

  1. ËÞÄÈ ÏÎÌÎÃÈÒÅ! !! ! Ïîìîãèòå íàéòè âðà÷à. ß èùó Àãðèíñêóþ Èðèíó Àíàòîëüåâíó...
    îò Ñâåòëàíà â ðàçäåëå Ãîìåîïàò è íåòðàäèöèîííàÿ ìåäèöèíà
    Îòâåòîâ: 2
    : 16.08.2013, 13:24
  2. Ëþäè îòçîâèòåñü!!!!!! ïîìîãèòå!!!!!!
    îò gre4kina â ðàçäåëå Àëëåðãèÿ, èììóíîëîãèÿ
    Îòâåòîâ: 16
    : 11.08.2009, 22:21
  3. Ëþäè, ïîìîãèòå,
    îò tanusha â ðàçäåëå Çäîðîâüå êîæè, äåðìàòîëîã
    Îòâåòîâ: 74
    : 04.07.2005, 21:49
  4. Ëþäè, îòçîâèòåñü! Íà êàêîì ñðîêå ìîãóò ïîêàçàòü áåðåìåííîñòü àïòå÷íûå òåñòû...
    îò Ìèëåíà â ðàçäåëå Ãèíåêîëîã-àêóøåð, áåðåìåííîñòü, ðîäû
    Îòâåòîâ: 3
    : 06.07.2004, 22:47
  5. Îòâåòîâ: 1
    : 11.06.2004, 20:35
  1. Àâàòàð äëÿ gre4kina Íîâè÷îê
    ñîîáùåíèé
    2
    ó ìåíÿ õðîíè÷åñêèé áðîíõèò ñ àñòìàòè÷åñêèì êîìïîíåíòîì, ÿ íå ìîãó íîðìàëüíî äûøàòü!! ó ìåíÿ àëëåðãèÿ àáñîëþòíî íà âñå, íåò òîëüêî åùå íà âîäó. ß ñèæó íà ãîðìîíàõ, ðàç â ìåñÿö ìíå êîëÿò äèïðîñïàí, 2 ðàçà â äåíü ìíå ïðèõîäèòüñÿ ïðèìåíÿòü Ñàëüáóòàìîë. ß íå ìîãó íîðìàëüíî æèòü. ß íà÷èíàþ çàäûõàòüñÿ, íåñêîëüêî ðàç â ìåñÿö ïîïîäàþ â ðåàíèìàöèþ. òàì ó ìåíÿ òîæå íà÷èíàþòüñÿ ïðèñòóïû îò çàïàõà õëîðêè è äðóãèõ ìîþùèõ ñðåäñòâ. ÿ òàê áîëüøå íå ìîãó. Îò ÷àñòîãî ïðèìåíåíèÿ ãàðìîíîâ â ùèòîâèäíîé æåëåçå îáðàçîâàëàñü êèñòà. Ïîìîãèòå, ñêàæèòå êóäà ìíå ìîæíî îáðàòèòüñÿ, ÷òî ñäåëàòü? Ìîæåò åñòü êàêèå íèáóäü ëå÷åíèÿ â ñàíàòîðèÿõ, â áîëüíèöàõ? Ïîìîãèòå ìíå õî÷åòüñÿ æèòü!

  2. Àâàòàð äëÿ rsfwater Íîâè÷îê
    ñîîáùåíèé
    2
    Öèòàòà Ñîîáùåíèå îò gre4kina
    ó ìåíÿ õðîíè÷åñêèé áðîíõèò ñ àñòìàòè÷åñêèì êîìïîíåíòîì, ÿ íå ìîãó íîðìàëüíî äûøàòü!! ó ìåíÿ àëëåðãèÿ àáñîëþòíî íà âñå, íåò òîëüêî åùå íà âîäó. ß ñèæó íà ãîðìîíàõ, ðàç â ìåñÿö ìíå êîëÿò äèïðîñïàí, 2 ðàçà â äåíü ìíå ïðèõîäèòüñÿ ïðèìåíÿòü Ñàëüáóòàìîë. ß íå ìîãó íîðìàëüíî æèòü. ß íà÷èíàþ çàäûõàòüñÿ, íåñêîëüêî ðàç â ìåñÿö ïîïîäàþ â ðåàíèìàöèþ. òàì ó ìåíÿ òîæå íà÷èíàþòüñÿ ïðèñòóïû îò çàïàõà õëîðêè è äðóãèõ ìîþùèõ ñðåäñòâ. ÿ òàê áîëüøå íå ìîãó. Îò ÷àñòîãî ïðèìåíåíèÿ ãàðìîíîâ â ùèòîâèäíîé æåëåçå îáðàçîâàëàñü êèñòà. Ïîìîãèòå, ñêàæèòå êóäà ìíå ìîæíî îáðàòèòüñÿ, ÷òî ñäåëàòü? Ìîæåò åñòü êàêèå íèáóäü ëå÷åíèÿ â ñàíàòîðèÿõ, â áîëüíèöàõ? Ïîìîãèòå ìíå õî÷åòüñÿ æèòü!
    HMS 90/Immunocal.
    Óíèêàëüíîå êîììåð÷åñêîå ïðåäëîæåíèå
    äëÿ ãîñóäàðñòâåííûõ, êîììåð÷åñêèõ ñòðóêòóð è ôèçè÷åñêèõ ëèö

    Òåìà: HMS 90/Immunocal - ñàìûé óíèêàëüíûé ïðîäóêò â èñòîðèè ÷åëîâå÷åñòâà (www.immunotec.com/rsf)

    Óâàæàåìûå Äàìû è Ãîñïîäà!

    Êîìïàíèÿ Immunotec Research Ltd., åäèíñòâåííûé â ìèðå îáëàäàòåëü óíèêàëüíîé çàïàòåíòîâàííîé òåõíîëîãèè,
    ïðåäîñòàâëÿåò âîçìîæíîñòü ïðèîáðåòåíèÿ â ÷àñòíóþ èëè ãîñóäàðñòâåííóþ ñîáñòâåííîñòü áåññðî÷íîé ëèöåíçèè
    íà ïðàâî ðàñïðîñòðàíåíèÿ íàòóðàëüíîãî ïðåïàðàòà HMS 90/Immunocal, íå èìåþùåãî ìèðîâûõ àíàëîãîâ.

    Ñòîèìîñòü ëèöåíçèè íà ðàñïðîñòðàíåíèå â Ðîññèè - 60 000 äîëëàðîâ ÑØÀ.

    Êðàòêàÿ ñïðàâêà î ïðîäóêòå

    Ñïåêòð ïðèìåíåíèÿ. Íåîãðàíè÷åííûé

    Ïðîèñõîæäåíèå. Ñûâîðîòêà íàòóðàëüíîãî êîðîâüåãî ìîëîêà

    Óíèêàëüíîñòü. Íå èìååò ìèðîâûõ àíàëîãîâ äëÿ ïðîôèëàêòèêè è ëå÷åíèÿ ðàêà, ñïèäà, äèàáåòà è äðóãèõ áîëåçíåé.

    Ñîñòàâ. àìèíîêèñëîòà öèñòåèí( â óíèêàëüíîé ìîëåêóëÿðíîé ôîðìóëå) 90% ÷èñòîãî ïðîòåèíà
    êàëüöèé 6%
    æåëåçî 6%

    Îñíîâíîå íàçíà÷åíèå. Ïîäúåì è êîíòðîëü óðîâíÿ ãëþòàòèîíà (âíóòðèêëåòî÷íûé òðèïåïòèä) -
    GSH - Glutathione - Äëÿ ÷åãî Ãëþòàòèîí? - http://www.thorne.com/altmedrev/fulltext/glut.html



    Ðåêîìåíäàöèè. Î÷èñòêà îðãàíèçìà (ëþáîé âèä òîêñèíîâ, òÿæåëûõ ìåòàëëîâ, ðàäèîíóêëèäîâ, ò.ä.)
    Ïðîòèâîðàêîâîå (ïàòåíòû ñìîòðèòå www.Immunotec.com/rsf - Company Profile/Research/Patents)
    Ïðîòèâîñïèäîâîå (ïàòåíòû)
    Ïðîòèâîâèðóñíîå
    Ðàíîçàæèâëÿþùåå
    Âîññòàíàâëèâàþùåå
    Èììóíîìîäóëèðóþùåå
    Àíòèîêñèäàíòíîå
    Óñïîêàèâàþùåå
    Ïðîôèëàêòèêà è ëå÷åíèå äðóãèõ çàáîëåâàíèé.( Êðàòêèé ñïèñîê - äèàáåò, ãåïàòèò À,Â,Ñ , ÖÍÑ (Àëüöãåéìåðà, Ïàðêèíñîíà, .....), ñåðäå÷íî-ñîñóäèñòûå, êîæíûå,
    íàðóøåíèå îñíîâíûõ ôóíêöèé îðãàíèçìà)
    Ïðîòèâîíàðêîòè÷åñêîå (ïîâûøàåò ñîïðîòèâëåíèå è âûâîäèò íàðêîòèê)
    Àíòèàëêîãîëüíîå (ñíèìàåò çàâèñèìîñòü, áûñòðî âûâîäèò àëêîãîëü)
    Ïîâûøåíèå ïîòåíöèè ôèçè÷åñêîé è ñåêñóàëüíîé
    Äëÿ ñïîðòñìåíîâ - ïîâûøàåò ñïîðòèâíûå ðåçóëüòàòû
    Äëÿ àëüïèíèñòîâ è íûðÿëüùèêîâ - ïðîòèâîñòîèò êèñëîðîäíî-àçîòíîìó ãîëîäàíèþ
    Äëÿ àðìèè è ôëîòà - øèðîêèé ñïåêòð ïðèìåíåíèÿ.
    Äëÿ ãîñïèòàëåé, ðîäèëüíûõ äîìîâ è ò.ä.
    Íàó÷íûå è êëèíè÷åñêèå èñïûòàíèÿ è èññëåäîâàíèÿ - ÄÀ
    Ïðîòèâîïîêàçàíèÿ. ÍÅÒ (èñêëþ÷åíèå - êîðîòêèé ïåðèîä ïðèåìà ñïåö ëåêàðñòâ ïîñëå ïåðåñàäêè îðãàíîâ)

    Ïîáî÷íûå ýôôåêòû. ÍÅÒ

    Ñèíäðîì ïðèâûêàíèÿ. ÍÅÒ

    Ïåðåäîçèðîâêà. ÍÅÒ

    Âîçðàñòíûå îãðàíè÷åíèÿ. ÍÅÒ

    Äëÿ áåðåìåííûõ è êîðìÿùèõ. - ÐÅÊÎÌÅÍÄÎÂÀÍÎ

    Çàêëþ÷åíèå.
    C ó÷åòîì òàêèõ õàðàêòåðèñòèê êàê óíèêàëüíîñòü, áåçîïàñíîñòü, âûñîêàÿ ýôôåêòèâíîñòü è ìíîãîôóíêöèîíàëüíîñòü, à òàêæå íèçêàÿ, äîñòóïíàÿ äëÿ øèðîêîãî íàñåëåíèÿ ñòîèìîñòü, íàëèöî ïåðñïåêòèâà óñïåøíîãî ïðîäâèæåíèÿ ïðîäóêòà íà ðûíêå ëþáîé ñòðàíû. Îñîáîå çíà÷åíèå ïðèîáðåòàåò ðàñïðîñòðàíåíèå ïðîäóêòà â Ðîññèè â ñèëó äðàìàòè÷åñêîé ñòàòèñòèêè - äèíàìèêè êðóïíîìàñøòàáíûõ ïðîáëåì ñ ðîñòîì çàáîëåâàíèé è âûñîêîé ñìåðòíîñòüþ íàñåëåíèÿ. Åæåãîäíî â Ðîññèè áîëåå 300 000 ðîññèÿí óìèðàþò îò ðàêà. Ýòî ðàâíîñèëüíî áîëüøîìó ãîðîäó êàê Ïåòðîçàâîäñê. Âñå ýòî îáåñïå÷èâàåò çàëîã âûñîêîïðèáûëüíîãî è ïåðñïåêòèâíîãîè ãóìàííîãî áèçíåñà, àáñîëþòíî íîâîãî äëÿ Ðîññèè, íàïðàâëåííîãî íà ðàçâèòèå ïðèîðèòåòíîé ñòðàòåãè÷åñêîé çàäà÷è ïî ïðîôèëàêòèêå è ëå÷åíèþ íàöèè îò òàêèõ áîëåçíåé êàê ÑÏÈÄ, ðàêîâûå, äèàáåò, ñåðäå÷íî-ñîñóäèñòîé ñèñòåìû, èíôåêöèîííûå è ìíîãèå ìíîãèå äðóãèå.

    Ñ óâàæåíèåì,
    Dr. Serguei Roudnev, Ph D
    îôèöèàëüíûé ïðåäñòàâèòåëü êàíàäñêîé êîìïàíèè Èììóíîòåê Ðèñ¸÷ Ëèìèòèä (Immunotec Research Ltd)
    è íåçàâèñèìûé äèñòðèáüþòåð ID # 90338
    e-mail address - rsfwater@rogers.com
    1+ 905-597-1127 (Êàíàäà)
    web site - www.immunotec.com/rsf

    Èíôîðìàöèÿ äëÿ êîíòàêòà ñ ìåæäóíàðîäíûì îòäåëîì ñáûòà ïðîäóêöèè êîìïàíèè Immunotec Research Ltd.-
    Immunotec Research Ltd
    Jacques J. Cohen
    Vice-President, International Operations
    E-mail: jcohen@immunotec.com

    ÑÀÌÛÉ ÓÍÈÊÀËÜÍÛÉ ÏÐÎÄÓÊÒ ÍÎÂÎÃÎ ÏÎÊÎËÅÍÈß ÄËß ÓÍÈÂÅÐÑÀËÜÍÎÉ ÇÀÙÈÒÛ ÇÄÎÐÎÂÜß ËÞÄÅÉ ËÞÁÎÃÎ ÂÎÇÐÀÑÒÀ È ÑÎÑÒÎßÍÈß ÇÄÎÐÎÂÜß, ÊÎÒÎÐÛÉ ÍÓÆÅÍ ÂÑÅÌ!

    Immunocal-Platinum - áàëàíñ ãëþòàòèîíà - 100% çäîðîâüå è ïðîäîëæèòåëüíîñòü æèçíè
    ïðîäóêò áóäóùåãî ñåãîäíÿ - äëÿ ïðîäîëæèòåëüíîé æèçíè áåç áîëåçíåé
    Ýòîò ïðîäóêò, íå èìåþùèé ìèðîâûõ àíàëîãîâ, êîíòðîëèðóåò áàëàíñ ãëþòàòèîíà.
    Äî òîãî, êàê âñå âðåäíîå èëè ïîëåçíîå, ÷òî ñîäåðæèòñÿ â âîäå, â âîçäóõå è ïèùå, îêàæåò âðåä èëè ïîëüçó íà îðãàíèçì, Îíî äîëæíî ïðîéòè ñêâîçü 3 ëèíèè îáîðîíû è ïðîíèêíóòü âãëóáü êëåòêè. Çäîðîâüå ÷åëîâåêà çàâèñèò îòòîãî, íàñêîëüêî êëåòêà õîðîøî óñâàèâàåò ïîëåçíîå è íàñêîëüêî ñèëüíî çàùèùåíî îò âðåäíîãî.
    Äëÿ áåçîïàñíîñòè è ïðîäîëæèòåëüíîé æèçíè áåç áîëåçíåé êàæäàÿ çäîðîâàÿ êëåòêà ïðîèçâîäèò ñîáñòâåííîå çàùèòíîå îðóæèå - âíóòðèêëåòî÷íûé òðèïåïòèä ÃËÞÒÀÒÈÎÍ
    Íî èç-çà íåóñâîåíèÿ ñ ïèùåé âñåãî ëèøü îäíîãî ìèêðîýëåìåíòà (öèñòåèíà), îáíàðóæèâàåòñÿ ñåðüåçíûé äåôèöèò ãëþòàòèîíà. Ïîýòîìó æèçíåííî âàæíî ïîìîãàòü êëåòêàì ïîääåðæèâàòü áàëàíñ ãëþòàòèîíà ïóòåì ïðèåìà HMS 90/Immunocal. Ýòî âàæíî äëÿ âñåõ çäîðîâûõ, íî èñêëþ÷èòåëüíî âàæíî äëÿ áîëüíûõ. Ïî÷åìó?
    Ïîòîìó ÷òî Ãëþòàòèîí êîíòðîëèðóåò ñàìûé âûñîêèé óðîâåíü êà÷åñòâà è ïðîäîëæèòåëüíîñòè æèçíè!
    Òðè ãëàâíûå õàðàêòåðèñòèêè ïðîäóêòà
    - àíòèîêñèäàíò
    - èììóííûé áóñòåð
    - ðàñòâîðèòåëü-î÷èñòèòåëü
    Íàòóðàëüíûé ïðîäóêò ïðîèçâîäèòñÿ ïî çàñåêðå÷åííîé òåõíîëîãèè èç ñûâîðîòêè êîðîâüåãî ìîëîêà, íî ïîñëå ïðîèçâîäñòâà óæå íå èìååò íèêàêîãî îòíîøåíèÿ íè ê ìîëîêó, íè ê ïðîòåèíó. Ïðîäóêò - óíèâåðñàëüíàÿ çàùèòà äëÿ ëþäåé âñåõ âîçðàñòîâ ïðîòèâ âèðóñîâ, ëþáîé èíôåêöèè, ëþáûõ òîêñèíîâ, ÿäîâ è ÿäîõèìèêàòîâ, îòðàâëåíèÿ, ÿäîâèòûõ òÿæåëûõ ìåòàëëîâ, ðàäèàöèè, âîññïàëèòåëüíûõ ïðîöåññîâ, áîëè. Ïðîòèâ ëþáûõ çàáîëåâàíèé îò ãðèïïà è àëëåðãèè äî ðåâìàòîèäíîãî àðòðèòà, áîëåçíåé ïå÷åíè, êðîâè, ðàêà, ÑÏÈÄÀ, Àëüöãåéìåðà è Ïàðêèíñîíà. Ïîâûøàåò íåìåäëåííî ôèçè÷åñêóþ è ñåêñóàëüíóþ ïîòåíöèþ! Óêðåïëÿåò èììóíèòåò, âûâîäèò òîêñèíû èç îðãàíèçìà, ÷èñòèò êðîâü è ïå÷åíü. Ïîâûøàåò óìñòâåííûå ñïîñîáíîñòè. Âûïîëíÿåò óíèêàëüíóþ âíóòðèêëåòî÷íóþ òåðàïèþ. Ðàñòâîðÿåò êàìíè â ïðîòîêàõ. Ðàñòâîðÿåò ñâèíåö, ðòóòü è êàäìèé è âûâîäèò èõ íà óëèöó íåìåäëåííî. Èìååò ñàìûé âûñîêèé ðåéòèíã ñðåäè âñåõ íàòóðàëüíûõ ïðîäóêòîâ. Çàíåñåí â íàñòîëüíóþ êíèãó òåðàïåâòîâ ÑØÀ (PDR book) è â Êðàñíóþ êíèãó ôàðìàöåâòîâ ÑØÀ. Ïîêðûâàåòñÿ ìåäèöèíñêîé ñòðàõîâêîé â ÑØÀ! Íå èìååò àíàëîãîâ â ìèðå.
    Çàìå÷àíèå. Íå ïóòàòü ïðîäóêò ñ àïòå÷íûì ãëþòàòèîíîì!!! Ñèíòåòè÷åñêèé ãëþòàòèîí íåáåçîïàñåí.
    Îäèí èç ìíîãî÷èñëåííûõ ïðèìåðîâ èçëå÷åíèÿ îò ðàêà - ìóæ èçâåñòíîé êàíàäñêîé ïåâèöû Ñåëèí Äèîí.
    Íà ñàéòå êëèêíèòå íà Company Profile - Research - Patents (ïîñìîòðèòå ïðîòèâîðàêîâûé ïàòåíò - 2,142,277)
    Ïðèîáðåòàéòå ïðîäóêò â èíòåðíåòå íà ñàéòå -


    www.Immunotec.com/rsf

    rsfwater@rogers.com

  3. Àâàòàð äëÿ Âðà÷ Îïûòíûé
    ñîîáùåíèé
    24
    Ñèòóàöèÿ ïàðàäîêñàëüíî òèïè÷íàÿ: ïàöèåíò èç ïîñëåäíèõ ñèë ïðîñèò ó âñåõ î ïîìîùè, à ïðåäñòàâèòåëè ôàðìôèðìû íà ýòîì ïûòàþòñÿ íåïðîôåññèîíàëüíî ïðîäâèíóòü ñâîé ïðåïàðàò íà Ðîññèéñêèé ðûíîê. Áåç êîììåíòàðèåâ... Âêëþ÷èòå ãîëîâó, äðóçüÿ... Èëè ìû æèâåì â êàìåííîì âåêå?

    Äëÿ ïàöèåíòà: ïðèøëèòå íà ìîé e-mail (÷åðåç ôîðìó íà ìîåì ñàéòå èëè ÷åðåç ëè÷íîå ñîîáùåíèå) áîëåå ïîäðîáíóþ èíôîðìàöèþ î Âàøåì çàáîëåâàíèè - ÿ ïîñòàðàþñü Âàì ïîìî÷ü.
    Medica mente non medicamentis!
    Ëå÷è óìîì, à íå ëåêàðñòâàìè!


    "Öåíòð àëëåðãîëîãèè èììóíîëîãèè äîêòîðà Ïîïîâè÷à": www.caidp.spb.ru

  4. Àâàòàð äëÿ Ckunsy Îïûòíûé
    ñîîáùåíèé
    45
    È íå ñòûäíî âàì? Îáîáðàòü äî íèòêè íóæäàþùåãîñÿ, à îòòîãî è ãîòîâîãî ïîâåðèòü â ëþáîå ÷óäîäåéñòâèå.
    çäðàâñòâóéòå

    Ñêóíñè

  5. Êàòÿ
    #5
    ×èòàòåëü Íåäóã.Ðó
    Âû íåïðàâèëüíî äûøèòå. Îáðàòèòåñü â êëèíèêó Áóòåéêî, òàì âàì ïîìîãóò
    buteykoclinik.ru

  6. Àâàòàð äëÿ gost_vash Íîâè÷îê
    ñîîáùåíèé
    7
    Öèòàòà Ñîîáùåíèå îò Âðà÷ Ïîñìîòðåòü ñîîáùåíèå
    Ñèòóàöèÿ ïàðàäîêñàëüíî òèïè÷íàÿ: ïàöèåíò èç ïîñëåäíèõ ñèë ïðîñèò ó âñåõ î ïîìîùè, à ïðåäñòàâèòåëè ôàðìôèðìû íà ýòîì ïûòàþòñÿ íåïðîôåññèîíàëüíî ïðîäâèíóòü ñâîé ïðåïàðàò íà Ðîññèéñêèé ðûíîê. Áåç êîììåíòàðèåâ... Âêëþ÷èòå ãîëîâó, äðóçüÿ... Èëè ìû æèâåì â êàìåííîì âåêå?

    Äëÿ ïàöèåíòà: ïðèøëèòå íà ìîé e-mail (÷åðåç ôîðìó íà ìîåì ñàéòå èëè ÷åðåç ëè÷íîå ñîîáùåíèå) áîëåå ïîäðîáíóþ èíôîðìàöèþ î Âàøåì çàáîëåâàíèè - ÿ ïîñòàðàþñü Âàì ïîìî÷ü.
    Óâàæàåìûé Âðà÷ è äðóãèå,
    ïî ïîâîäó Èììóíîêàëà , Immunocal, ýòî ïðàâäà !
    Ãîâîðþ âàì êàê "íåâåðóþùèé Ôîìà" îññîáåííî â ðàçíîãî ðîäà áàäû , ïðîäóêòû è òò...

    Óçíàéòå áîëüøå èíôîðìàöèè îá Èììóíîêàëå, â ÑØÀ è Êàíàäå ïðîäóêò çàíåñ¸í â Äîêòîðñêèå è Ôàðìàöåòè÷åñêèå êíèãè .
    Òàêîãî â èñòîðèè ìåäèöèíû íå áûëî.
    Íàòóðàëüíûé ïðîäóêò - òàêîå ïðèçíàíèå.
    Âñ¸ ïðîñòî - Îíè ïðèäóìàëè ìàòåðèàë äëÿ ïîñòðîåíèÿ ÃËÓÒÀÒÈÎÍ - ÂÍÓÒÐÈ êëåòêè.
    Î÷åíü ïðîñòî - ÃÅÍÈÀËÜÍÎ ! à ãëàâíîå ðàáîòàåò.
    Òàêèå - ïàòåíòû êàê Àíòè - Ðàêîâàÿ òåðàïèÿ è ÂÈ× - òåðàïèÿ â ÑØÀ ïðîñòî òàê íàòóðàëüíîìó ïðåïàðàòó íè âûäàäóò ïîâåðòå !

    À ðàñïîñòðàíÿåòñÿ ïðîäóê ÷åðåç ìàðêåò ñåòü - Ïî÷åìó ?
    Äà ïîòîìó,÷òî Õèìèêî - Îòðàâëÿùèì ôàðöåâòè÷åñêèì êîìïàíèÿì ÍÅ ÂÛÃÎÄÅÍ ! òàêîé ïðåïàðàò !
    ÑØÀ,Êàíàäà íàêëàäûâàþò ðàçíûå îãðàíè÷åíèÿ.
    Íàïðèìåð â Êàíàäå Èììóíîêàëó âûäàí íåñëûõàííûé ïàòåíò äëÿ Ïîääåðæàíèÿ Èììóííîé Ñèñòåììû ! Íî ñàìè æå îíè çàïðåòèëè íàçâàíèå ÈÌÌÓÍÎ - ÊÀË ,ïîòîìó ÷òî ñëîâî ÈÌÌÓÍÍÎ â íàçâàíèå , àáñóðä !!! Ïîýòîìó òàì Èììóíîêàë - HMS90 , âîò êàê áûâàåò .
    Ïîýòîìó - ÷åðåç óñòà â óñòà ... ìàðêåòèíã.

    Ïðåäñòàâüòå ëþäè - áåç Äèàáåòà, Àëëåðãèè, Àñòìû, Ðàêà, æèâóò ñ ÂÈ× è Ñïèäîì ... è ìíîãîå äðóãîå äåëàåò Èììóíîêàë , òî÷íåå Ãëóòàòèîí.

    Ãëóòàòèîí - íåâîçìîæíî ïîëíîöåííî çàâåñòè ÷åðåç øïðèö èëè ñ åäîé, òàáëåòêè è òò.. Îí äîëæåí áûòü âûðàáàòàí ÑÀÌÎÉ ÊËÅÒÊÎÉ.
    Èììóíîêàë - ýòî áëîêè äëÿ ïîñòðîåíèÿ Ãëóòàòèîíà ( GSH ) âíóòðè êëåòêè.


    Ìîé äðóã ïîñëå Ðàäèî è Õèìèî òåðàïèè ïîñåòèâ âðà÷à óø¸ë äîìîé ñ ìåòàñòàçàììè - 0ò 2 íåä äî 2 ìåñ æèçíè (ñòîëüêî äàëîñü Âðà÷îì).
    Íå âåðÿ â ðàçíûå ìîðêîâíûå ñîêè , êàê îí ãîâîðèò âñ¸òàêè çàñòàâèëè ñ àïåëüñèíîâûì ñîêîì ïèòü Èììóíîêàë. 8 ïà÷åê â äåíü.

    Ñïîðòñìåííû Îëèìïèéñêèõ ñáîðíûõ ñøà è êàíàäû ïüþò èììóíîêàë êàæäûé äåíü ïî 1 ïà÷êå - äëÿ ñðàâíåíèÿ.

    ×åðåç ìåñÿö, æåëòèçíà ñïàëà, à ÷åðåç 2 ìåñÿöà , ñäåëàâ Ìàãò Ðåçîí ðåíòãåí - âðà÷ îõíóë - ìåòàñòàç íå îáíàðóæåííî !Æèâ äðóã è ðàä...

    Âñ¸ ïðîñòî ÄÎÊòîð - ÃËÓÒÀÒÈÎÍ - ÃËÀÂÍÛÉ Àíòèîêñèäàíò ÍÀ Óðîâíå Êëåòêè ,ïîýòîìó òàêèå ðåçóëüòàòû.

    Ïðîâåäèòå Äîìàøíþþ ðàáîòó ïðåæäå ÷åì êîãî-òî ñòûäèòü , è îáâèíÿòü â çàðàáàòûâàíèè äåíåã !!!
    Immunocal - ñîòâîð¸í Áîíóñîì Ãóñòàâî âî ãëàâå ñ âåäóùèìè Èììóíîëàãàìè ìèðà.
    Áîíóñ Ãóñòàâî - ñîçäàòåë Äàåò Ýëåìýíòîðó , êîðìëåíèå ÷åðåç òðóáó ìåòîä.
    Âû íàâåðíîå ó÷èòèñü ïî èõ êíèãàì ?!
    Íå íàäî ïóòàòü - "êîìïîò ñ æàðåííîé êàðòîøêîé" - øóòêà...
    ïðîäâèæåíèÿ Èììóíîêàëà äëÿ ìíîãèõ êàê Ìèññèÿ (íå ïðîñòî çàðàáàòîê),ýòî ïðîäóêò êîòîðûé îòëè÷åí îò âñåãî äðóãîãî (íà äàííîå âðåìÿ), â òðàäèö è íå òðàäèö ìåäèöèíå.
    Âðà÷è òîæå áåðóò äåíüãè çà ïðè¸ìû è òàáëåòîê è òä... ìíîãî ÷åãî åù¸..È ìíîãî ðàç âñå ìåòîäû áåçóñïåøíû,õîòÿ è èñêðåííå, ïðàâäà ?!

    ***
    Ìîé äðóã ÁËÀÃÎÄÀÐÅÍ òîìó ÷åëîâåêó êîòîðûé ðàññêàçàë åìó ïðî Èììóíîêàë !

    ÌÎÆÍÎ ÎÁÌÀÍÓÒÜ ÎÄÍÎÃÎ - ÌÍÎÃÎ ÐÀÇ !
    èëè
    ÌÍÎÃÈÕ ÎÄÈÍ ÐÀÇ !
    íî
    ÍÅÂÎÇÌÎÆÍÎ ÎÁÌÀÍÛÂÀÒÜ ÂÑÅÕ - ÌÍÎÃÎ ÐÀÇ !

    _____

    ÃËÓÒÀÒÈÎÍ - ÆÈÇÍÜ ñ Êëåòêè !
    Äîìàøíÿÿ Ðàáîòà - Äîêòîð !

    Ñïàñèáî,
    Âàø Ãîñòü...
    Ïîñëåäíèé ðàç ðåäàêòèðîâàëîñü gost_vash; 08.04.2008 â 23:39.

  7. êàòåãîðèÿ: ìåäèöèíñêèå ÝÊÑÏÅÐÒÛ, ìîäåðàòîðû, êîíñóëüòàíòû Nedug.Ru :::::
    ñîîáùåíèé
    1,998
    "ÑØÀ,Êàíàäà íàêëàäûâàþò ðàçíûå îãðàíè÷åíèÿ". ×òîáû áûòü òî÷íûì îòêàçàëè â ñâÿçè ñ îòñóòñòâèåì äîêàçàííîé ýôôåêòèâíîñòè. Äà è òðóäíî îò îáû÷íîãî (òàêèõ ìíîæåñòâî) àíòèîêñèäàíòîâ îæèäàòü ïàíàöåè îò ÂÑÅÕ áîëåçíåé.
    Âëîæåíèÿ Âëîæåíèÿ
    Ïîñëåäíèé ðàç ðåäàêòèðîâàëîñü Chill; 09.04.2008 â 11:52.
    Àíäðååâ Àíäðåé Âëàäèìèðîâè÷
    âðà÷-èíôåêöèîíèñò

  8. Àâàòàð äëÿ gost_vash Íîâè÷îê
    ñîîáùåíèé
    7
    "ÑØÀ,Êàíàäà íàêëàäûâàþò ðàçíûå îãðàíè÷åíèÿ". ×òîáû áûòü òî÷íûì îòêàçàëè â ñâÿçè ñ îòñóòñòâèåì äîêàçàííîé ýôôåêòèâíîñòè. Äà è òðóäíî îò îáû÷íîãî (òàêèõ ìíîæåñòâî) àíòèîêñèäàíòîâ îæèäàòü ïàíàöåè îò ÂÑÅÕ áîëåçíåé.
    Èçîáðàæåíèÿ





    __________________
    Àíäðååâ Àíäðåé Âëàäèìèðîâè÷
    âðà÷-èíôåêöèîíèñò
    aptekapl@list.ru

    Óâàæàåìûé Àíäðåé Âëàäèìèðîâè÷,

    Ñïàñèáî çà Âàø îòâåò.

    Êîãäà ÿ íàïèñàë "ÑØÀ, Êàíàäà íàêëàäûâàþò ðàçíûå îãðàíè÷åíèÿ". , èìåëîñü â âèäå íå òî ÷òî Îíè íå îäîáðèëè APPROVED ,
    Immunocal – 11 ëåò ïîäðÿä âûäàÿòñÿ Ïàòåíòû, ÍÈ ÊÀÊÈÕ ÎÒÊÀÇÎÂ !
    ß ïèñàë îá îãðàíè÷åíèÿõ ñâîáîäíî îïèñûâàòü òå Ïàòåíòû êîòîðûå îíè æå ÑØÀ è Êàíàäà âûäàþò.
    Èììóíîêàëó ,òîëüêî â ÑØÀ âûäàëè 6 ÏÀÒÅÍÒÎÂ ! îäèí èç êîòîðûõ Ïðîòèâî – Ðàêîâûé >>>

    United States Patent

    5,888,552



    Anti-cancertherapeutic compositions containing whey protein concentrate

    Abstract

    This invention relates to a method of treatment of patients having lesions resulting from cancer cells and to an application as an anti-cancer composition of undenatured whey protein concentrate.

    ÏÀÒÅÍÒ - ìåòîä ëå÷åíèÿ ÂÈ× çàáîëåâàíèÿ !!!
    Ïîêîðî÷å – ýòî îçíà÷àåò êîãäà îíè åãî ïðèíèìàþò ,ïîâûøàåòñÿ Óðîâåíü ÃËÓÒÀÒÈÎÍÀ, ÏÐÈÁÀÂËßÅÒÑß ÂÅÑ Òåëà,è Óëó÷øåíèå Ñàìî÷óñòâèÿ.
    Òàêæå Ò – Êëåòêè (çàùèòà Èììóííîé Ñèñòåìû) , Óâåëè÷èâàþòñÿ !!!!
    È ëþäè ñ ÂÈ× ïðîäîëæàþò æèòü Íîðìàëüíî ïîêà ïðèíèìàþò Èììóíîêàë !


    ÍÀÇÎÂÈÒÅ ïîæàëóéñòà ÷òî-ëèáî ÏÎÄÎÁÍÎÅ – èç Õèìèêî – èëè Íåòðàäèöèîííîãî ???? ÷òî – áû âûòâîðÿëî òàêîå ?

    ÑØÀ – Ïàòåíòàìè íå ðàñêèäûâàåòñÿ !

    United States Patent

    5,456,924



    Method of treatment of HIV-seropositive individuals with dietary whey proteins

    Abstract

    Undenatured whey protein concentrate is administered to HIV-seropositive individuals to elevate their blood mononuclear cells, glutathione (GSH) level, body weight and sense of well being. In addition T-helper cells concentration and their T-helper cells/T-suppressor cells ratio are slightly elevated.



    Ññûëêè íà Ïàòåíòû ÑØÀ-

    5,888,552
    5,290,571
    5,451,412
    5,230,902
    5,456,924
    5,846,939


    Îãðàíè÷åíèÿ - Èìååòñÿ Ââèäó íå äàþò âîçìîæíîñòü äîíîñèòü òî, ÷òî îíè ñàìè æå ÎÄÎÁÐÈËÈ è âûäàëè Ïàòåíòû.
    Åñëè ýòî Ïðîòèâîðàêîâûé Ïàòåíò – òî ïî÷åìó íà êîðîáêàõ ðàçðåøàåòñÿ ïå÷àòàòü Òîëüêî íîìåðà Ïàòåíòîâ à íå èõ îïèñàíèå.

    Õîòèòå çíàòü Ïî÷åìó ?
    Äà ïîòîìó ÷òî ÎÃÐÎÌÍÛÅ Äåíüãè â Ôàðìî áèçíåñå – Õèìèêî-òàáëåòêè.
    ÑØÀ è Êàíàäà ïîäñåëà íà ðàçíûå Îïèàíòû è Ãåðîèíòû òèïà – ÒÐÀÌÀÄÎË , Vicodine, Codein – è äðóãîå Íàðêî- Ñíàäîáüå – êîòîðîå ïðîïèñûâàåòñÿ Äîêòîðàìè íàïðàâî , íàëåâî ïðè Ìàëåéøèõ áîëÿõ !
    Ïî÷åìó ? Ä Å Í Ü Ã È !!! Áîëüøå îáîðîò ÷åì íåôòå äåíüãè !

    - Ïîýòîìó íå îáîñíîâàííûå Îãðàíè÷åíèÿ – íå “ â ñâÿçè ñ îòñóòñòâèåì äîêàçàííîé ýôôåêòèâíîñòè” - Ïàòåíòîâ îò Íèõ áîëüøå ÷åì äîñòàòî÷íî !

    Ýòî ïåðâûé Íàòóðàëüíûé Ïðåïàðàò ïîëó÷èâøèé òàêîå Ïðèçíàíèå.
    Âî ìíîãèõ ñòðàíàõ åãî âûïèñûâàþò ïî ðåöåïòàì.


    Àíäðåé Âëàäèìèðîâè÷,


    Âû ïèøèòå,
    òðóäíî îò îáû÷íîãî (òàêèõ ìíîæåñòâî) àíòèîêñèäàíòîâ îæèäàòü ïàíàöåè îò ÂÑÅÕ áîëåçíåé.

    Äåëî â òîì ÷òî ÃËÓÒÀÒÈÎÍ íå ìíîæåñòâî Àíòèîêñèäàíòîâ –
    ÃËÓÒÀÒÈÎÍ – ýòî òî, ÷òî ó Âàñ (Íàñ) – óæå åñòü â òåëå/êëåòêå.
    ÂÑÅ Îñòàëüíûå ÀíòèÎêñèäàíòû íå ðîäíûå Íàì – îíè èçâíå – ÷óææåðîäíûå !
    Ýòî – Âèòàìèíû C,E,Selenium è äðóãèå.
    ÃËÓÒÀÒÈÎÍ – ÍÀØ ÐÎÄÍÎÉ ÀÍÒÈÎÊÑÈÄÀÍÒ !
    Íàõîäèòüñÿ â êàæäîé êëåòêè îðãàíèçìà.
    Ïîýòîìó òàêèå ðåçóëüòàòû !

    Íå ÿ Âàñ äîëæåí â ýòî ïîñâÿùàòü à ÂÛ êàê Äîêòîð/Âðà÷ !

    Âîò ÷òî ïèøåòñÿ î ÃËÓÒÀÒÈÎÍÅ è Îññîáåííî Èíôåêöèîíèñòû – ÎÁßÇÀÍÍÛ çíàòü îá ýòîì !
    ÃËÓÒÀÒÈÎÍ - Âèêèïåäèÿ ññûëêà >>>
    http://ru.wikipedia.org/wiki/%D0%93%...B8%D0%BE%D0%BD


    *************************************************
    Ãëóòàòèîí, g-ãëóòàìèíèë-öèñòñèíèë-ãëèöèí, òðèïåïòèä, îáðàçîâàííûé îñòàòêàìè òð¸õ àìèíîêèñëîò — ãëóòàìèíîâîé êèñëîòû, öèñòåèíà è ãëèöèíà. Îñîáåííîñòü ñòðîåíèÿ Ã. — ïåïòèäíàÿ ñâÿçü ìåæäó öèñòåèíîì è ãëóòàìèíîâîé êèñëîòîé, â êîòîðîé ó÷àñòâóåò å¸ g-êàðáîêñèëüíàÿ ãðóïïà. Ã. ñîäåðæèòñÿ âî âñåõ æèâûõ îðãàíèçìàõ è èìååò âàæíîå çíà÷åíèå äëÿ îêèñëèòåëüíî-âîññòàíîâèòåëüíûõ ðåàêöèé â ñâÿçè ñî ñïîñîáíîñòüþ ñóëüôãèäðèëüíîé ãðóïïû (SH—) öèñòåèíà âñòóïàòü â îáðàòèìóþ ðåàêöèþ:


    Ã. ìîæåò âûñòóïàòü â êà÷åñòâå êîôåðìåíòà ïðè äåéñòâèè êàòåïñèíîâ, ïàïàèíà è äð. ïðîòåîëèòè÷åñêèõ ôåðìåíòîâ. Ïî-âèäèìîìó, ôóíêöèè Ã. â îáìåíå âåùåñòâ âêëþ÷àþò â ñåáÿ òàêæå çàùèòó SH-ãðóïï áåëêîâ öèòîïëàçìû îò îêèñëåíèÿ.




    Ãëþòàòèîí ñàìûé ìîùíûé çàùèòíèê âàøåãî îðãàíèçìà

    (Ïî ìàòåðèàëàì êíèãè äîêòîðà Jimmy Gutman MD, FACEP "Glutathione (GSH) - Your Body's Most Powerful Protector", ISBN 0-973I409-0-9
    ×òî òàêîå ãëþòàòèîí?
    Ãëþòàòèîí - ýòî íåáîëüøîé ïðîòåèí, êîòîðûì ïðèðîäà íàäåëèëà êàæäóþ êëåòêó íàøåãî îðãàíèçìà. Îí âûïîëíÿåò íåñêîëüêî ôóíêöèé â íàøåì îðãàíèçìå:

    Ðîëü Ãëþòàòèîíà â òåëå ÿâëÿåòñÿ òðîéñòâåííîé.

    * Àíòèîêèñëèòåëü
    * Èììóííàÿ ñèñòåìà
    *Ïðîòèâîÿä (ïðîòèâî-îòðàâèòåëü)

    Ïðèøëî âðåìÿ íà÷èíàòü äóìàòü î íàøèõ òåëàõ íà êëåòî÷íîì óðîâíå. È íà÷èíàòü ïîääåðæèâàòü íàøó êëåòêó çà êëåòêîé. Íàøè òåëà èçãîòîâëèâàþò ñîáñòâåííûå åñòåñòâåííûå àíòèîêèñëèòåëè, èç êîòîðûõ Ãëþòàòèîíÿâëÿåòñÿ ñàìûì âàæíûì.

    Áîëåçíü ïðîèñõîäèò èç-çà îêèñëèòåëüíûõ íàïàäåíèé ñâîáîäíûìè ðàäèêàëàìè. Âñå âèäû áîëåçíåé áûëè âûçâàíû ñâîáîäíûì ðàäèêàëüíûì ïîâðåæäåíèåì, âêëþ÷àÿ ñåðäå÷íóþ áîëåçíü, Ðàññåÿííûé ñêëåðîç, Äèàáåò, ñòàðåíèå, Ïàðêèíñîíà, Àëæåèìåðà è ìíîæåñòâî ðàêîâûõ îáðàçîâàíèé.

    Âàæíî íå äîïóñòèòü, ÷òîáû îêèñëåíèå â òåëåñòàëî,êàê î÷èùåííîå ÿáëîêî ,êîòîðîå óæå íà÷àëî îêèñëÿòüñÿ? Ïðîöåññ îêèñëåíèÿ èä¸ò êëåòêà çà êëåòêîé. Ìû èìååì ïðîáëåìû òîãî æå ñàìîãî 'îêèñëèòåëüíîãî ïðîöåññà â íàøèõ ñîáñòâåííûõ òåëàõ, Íåêîòîðûå õîðîøî-ïðèçíàííûå àíòèîêèñëèòåëè, êîòîðûå øèðîêî èñïîëüçóþòñÿ, ÷òîáû ðàçðóøèòü ñâîáîäíûå ðàäèêàëû - âèòàìèíû C, E è Ñåëåí.
    Ãëàâíûé Àíòèîêñèäàíò
    Ñâîáîäíûå ðàäèêàëû - ýòî îïàñíûå ìîëåêóëû, êîòîðûå ðàçðóøàþò êëåòêè, òêàíè, íàðóøàþò ñòðóêòóðó ÄÍÊ. Ñâîáîäíûå ðàäèêàëû âîâëå÷åíû âî âñå âèäû çàáîëåâàíèé, âêëþ÷àÿ èíôàðêò, ðàê, äèàáåò è ñòàðåíèå ñàìî ïî ñåáå. Èõ îáðàçîâàíèþ ñïîñîáñòâóþò ãðÿçíàÿ îêðóæàþùàÿ ñðåäà, ïëîõîå ïèòàíèå, ðàäèàöèÿ, ñòðåññû, òðàâìû, áîëåçíè, èíôåêöèè, âûçâàííûå áàêòåðèÿìè è âèðóñàìè, òàáà÷íûé äûì è äðóãèå. Èçáåæàòü îáðàçîâàíèÿ ñâîáîäíûõ ðàäèêàëîâ íåâîçìîæíî, ò.ê. îíè ÿâëÿþòñÿ è ðåçóëüòàòîì îáû÷íûõ ìåòàáîëè÷åñêèõ ïðîöåññîâ, ïðîèñõîäÿùèõ â êëåòêàõ. Ýêñïåðòû ãîâîðÿò, ÷òî ìû ñòàðååì íè äåíü çà äíåì, à êëåòêà çà êëåòêîé.

    Àíòèîêñèäàíòû - ýòî àãåíòû, êîòîðûå íåéòðàëèçóþò ñâîáîäíûå ðàäèêàëû. Íàïðèìåð, õîðîøî èçâåñòíûìè è øèðîêî èñïîëüçóåìûìè àíòèîêñèäàíòàìè ÿâëÿþòñÿ âèòàìèí Ñ, âèòàìèí Å è ñåëåíèóì. Îíè íå âîñïðîèçâîäÿòñÿ îðãàíèçìîì è äîëæíû áûòü ïðèâíåñåíû êàê ÷àñòü ñáàëàíñèðîâàííîé äèåòû. Íå óäèâèòåëüíî, ÷òî îðãàíèçì ñàì ïðîèçâîäèò è ñâîè ñîáñòâåííûå åñòåñòâåííûå àíòèîêñèäàíòû. Ñàìûé âàæíûé èç íèõ - ýòî ãëþòàòèîí. Òàê êàê âñå äðóãèå àíòèîêñèäàíòû çàâèñÿò îò íàëè÷èÿ ãëþòàòèîíà äëÿ òîãî, ÷òîáû ïðàâèëüíî ôóíêöèîíèðîâàòü, ó÷åíûå íàçûâàþò åãî "Ãëàâíûé Àíòèîêñèäàíò".
    Ïèòàíèå äëÿ èììóííîé ñèñòåìû
    Èììóííàÿ ñèñòåìà - îäíà èç ñëîæíåéøèõ è âàæíåéøèõ â îðãàíèçìå. Åå ôóíêöèè - çàùèùàòü îðãàíèçì îò òîêñèíîâ, èíôåêöèîííûõ è îíêîëîãè÷åñêèõ çàáîëåâàíèé. Èììóííàÿ ñèñòåìà - ýòî ïåðåäíèé êðàé íàøåé çàùèòû, ïîñòîÿííî àòàêóåìûé ôàêòîðàìè âíåøíåé è âíóòðåííåé ñðåäû. Îðãàíèçì ñ áîëüøèì êîëè÷åñòâîì ãëþòàòèîíà ñïðàâëÿåòñÿ ñ ýòîé óãðîçîé ëåãêî. Âûñîêèé óðîâåíü ãëþòàòèîíà äàåò âîçìîæíîñòü îðãàíèçìó ïðîèçâåñòè áîëüøå áåëûõ êðîâÿíûõ êëåòîê - ñàìóþ âàæíóþ ïåðâóþ ëèíèþ çàùèòû èììóííîé ñèñòåìû. Äðóãèìè ñëîâàìè, çäîðîâûé ðîñò è àêòèâíîñòü èììóííûõ êëåòîê çàâèñèò îò íàëè÷èÿ ãëþòàòèîíà â íèõ. Èëè ïðîñòî, ãëþòàòèîí - ýòî ïèùà äëÿ èììóííîé ñèñòåìû.
    Åñòåñòâåííûé Äåòîêñèôèêàòîð
     ñîâðåìåííîì ìèðå ìû íåèçáåæíî è ïîñòîÿííî âäûõàåì è ãëîòàåì åñòåñòâåííûå è ñèíòåòè÷åñêèå òîêñèíû. Âðåäíûå âåùåñòâà íàêàïëèâàþòñÿ â îðãàíèçìå è ïîñëå ïðèìåíåíèÿ ëåêàðñòâåííûõ ïðåïàðàòîâ, õèìèîòåðàïèè. Êîãäà îðãàíèçì çäîðîâ, ïîëó÷àåò íåîáõîäèìîå ïèòàíèå è èìååò âûñîêèé óðîâåíü ãëþòàòèîíà îí íåóòîìèìî è ýôôåêòèâíî óíè÷òîæàåò âðåäíûå âåùåñòâà è çàùèùàåò ñåáÿ, íî óâåëè÷èâàþùèéñÿ óðîâåíü çàãðÿçíåíèÿ îêðóæàþùåé ñðåäû èñòîùàåò çàïàñû ãëþòàòèîíà. Èññëåäîâàíèÿ ïîêàçûâàþò, ÷òî íèçêèé óðîâåíü ãëþòàòèîíà âåäåò ê ïëîõîé ðàáîòå ïå÷åíè, âûçûâàÿ òî, ÷òî âñå áîëüøåå êîëè÷åñòâî òîêñèíîâ íà÷èíàåò öèðêóëèðîâàòü ïî òåëó, íàíîñÿ âðåä êëåòêàì è öåëûì îðãàíàì. Îðãàíèçìó íåîáõîäèì ãëþòàòèîí äëÿ âûâåäåíèÿ òàêèõ òîêñèíîâ, êàíöåðîãåíîâ è äðóãèõ âðåäíûõ ñóáñòàíöèé.


    Òàêæå ìîæíî ïðîñìîòðåòü Video english 8 min www.Immunocal.ws



    Ãëþòàòèîí è åãî ðîëü â ëå÷åíèè îíêîëîãè÷åñêèõ çàáîëåâàíèé
    (Ïî ìàòåðèàëàì êíèãè äîêòîðà Jimmy Gutman MD, FACEP "Glutathione (GSH) - Your Body's Most Powerful Protector", ISBN 0-973I409-0-9
    ×òî òàêîå ðàê?
    Ðàê - ýòî âûõîäÿùèé èç íîðìû, áûñòðûé ðîñò îïðåäåëåííûõ êëåòîê è òêàíåé â îðãàíèçìå. Ýòîò íåíîðìàëüíî áûñòðûé ðîñò ìîæåò âûòåñíèòü æèçíåííî âàæíûå îðãàíû, íàðóøèòü èõ ôóíêöèè è èçðàñõîäîâàòü çàïàñû ýíåðãèè.
    Èçâåñòíî áîëåå ñîòíè âèäîâ ðàêà, íåêîòîðûå èç íèõ ðàñïðîñòðàíÿþòñÿ áûñòðåå, ÷åì äðóãèå, íåêîòîðûå èç íèõ ìîæíî ëå÷èòü, à îò íåêîòîðûõ ìîæíî äàæå ïîëíîñòüþ âûëå÷èòüñÿ. Òåì íå ìåíåå, ðàê ïðîäîëæàåò îñòàâàòüñÿ óáèéöåé íîìåð äâà â Ñåâåðíîé Àìåðèêå ïîñëå ñåðäå÷íî-ñîñóäèñòûõ çàáîëåâàíèé. Îäíà òðåòü àìåðèêàíöåâ óìèðàåò îò ðàçëè÷íûõ ôîðì ðàêà. Ìíîãèå îíêîëîãè÷åñêèå çàáîëåâàíèÿ ìîãóò áûòü ïðåäîòâðàùåíû ñ ïîìîùüþ ñòðîãîé äèåòû, óìåíüøåíèÿ âëèÿíèÿ êàíöåðîãåíîâ è óñèëåíèÿ çàùèòíûõ ñèë îðãàíèçìà.
    Êàê ðàçâèâàåòñÿ ðàê?
    Çäîðîâûå êëåòêè èìåþò âñòðîåííûé ìåõàíèçì ðàçìíîæåíèÿ, êîòîðûé ïðè õîðîøåì ñîñòîÿíèè çäîðîâüÿ èñïîëüçóåòñÿ òîëüêî äëÿ òðåõ öåëåé: íîðìàëüíûé ðîñò, èñöåëåíèå ïîâðåæäåííûõ òêàíåé è çàìåùåíèå ïîòåðÿííûõ êëåòîê â ïðîöåññå æèçíåäåÿòåëüíîñòè. Îäíàêî, â îïðåäåëåííûõ óñëîâèÿõ, êîòîðûå ìû ïîëíîñòüþ íå çíàåì, ýòîò ìåõàíèçì ðàáîòàåò íåïðàâèëüíî. Ðîñò êëåòîê ìîæåò ñòàòü íå ðåãóëèðóåìûì, ÷òî ïðèâîäèò áåñêîíòðîëüíîìó ðàçìíîæåíèþ è â êîíöå êîíöîâ ê îáðîçîâàíèþ îïóõîëåé.
    Îïóõîëè ðàñòóò è âûïóñêàþò îòäåëüíûå êëåòêè â ëèìôàòè÷åñêóþ è êðîâåíîñíóþ ñèñòåìû, òåì ñàìûì ðàñïðîñòðàíÿÿ çàáîëåâàíèå íà äðóãèå ÷àñòè òåëà è îáðàçóÿ äðóãèå îïóõàëè â ïðîöåññå ìåòàñòàçà.  çàâèñèìîñòè îò ðàçìåðà è ðàñïîëîæåíèÿ îïóõîëü âûòåñíÿåò íîðìàëüíûå òêàíè âîçäåéñòâóÿ íà ôóíêöèè òåëà è ïîòðåáëÿÿ çàïàñû ýíåðãèè, ÷òî ïðèâîäèò ê ñèìïòîìàì, êîòîðûå â êîíå÷íîì èòîãå âåäóò íà ïðèåì ê âðà÷ó.
    ×òî çàñòàâëÿåò êëåòêó ñòàíîâèòüñÿ ðàêîâîé?
    Òî÷íî íå ÿñíî êàê è ïî÷åìó êëåòêè òåðÿþò ñïîñîáíîñòü ñàìîðåãóëèðîâàòüñÿ è ñòàíîâÿòñÿ çëîêà÷åñòâåííûìè, õîòÿ ìíîãèå âîçìîæíûå ïðè÷èíû óæå èçâåñòíû. Ìíîãèå êàíöåðîãåíû èç îêðóæàþùåé ñðåäû ñïîñîáñòâóþò ðîñòó ðàêîâûõ êëåòîê, â îñîáåííîñòè íåêîòîðûå õèìèêàòû è âûñîêèé óðîâåíü ðàäèàöèè.
    Îêñèäàòèâíûé ñòðåññ è ñâîáîäíûå ðàäèêàëû èãðàþò âàæíóþ ðîëü âî ìíîãèõ òåîðèÿõ. Äðóãèå ôàêòîðû ìåíåå ïðåäñêàçóåìû. Èçìåíåíèÿ â ãåíåòè÷åñêîì êîäå èëè â èììóííîé ñèñòåìå, î÷åâèäíî, ìîæåò çàùèùàòü íåêîòîðûõ ëþäåé â òî âðåìÿ êàê äðóãèå ìîãóò ñòàòü æåðòâîé ýòîãî èçìåíåíèÿ. Ìû òàêæå çíàåì, ÷òî ïðåäðàñïîëîæåííîñòü ê îïðåäåëåííûì âèäàì ðàêà ïåðåäàåòñÿ ïî íàñëåäñòâó îò ðîäèòåëåé èëè ãåíîôîíäà íàöèè. Íî âñå åùå íåîáõîäèìî âûÿñíèòü ôàêòîðû, êîòîðûå çàïóñêàþò ìåõàíèçì.
    ×òî ìîæåò ïðèâåñòè ê ðàêó?
    Ìíîãèå ïðè÷èíû ïðèâîäÿùèå ê ðàêó óæå èçâåñòíû. Ýòî ãåíåòèêà è îêðóæàþùàÿ ñðåäà. Äàæå ñòàðåíèå ñàìî ïî ñåáå óâåëè÷èâàåò ðèñê. Íà÷àëî ðàêà õàðàêòåðèçóåòñÿ èçìåíåíèåì ãåíåòè÷åñêîãî êîäà êëåòîê - ïåðåïðîãðàììèðîâàíèåì ìåõàíèçìà ðîñòà êëåòîê, ÷òî âåäåò ê èõ íåêîíòðîëèðóåìîìó ðîñòó. Êîìáèíàöèÿ ãåíåòè÷åñêèõ ôàêòîðîâ è ôàêòîðîâ îêðóæàþùåé ñðåäû, âêëþ÷àÿ ïðèâû÷êè ïèòàíèÿ, ìîæåò âíåñòè âêëàä â ýòî îòêëîíåíèå.
    Ñîãëàñíî îäíîé òåîðèè ñòðóêòóðà ÄÍÊ íàðóøàåòñÿ â ðåçóëüòàòå ôîðìèðîâàíèÿ ñâîáîäíûõ ðàäèêàëîâ â ÿäðàõ êëåòîê. Äðóãàÿ òåîðèÿ ãîâîðèò î òîì, ÷òî òàêèå ôàêòîðû êàê ïëîõîå ïèòàíèå è êóðåíèå ïîäâåðãàþò ðèñêó èììóííóþ ñèñòåìó è îñëàáëÿþò çàùèòíûå ìåõàíèçìû òåëà, êîòîðûå ñïîñîáíû îñòàíîâèòü ðàê íà ðàííèõ ñòàäèÿõ. Íå ñìîòðÿ íà âñå òåîðèè ìû äîëæí èñïîëüçîâàòü âñå âîçìîæíîñòè â áîðüáå ïðîòèâ ðàêà, îäíà èç êîòîûõ - ãëþòàòèîí.

    Êàêàÿ ñâÿçü ìåæäó Ãëþòàòèîíîì è ðàêîì?
    Ãëþòàòèîí ïîìîãàåò íàì áîðîòüñÿ ñ ðàêîì, ïî êðàéíåé ìåðå, â òðåõ íàïðàâëåíèÿõ:
    Âî ïåðâûõ, Ãëþòàòèîí ïîìîãàåò ïðåäîòâðàòèòü ðàê íà ðàííèõ ñòàäèÿõ.
    Âî âòîðûõ, ãëþòàòèîí áîðåòñÿ ñ ðàêîì, êîòîðûé óæå åñòü â òåëå.
    È ïîñëåäíåå, îí îáëåã÷àåò ïîñëåäñòâèÿ ðàêà, âêëþ÷àÿ ñèëüíóþ ïîòåðþ âåñà, è ïîáî÷íûå ýôôåêòû õèìèî è ðàäèîòåðàïèè.
    Ïðåäóïðåæäåíèå ðàêà

    1. Àíòèîêñèäàíòû ïðîòèâ ìóòàöèè ÄÍÊ
    Ñâîáîäíûå ðàäèêàëû ÿâëÿþòñÿ ñîïóòñòâóþùèì ïðîäóêòîì ïðîèçâîäñòâà ýíåðãèè è äðóãèõ ïðîöåññîâ ïðîèñõîäÿùèõ â êëåòêàõ. Ñâîáîäíûå ðàäèêàëû ìîãóò ïðèâîäèò ê ìóòàöèè ÄÍÊ.  ñòàòüå â Åâðîïåéñêîì Æóðíàëå îíêîëîãè÷åñêèõ çàáîëåâàíèé (European Journal of Cancer) ãîâîðèòñÿ î òîì, ÷òî ñâîáîäíûå ðàäèêàëû ìîãóò ðàññìàòðèâàòüñÿ êàê âàæíûé êëàññ êàíöåðîãåíîâ.
    Êàê îñíîâíîé êëåòî÷íûé àíòèîêñèäàíò Ãëþòàòèîí íåéòðàëèçóåò ðàçðóøèòåëüíûé ïîòåíöèàë ñâîáîäíûõ ðàäèêàëîâ, â îñîáåííîñòè, îêñèðàäèêàëîâ (oxyradicals) êàê òîëüêî îíè îáðàçóþòñÿ â êëåòêàõ. Ãëþòàòèîí ïðèíîñèò äîïîëíèòåëüíóþ ïîëüçó óñèëèâàÿ äåéñòâèå äðóãèõ àíòèîêñèäàíòîâ òàêèõ êàê âèòàìèí Ñ, Å è ñåëåíèóì, êàæäûé èç êîòîðûõ èãðàåò âàæíóþ ðîëü â áîðüáå ïðîòèâ ñâîáîäíûõ ðàäèêàëîâ.
    Ãëþòàòèîí íå òîëüêî ïðåäîòâðàùàåò ìóòàöèþ ÄÍÊ, îí òàêæå âîññòàíàâëèâàåò ÄÍÊ è âíîñèò âêëàä â ñîçäàíèå íîâîãî ÄÍÊ.
    2. Óñèëåíèå ðåàêöèè èììóííîé ñèñòåìû
    Ãëþòàòèîí èãðàåò ðåùàþùóþ ðîëü â ðàáîòå èììóííîé ñèñòåìû è íàïðÿìóþ ñâÿçàí ñ âîñïðîèçâîäñòâîì è ðîñòîì Ò-ëèìôîöèòîâ - áåëûõ êðîâÿíûõ êëåòîê, êîòîðûå óíè÷òîæàþò ðàñïðîñòðàíèòåëåé ðàçëè÷íûõ çàáîëåâàíèé è ïîìîãàþò êîîðäèíèðîâàòü ðåàêöèþ îðãàíèçìà. Íèçêèé óðîâåíü Ãëþòàòèîíà âåäåò ê íåàäåêâàòíîé àêòèâíîñòè Ò-ëèìôîöèòîâ òàêîé, êîòîðàÿ íàáëþäàåòñÿ ó ÂÈ× èíèôèöèðîâàííûõ. Òàêèå áîëüíûå îñîáåííî ïîäâåðæåíû ñàðêîìå Êàðïîçè (Karposi's sarcoma) - âèäó ðàêà, ñ êîòîðîé çäîðîâàÿ èììóííàÿ ñèñòåìà óñïåøíî ñïðàâëÿåòñÿ.
    3. Äåòîêñèôèêàöèÿ êàíöåðîãåíîâ
    Äîïîëíèòåëüíî ê òîìó, ÷òî Ãëþòàòèîí ÿâëÿåòñÿ ìîùíûì àíòèîêñèäàíòîì, Ãëþòàòèîí ÿâëÿåòñÿ òàêæå ñèëüíåéøèì äåòîêñèôèêàòîðîì, êîòîðûé íåéòðàëèçóåò è óíè÷òîæàåò èçâåñòíûå êàðöèíîãåíû è ìóòàãåíû. Íå óäèâèòåëüíî, ÷òî Ãëþòàòèîí èìååò íàèáîëüøóþ êîíöåíòðàöèþ â ïå÷åíè, ðîëü êîòîðîé âûâîäèòü âðåäíûå âåùåñòâà èç îðãàíèçìà.
    Äîêàçàíî, ÷òî ïîâûøåííûé óðîâåíü Ãëþòàòèîíà ÿâëÿåòñÿ âûñîêîýôôåêòèâíûì ñðåäñòâîì ïðîòèâ ðàêà. Äåïàðòàìåíò Õèìèîòåðàïèè Íàöèîíàëüíîãî Îíêîëîãè÷åñêîãî Èíñòèòóòà (ÑØÀ) (Chemoprevenrtion Branch of the US National Cancer Institute) â ïîñëåäíåå äåñÿòèëåòèå ðàçðàáàòûâàë ïðåïàðàò äëÿ òîãî ÷òîáû óìåíüøèòü äåéñòâèå ðàêà, è äâà íàèáîëåå ýôôåêòèâíûõ îðóæèÿ â àðñåíàëå - NAC - ìîùíîå ôàðìàöåâòè÷åñêèé ïðåïàðàò, êîòîðûé ïîâûøàåò óðîâåíü Ãëþòàòèîíà, è ñåëåíîìåòèîíèí (selenomethionine) - ïðîèçâîäíàÿ ñåëåíà ñ ïîäîáíûì ýôôåêòîì.
    Ïîñëåäíèå ðàçðàáîòêè ïîêàçàëè, ÷òî ïðîñòîå äîáàâëåíèå â ðàöèîí ñåëåíà â âèäå ïèùåâîé äîáàâêè óìåíüøàåò ðèñê çàáîëåòü ðàêîì ïðåäñòàòåëüíîé æåëåçû. Äðóãèå èññëåäîâàíèÿ ïîêàçàëè ðîëü ñåëåíà â çàùèòå îò ðàêà îáîäî÷íîé êèøêè, ïðÿìîé êèøêè, ðàêà ëåãêèõ, à òàêæå ïðîòèâ ïîëèïîâ îáîäî÷íîé êèøêè.
    Àìåðèêàíñêèå è åâðîïåéñêèå èññëåäîâàòåëè âêëþ÷àÿ Ð. Ì. Áàëàíñêè (R. M. Balansky), Ñ. Ñ. Êîíàâåé (C. C. Conaway) è À. Âèòñ÷è (A. Witschi) óñïåøíî ïðîäåìîíñòðèðîâàëè, ÷òî NAC ñäåðæèâàåò òå âèäû ðàêà âûçâàííûå òàêèìè òîêñèíàìè êàê óðåòàí (urethane), íèòðîçîìèíû (nitrosamines), äîêñîðóáèöèí (doxorubicin) è ýòèëíèòðîñàóðåÿ (ethylnitrosourea).
    NAC òàêæå ñïîñîáåí çàùèùàòü îò êàíöèðîãåííîãî äåéñòâèÿ ñèãàðåò, ýòî îïðåäåëåííî õîðîøàÿ íîâîñòü. Í. Âàí Çàíäâèê èç Íèäåðëàíäñêîãî èíñòèòóòà îíêîëîãèè (N. Van Zandwijk of the Cancer Institue of the Netherlands) ïèøåò: "NAC ïðîÿâèë ñåáÿ êàê íàèáîëåå îáåùàþùèé õèìèîïðåïàðàò ïðåäîòâðàùàþùèé ðàê". Î÷åíü ñåðüåçíûå èññëåäîâàíèÿ ñïîíñèðóåìûå "Ïðîåêò Åâðîñêàí" áûëè íàïðàâëåíû íà èçó÷åíèå ïîòåíöèàëüíûõ âîçìîæíîñòåé NAC ïðîòèâ ðàêà ëåãêèõ, ìîëî÷íîé æåëåçû, êèøå÷íèêà è ðàêà êîæè. Ýòè èññëåäîâàíèÿ ïîêàçàëè (Ñ. Äå Ôëîðà) ïîçèòèâíûå ýôôåêòû NAC è Ãëþòàòèîíà â ïðåäîòâðàùåíèè ðàêà.

    Ñïîñîáñòâóåò ëè íèçêèé óðîâåíü Ãëþòàòèîíà âîçíèêíîâåíèþ ðàêà?
    Ãëþòàòèîí ÿâëÿåòñÿ êîìïîíåíòîì äëÿ íåñêîëüêèõ ôåðìåíòîâ, êàæäûé èç êîòîðûõ èãðàåò âàæíóþ ðîëü â çàùèòíîé ñèñòåìå îðãàíèçìà.  èññëåäîâàíèÿõ îïóáëèêîâàííûõ â æóðíàëå Íàöèîíàëüíîãî èíñòèòóòà îíêîëîãèè ðàññìàòðèâàåòñÿ îäèí èç íèõ - Ãëþòàòèîí-Ñ òðàíñôåðýç-ìó-1 (glutathione-S transferase-mu-1) GSTM1, êîòîðûé ïðîèçâîäèòñÿ ñîãëàñíî ãåíåòè÷åñêîìó êîäó. Îäèí ÷åëîâåê èç äâóõ íàñëåäóåò äâå äåôåêòèâíûå êîïèè ãåíà îòâå÷àþùåãî çà GSTM1 è 25% èç âñåõ ñëó÷àåâ çàáîëåâàíèÿ ðàêîì ìî÷åâîãî ïóçûðÿ ìîæíî îòíåñòè ê ïëîõîé ðàáîòå ýòîãî ãåíà. GSTM1 ÿâëÿåòñÿ àíòèîêñèäàíòîì, êîòîðûé òàêæå âûâîäèò êàíöåðîãåíû ìî÷åâîãî ïóçûðÿ è êàíöåðîãåíû òàáà÷íîãî äûìà.
    Äðóãèå èññëåäîâàíèÿ ïîêàçûâàþò, ÷òî äðóãîé ôåðìåíò - Ãëþòàòèîí-Ñ òðàíñôåðýç-ïè-1 (glutathione-S transferase-pi-1) GSTP1 ïî÷òè âñåãäà îòñóòñòâóåò ó ìóæ÷èí ñ ðàêîì ïðåäñòàòåëüíîé æåëåçû. Òàêèì îáðàçîì ïðåäñòàâëÿåòñÿ áîëåå âåðîÿòíûì, ÷òî íåäîñòàòîê ýòîãî ôåðìåíòà ïîçâîëÿåò ñ áîëüøåé ëåãêîñòüþ ðàçâèâàòüñÿ ðàêó ïðåäñòàòåëüíîé æåëåçû. Ìíîãèå èññëåäîâàíèÿ ïîäòâåðæäàþò ýòî ïðåäïîëîæåíèå. Ïîäîáíûì îáðàçîì íåäîñòàòîê äðóãèõ ôåðìåíòîâ Ãëþòàòèîíà ñâÿçàíû ñ ðàêîì ìîëî÷íîé æåëåçû è ðàêîì ëåãêèõ, îñîáåííî äëÿ êóðèëüøèêîâ. Ïî ýòîé ïðè÷èíå âñå áîëüøå ó÷åíûõ â îáëàñòè ìåäèöèíû ñ÷èòàþò, ÷òî ìóæ÷èíû è æåíùèíû äîëæíû îáñëåäîâàòüñÿ íà íåäîñòàòîê ýòèõ ôåðìåíòîâ èëè äàæå íà ãåíåòè÷åñêèå ïðè÷èíû ïðèâîäÿùèåê èõ íåäîñòàòêó, êàê îäèí èç ïóòåé áîëåå òî÷íîãî îïðåäåëåíèÿ ðèñêà çàáîëåòü ðàêîì.
    Åñëè íåêîòîðûå ðàêîâûå êëåòêè ñîäåðæàò âûñîêèé óðîâåíü Ãëþòàòèîíà, òî ìîæåò ëè óâåëè÷åíèå óðîâíÿ Ãëþòàòèîíà äåëàòü ðàê åùå áîëåå ñèëüíûì?
    Ìíîãèå òèïû îïóõîëåé ñîäåðæàò â ñåáå ìíîãî Ãëþòàòèîíà, ÷òî ïîçâîëÿåò çëîêà÷åñòâåííûì îïóõîëÿì èìåòü ñîïðîòèâëÿåìîñòü ê õèìèî è ðàäèîòåðàïèè. Îäíàêî, ðàêîâûå êëåòêè íå ìîãóò ñàìîðåãóëèðîâàòü ñâîé ðîñò è äðóãèå ôóíêöèè èõ æèçíåäåÿòåëüíîñòè. Ðàêîâûå êëåòêè ïëîõî ðåãóëèðóþò ìåòàáîëèçì Ãëþòàòèîíà. Êîãäà ðàêîâûì êëåòêàì ïðåäîñòàâëÿþò áîëüøîå êîëè÷åñòâî ïðåêóðñîðîâ (ñòðîèòåëüíûõ áëîêîâ) Ãëþòàòèîíà, îíè ïðåêðàùàþò ïðîèçâîäñòâî Ãëþòàòèîíà. Ýòî òî, ÷òî ó÷åíûå íàçûâàþò "ñíèæàþùåé ðåãóëÿöèåé" (down-regulation) èëè "ïîäàâëÿþùàÿ îòðèöàòåëüíàÿ îáðàòíàÿ ñâÿçü" (negative feedback inhibition).  îòëè÷èå îò ðàêîâûõ êëåòîê çäîðîâûå êëåòêè íå ðåàãèðóþò òàêèì îáðàçîì.
    Êàêèì îáðàçîì óâåëè÷åíèå óðîâíÿ Ãëþòàòèîíà ïîìîãàåò áîðîòüñÿ ñ ðàêîì?
    Èñïîëüçóÿ ïîäõîäÿùèå ïðåêóðñîðû èëè ñòðîèòåëüíûå áëîêè, óðîâåíü Ãëþòàòèîíà ìîæåò áûòü âûáîðî÷íî ïîäíÿò â çäîðîâûõ êëåòêàõ è ñíèæåí â ðàêîâûõ êëåòêàõ. Òàêèì îáðàçîì ðàêîâûå êëåòêè ìîãóò áûòü ñ áîëüøåé ëåãêîñòüþ ðàçðóøåíû è çàòåì óäàëåíû èììóííîé ñèñòåìîé.

    Êàêèì îáðàçîì óâåëè÷åíèå óðîâíÿ Ãëþòàòèîíà ìîæåò ïîìî÷ü ïðè ðàäèî è õèìèîòåðàïèè?
    ÈÑíèæåíèå óðîâíÿ Ãëþòàòèîíà äåëàåò ðàêîâûå êëåòêè áîëåå óÿçâèìûìè ê ðàçðóøèòåëüíûì ôàêòîðàì, âêëþ÷àÿ õèìèî è ðàäèîòåðàïèþ.  òî âðåìÿ êàê âîçðîñøèé óðîâåíü Ãëþòàòèîíà äàåò çäîðîâûì êëåòêàì áîëüøóþ ñîïðîòèâëÿåìîñòü ê âîçäåéñòâèÿì õèìèî è ðàäèîòåðàïèè. Ýòî ïðèâîäèò ê óìåíüøåíèþ ïîáî÷íûõ ýôôåêòîâ, òàêèõ êàê òîøíîòà, ðâîòà, äèàðåÿ, ïîòåðÿ âîëîñ è ëåéêîïåíèÿ (ïîòåðÿ áåëûõ êëåòîê êðîâè).
    Ãëþòàòèîí è èììóííàÿ ñèñòåìà ïðîòèâ ðàêà
    Ãëþòàòèîí ïîìîãàåò èììóííîé ñèñòåìà íåñêîëüêèìè ñïîñîáàìè. Ïåðâîå, îí ñïîñîáñòâóåò ðîñòó è ïðàâèëüíîìó ôóíêöèîíèðîâàíèþ áåëûõ êëåòîê êðîâè, êîòîðûå ðàçðóøàþòñÿ ïðè àíòèðàêîâîé òåðàïèè, è ýòî ïîçâîëÿåò èììóííîé ñèñòåìå ñàìîé áîðîòüñÿ ñ ðàêîì.
    Íîâàÿ ñòðàòåãèÿ áîðüáû ñ ðàêîì - ýòî èñïîëüçîâàíèå "èììóíîòåðàïèè" - óñèëåíèå ïðèðîäíîé ñïîñîáíîñòè èììóííîé ñèñòåìû áîðîòüñÿ ñ ðàêîì. Ãðóïïà èññëåäîâàòåëåé èç Êèîòñêîãî óíèâåðñèòåòà â ßïîíèè ïîêàçàëà, ÷òî NAC äîáàâëÿåìûé â öèòîêèí (cytokines - êëàññ èììóíîòåðàïåâòè÷åñêèõ àãåíòîâ) óñèëèâàåò ñòèìóëÿöèþ èììóííûõ êëåòîê è èõ áèîõèìè÷åñêèå ïðîäóêòû. Èññëåäîâàòåëè ïîëàãàþò, ÷òî ýòî ìîæåò áûòü ýôôåêòèâíûì äîïîëíåíèåì ïðè ëå÷åíèè ðàêà ïå÷åíè.
    Äðóãèå àíòèðàêîâûå âåùåñòâà ïðîèçâîäèìûå èììóííîé ñèñòåìîé âêëþ÷àåò ðàçëè÷íûå ôàêòîðû íåêðîçà îïóõîëè (tumor necrosis factors - TNF) è IL2 (interleukin 2). Ó÷åíûå èç èññëåäîâàòåëüñêîãî öåíòðà Ãëàêñî (Glaxo Wellcome Research and Development) ïðåäïîëîæèëè, ÷òî ïðåïàðàò NAC óâåëè÷èâàþùèé óðîâåíü Ãëþòàòèîíà áîðåòñÿ ñ îïóõîëüþ ïóòåì óñèëåíèÿ äåéñòâèÿ TNF (ôàêòîðà íåêðîçà îïóõîëè) è ïðîäåìîíñòðèðîâàëè êàê åãî èñïîëüçîâàíèå ïðåäîòâðàùàåò ðàçâèòèå ðàêà ó îäíîé òðåòè ìûøåé çàðàæåííûõ êëåòêàìè ëèïîìû. Ñ. Èì è Ä. Õèáñ èç óíèâåðñèòåòà Þòà (S. Yim and D. Hibbs at the University Utah) òàêæå èìåëè óñïåõ â ïîäàâëåíèè ðîñòà îïóõîëè ïîäîáíûì ñòèìóëðîâàíèåì IL2 â âåùåñòâå, âûðàáàòûâàåìûì èììóíûìè êëåòêàìè.
    Ãëþòàòèîí ïðè îïåðàöèÿõ è â âîñòàíîâèòåëüíîì ïåðèîäå
    Îïåðàöèÿ ñàìà ïî ñåáå âûñâîáîæäàåò òðèëèîíû ñâîáîäíûõ ðàäèêàëîâ â òî âðåìÿ êàê àíåñòåçèÿ è äðóãèå ïðèìåíÿåìûå ïðè îïåðàöèÿõ ëåêàðñòâà âíîñÿò äîïîëíèòåëüíûé âðåä. Ãëþòàòèîí â ðîëè àíòèîêñèäàíòà è äåòîêñèôèêàòîðà ìîæåò óìåíüøèòü ýòó óãðîçó. Èçâåñòíî òàêæå, ÷òî áîëåå âûñîêèé óðîâåíü Ãëþòàòèîíà óñêîðÿåò ïðîöåññû çàæèâëåíèÿ è óìåíüøàåò âîçìîæíîñòü çàðàæåíèÿ ïîñëå îïåðàöèè.


    Òàêæå ìîæíî ïðîñìîòðåòü Video english 8 min www.Immunocal.ws


    Ïðåîáðåñòè Ïðîäóêò ìîæíî www.ImmunoSupporter.com

    Ãëþòàòèîí è ñïîðòèâíûå äîñòèæåíèÿ


    (Ïî ìàòåðèàëàì êíèãè äîêòîðà Jimmy Gutman MD, FACEP "Glutathione (GSH) - Your Body's Most Powerful Protector", ISBN 0-973I409-0-9
    Ôèçè÷åñêèå óïðàæíåíèÿ è èììóííàÿ ñèñòåìà
    Ôèçè÷åñêèå óïðàæíåíèÿ âçðàùèâàþò äåéñòâèå èììóííîé ñèñòåìû, íî ñëèøêîì èíòåíñèâíûå óïðàæíåíèÿ ìîãóò ïðèâåñòè ê ïðîòèâîïîëîæíîìó ýôôåêòó. Ìíîãèå ýëèòíûå ñïîðòñìåíû áûëè "ñâàëåíû" âèðóñíûìè èíôåêöèÿìè âî âðåìÿ èíòåíñèâíûõ òðåíèðîâîê. Øèðîêîðàñïðîñòðàííåíûé âèðóñ ñâàëèë ñïîðòñìåíîâ ïåðåä ïðåäñòîÿùèìè Îëèìïèéñêèìè èãðàìè â Àòëàíòå â 1996 ãîäó, ðàçðóøèâ èõ ìíîãîëåòíèé òÿæåëûé òðóä.
    Õîòÿ èììóííàÿ ñèñòåìà ðåàãèðóåò ïîëîæèòåëüíî íà óìåðåííûå òðåíèðîâêè, ÷ðåçìåðíàÿ ôèçè÷åñêàÿ àêòèâíîñòü ïðèâîäèò ê ïîäàâëåíèþ èìììóííîé ñèñòåìû.

    Ñèíäðîì ïåðåòðåíèðîâîê
    Êðîìå î÷åâèäíîé âîçìîæíîñòè ïîëó÷èòü òðàâìó ñåðüåçíûå ñïîðòñìåíû ðèñêóþò ïîäõâàòèòü ëþáóþ áîëåçíü. Èìììóííàÿ ðåàêöèÿ èõ îðãàíèçìà îñëàáëÿåòñÿ èñòîùàþùèìè òðåíèðîâêàìè, ÷òî ÿâëÿåòñÿ îäíèì èç àñïåêòîâ "ñèíäðîìà ïåðåòðåíèðîâîê". Òàêèå ñëîâà êàê "ñãîðåë", "âûäîõñÿ", "ïåðåòðåíèðîâàëñÿ" è "ðåçóëüòàò íå èäåò", "çàñòðÿë íà ìåñòå" èñïîëüçóþòñÿ ñïîðòñìåíàìè äëÿ îïèñàíèÿ ñâîèõ ôèçè÷åñêèõ îùóùåíèé.
    Íåêîòîðûå ñïîðòñìåíû óïðÿìî ïðîäîëæàþò ñòàðàòüñÿ åùå ñèëüíåå, ÷òî ïðèâîäèò ê óñèëåíèþ íåãàòèâíîãî ýôôåêòà. Ó÷åíûå â îáëàñòè ñïîðòà ïîêàçàëè, ÷òî óìåíüøåíèå èíòåíñèâíîñòè òðåíèðîâîê ìîæåò â äåéñòâèòåëüíîñòè óëó÷øèòü ðåçóëüòàòèâíîñòü ñïîðòñìåíîâ.
    Ïåðåòðåíèðîâàøèéñÿ ñïîðòñìåí èñïûòûâàåò öåëîå ìíîæåñòâî ôèçèîëîãè÷åñêèõ ýôôåêòîâ, êîòîðûå âåäóò ê ñíèæåíèþ ðåçóëüòàòèâíîñòè è áîëåçíÿì. Ýòè ýôôåêòû âêëþ÷àþò â ñåáÿ ôëóêòóàöèþ ñåêðåöèè èíñóëèíà, èçìåíåíèÿ óðîâíÿ ãëþêîêîðòèêîèäà è ãîðìîíîâ, çàäåðæêó äîñòàâêè ãëþêîçû ê òêàíÿì, êàòàáîëè÷åñêèå ýôôåêòû íà áåëêîâóþ è àçîòíóþ ýêñêðåöèþ è ïåðåïðîèçâîäñòâî ìîëî÷íîé êèñëîòû.
    Îêñèäàòèâíûé ñòðåññ
    Îêñèäàòèâíûé ñòðåññ ÿâëÿåòñÿ îñíîâíûì ôàêòîðîì ïðè ôèçè÷åñêèõ íàãðóçêàõ, ò.ê. ôèçè÷åñêàÿ àêòèâíîñòü óâåëè÷èâàåò ïîòðåáëåíèå êèñëîðîäà è óñèëèâàåò ìíîãî÷èñëåííûå ìåòàáîëè÷åñêèå ïðîöåññû.  ðåçóëüòàòå ïðîèñõîäèò îáðàçîâàíèå è öèðêóëÿöèÿ âûñâîáîäèâøèõñÿ â ðåçóëüòàòå îêèñëåíèÿ ïðîäóêòîâ ðàñïàäà - ñâîáîäíûõ ðàäèêàëîâ.
    Íåêîòîðûå ó÷åíûå ïîëàãàþò, ÷òî ñâîáîäíûå ðàäèêàëû èãðàþò âàæíóþ ðîëü â ïðîöåññàõ, âåäóùèõ ê âîñïàëåíèþ è ïîâðåæäåíèþ ìûøö. Åñòü ìíîãî äîêàçàòåëüñòâ ýòîé òåîðèè. Êîãäà êëåòêàì íåîáõîäèìî áîëüøå ýíåðãèè èõ ìåòàõîíäðèè (ýëåêòðîñòàíöèè êëåòîê) ðàáîòàþò ñ íàïðÿæåíèåì.  äîáàâîê ê óâåëè÷åíèþ ýíåðãèè ìåòàõîíäðèè òàêæå óâåëè÷èâàþò ïðîèçâîäñòâî âðåäíûõ ïîáî÷íûõ ïðîäóêòîâ, ÷òî ïðèâîäèò ê ëèïèäíîé ïåðîêñèäàöèè - âðåäíîìó îêèñëåíèþ æèðà. Ïëîõîé õîëåñòåðîë è æèð, íàïðèìåð, ðàñùåïëÿþòñÿ íà áîëåå âðåäíûå âåùåñòâà â ðåçóëüòàòå ïåðîêñèäàöèè.
    Äðóãîå ïîñëåäñòâèå óâåëè÷åíèÿ àêòèâíîñòè ìåòàõîíäðèé - ïîòîê ïåðåíîñÿùèé ýëåêòðîíû (electron transport flux) - öåïíàÿ ðåàêöèÿ àòîìîâ, êîòîðûå óðûâàþò äðóã ó äðóãà ýëåêòðîíû è ïîñòåïåííî äåñòàáèëèçèðóþò ñòðóêòóðó êëåòîê. Ýêçîãåííûå àíòèîêñèäàíòû, òàêèå êàê âèòàìèí Ñ è Å èç ïðîäóêòîâ ïèòàíèÿ è ýíäîãåííûå àíòèîêñèäàíòû - òå, êîòîðûå ïðîèçâîäÿòñÿ âíóòðè òåëà, ñäåðæèâàþò ýòè äâå óãðîçû. Ñàìûì âàæíûì ýíäîãåííûì àíòèîêñèäàíòîì ÿâëÿåòñÿ ãëþòàòèîí.
    Òåëî íå ÿâëÿåòñÿ àáñîëþòíî áåççàùèòíûì . Óïðàæíåíèÿ òàêæå óâåëè÷èâàþò óðîâåíü è àêòèâíîñòü ìíîãèõ àíòèîêñèäàíòîâ. Õîðîøî òðåíèðîâàííîå òåëî áóäåò àäàïòèðîâàòüñÿ ê óâåëè÷åíèþ îêñèäàòèâíîãî ñòðåññà, íî ñòðåìëåíèå çà ëó÷øèìè ðåçóëüòàòàìè ìîæåò ñäåðæèâàòü àäàïòàöèþ è ïðèâåñòè ê óâåëè÷åíèþ ìûøå÷íîé óñòàëîñòè, òðàâìàì è óâåëè÷åíèþ ïåðèîäà âîññòàíîâëåíèÿ. Àíòèîêñèäàíòû òàêæå ìîãóò áûòü ñ ëåãêîñòüþ ðàñòðà÷åíû â ðåçóëüòàòå ïåðåòðåíèðîâîê. Ïîýòîìó ìû ïîîùðÿåì èñïîëüçîâàíèå îðàëüíûõ àíòèîêñèäàíòîâ êàê äîïîëíåíèå ê ïèòàíèþ.
    Ïðèíèìàòü ãëþòàòèîí â ïîðîøêàõ èëè òàáëåòêàõ -áåñïîëåçíî, ò.ê. ïðàêòè÷åñêè âåñü ãëþòàòèòîí ðàçðóøàåòñÿ â ïèùåâàðèòåëüíîì òðàêòå. Óíèêàëüíûé, íå èìåþùèé àíàëîãîâ â ìèðå, ïðîäóêò Immunocal - ýòî åñòåñòâåííûé è áåçîïàñíûé ïóòü óâåëè÷èòü óðîâåíü âíóòðèêëåòî÷íîãî ãëþòàòèîíà.
    Ïðåîáðåñòè Ïðîäóêò ìîæíî www.ImmunoSupporter.com

    Ãëþòàòèîí è ñïîðòèâíûå äîñòèæåíèÿ

    Ïîñêîëüêó àíòèîêñèäàíòû îñîáåííî âàæíû äëÿ òåõ êòî çàíèìàåòñÿ óïðàæíåíèÿìè èññëåäîâàòåëè ïðîâåëè íåìàëî âðåìåíè íàáëþäàÿ çà èõ äåéñòâèåì è òåñòèðóÿ èõ. Ýòè èññëåäîâàíèÿ èìåëè äâå öåëè - íàéòè âîçìîæíîñòü èçáåæàòü íåãàòèâíûõ ïîñëåäñòâèé ïåðåòðåíèðîâîê è èññëåäîâàòü âîçìîæíîñòü óëó÷øåíèÿ ñïîðòèâíûõ äîñòèæåíèé. Áîëüøèíñòâî èç ýòèõ èññëåäîâàíèé è ñòàòåé ñôîêóñèðîâàíû íà íàèáîëåå âàæíîì ýíäîãåííîì àíòèîêñèäàíòå - ãëþòàòèîíå.
    Ïîâûøåííûå óðîâíè ãëþòàòèîíà îáåñïå÷èâàþò ëó÷øóþ èììóííóþ çàùèòó è óìåíüøàþò âîñïðèèì÷èâîñòü ê èíôåêöèîííûì çàáîëåâàíèÿì. Îíè ïîìîãàþò ñîêðàòèòü âðåìÿ âîññòàíîâëåíèÿ ïîñëå òðåíèðîâîê, óìåíüøèòü óñòàëîñòü ìûøö, áîëåçíåííîñòü è óëó÷øèòü ñïîðòèâíûå ðåçóëüòàòû.
    Ãðóïïà èññëåäîâàòåëåé èç óíèâåðñèòåòà Èëëèíîéñ (L. L. Ji, C. Leeuwenburgh è äð.) ïðîâåëè ðÿä èññëåäîâàíèé íà òðàâìàõ ìûøö ïîä âëèÿíèåì ñâîáîäíûõ ðàäèêàëîâ. Èõ öåëüþ áûëî îöåíèòü ïîëüçó ãëþòàòèîíà ïðè êîíòðîëå ïîâðåæäåíèÿ êëåòîê. Íå ëåãêî òåñòèðîâàòü àäàïòèâíóþ ðåàêöèþ òåëà íà ôèçè÷åñêèå íàãðóçêè.  ÷àñòíîñòè, åñòü äâà íåïðåäñêàçóåìûõ ìåòàáîëè÷åñêèõ ïðîöåññà. Îäèí èç íèõ - ýòî èçìåí÷èâîñòü óðîâíÿ ãëþòàòèîíà â ëþáîé äàííîé ÷àñòè òåëà. Äðóãîé ïðîöåññ îòíîñèòñÿ ê ïåðåìåùåíèþ ãëþòàòèîíà ìåæäó òêàíÿìè òåëà. Òåì íå ìåíåå, íàáëþäàëîñü èçìåíåíèå óðîâíÿ ãëþòàòèîíà ïðîïîðöèîíàëüíî óðîâíþ ôèçè÷åñêèõ íàãðóçîê, ôèçè÷åñêîé ôîðìå è òèïó ïèòàíèÿ.
    Âî âðåìÿ ýêñïåðåìåíòîâ Á. Äóôîêñà (B. Dufaux) ïðîâîäèëèñü èçìåðåíèÿ óðîâíÿ ãëþòàòèîíà äî íà÷àëà, ñðàçó ïîñëå, ÷åðåç ÷àñ è ÷åðåç íåñêîëüêî äíåé ïîñëå òîãî, êàê îáúåêò èññëåäîâàíèÿ çàêîí÷èë áåã íà äëèííóþ äèñòàíöèþ.  ýòèõ ýêñïåðèìåíòàõ áûë âûÿâëåí çíà÷èòåëüíûé ðàñõîä ãëþòàòèîíà. Âîññòàíîâëåíèå óðîâíÿ ãëþòàòèîíà êîëåáàëîñü îò íåñêîëüêèõ ÷àñîâ äî íåñêîëüêèõ äíåé. Îáúåêòû èññëåäîâàíèÿ â ýòîò ïåðèîä îñòàâàëèñü âîñïðèèì÷èâûìè ê áîëåçíÿì. Ïîäîáíûå èññëåäîâàíèÿ òàêæå ïðîâîäèëèñü íà âåëîñèïèäèñòàõ è íà äðóãèõ ñïîðòñìåíàõ. Âî âñåõ ýòèõ èññëåäîâàíèÿõ áûëî îáíàðóæåíî ïàäåíèå óðîâíÿ ãëþòàòèîíà â òêàíÿõ òåëà âî âðåìÿ ôèçè÷åñêèõ íàãðóçîê.
    Ó÷èòûâàÿ âñå ýòî, ïðåäñòàâëÿåòñÿ ïîëåçíûì ïðèíèìàòü àíòèîêñèäàíòû èëè äîáàâêè, ïîâûøàþùèå óðîâåíü ãëþòàòèîíà äî èíòåíñèâíûõ òðåíèðîâîê. Äæ. Ñàñòð (J. Sastre) è åãî ãðóïïà èç óíèâåðñèòåòà Âàëåíñèÿ â Èñïàíèè ïðîâåðÿëè ýòó èäåþ, èñïîëüçóÿ âèòàìèí Ñ è NAC (õèìè÷åñêèé ïðåïàðàò ïîâûøàþùèé óðîâåíü ãëþòàòèîíà) â îïûòàõ íà æèâîòíûõ. Ðåçóëüòàòîì áûëî óìåíüøåíèå ïîâðåæäåíèé òêàíåé â ðåçóëüòàòå îêñèäàòèâíîãî ñòðåññà è ñîõðàíåíèå óðîâíÿ ãëþòàòèîíà â êðîâè. Äðóãàÿ ãðóïïà èç óíèâåðñèòåòà Êàëèôîðíèÿ (Berkeley), âîçãëàâëÿåìàÿ Ñ. Ê. Ñåí (C. K. Sen), äîêàçàëà, ÷òî âûñîêèå óðîâíè ãëþòàòèîíà óëó÷øàëè ðàáîòó àíòèîêñèäàíòîâ, à íèçêèå óðîâíè óõóäøàëè åå. Èññëåäîâàòåëè ïðèíóäèòåëüíî ñíèæàëè óðîâåíü ãëþòàòèîíà ñ ïîìîùüþ ïðåïàðàòà BSO è âûíîñëèâîñòü ê ôèçè÷åñêèì íàãðóçêàì ó ïîäîïûòíûõ æèâîòíûõ ïàäàëà äî 50%.
    Çàìå÷àòåëüíûé ïðèìåð óâåëè÷åíèÿ ìûøå÷íîé ñèëû ïðèâîäèò äîêòîð Ëàðè Ëàíäñ èç óíèâåðñèòåòà ÌàêÃèëë â Ìîíðåàëå. Ïîëàãàÿ, ÷òî îêñèäàòèâíûé ñòðåññ ñïîñîáñòâóåò ìûøå÷íîé óñòàëîñòè, åãî ãðóïïà èññëåäîâàòåëåé äàâàëà ìîëîäîìó ÷åëîâåêó ïðîäóêò Immunocal, ñîäåðæàùèé ìîëî÷íî-ñûâîðîòî÷íûå ïðåêóðñîðû (ñòðîèòåëüíûå áëîêè) ãëþòàòèîíà, â òå÷åíèè òðåõ ìåñÿöåâ.  òå÷åíèè ýòîãî âðåìåíè îíè èçìåðÿëè ìàêñèìàëüíóþ ñèëó è ðàáîòîñïîñîáíîñòü êàê èíäèêàòîð ñèëû è âûíîñëèâîñòè. Îíè îáíàðóæèëè, ÷òî ðåçóëüòàòèâíîñòü ìîæåò áûòü çíà÷èòåëüíî óëó÷øåíà îò 10 äî 15%.
    Ãðóïïà èññëåäîâàòåëåé èç ëàáîðàòîðèè Ïèê Âåëíåñ â Êîííåòèêóòå èññëåäîâàëà êàêîé ýôôåêò îêàçûâàåò ïðîòåèí èç ìîëî÷íîé ñûâîðîòêè íà ñïîðòñìåíîâ. Îíè ïîêàçàëè, ÷òî äîáàâêà ê ïèùå ýòèõ ïðîòåèíîâ ìîãëà ñîõðàíÿòü óðîâåíü áåëûõ êðîâÿíûõ òåëåö (CD4 T-ëèìôîöèòû è íèòðîôèëüíûé ëåéêîöèò), êîòîðûé ïàäàë â òå÷åíèè èíòåíñèâíûõ òðåíèðîâîê. Ìîëî÷íî-ñûâîðîòî÷íûé ïðîòåèí îáëàäàåò ýêñòðîîðäèíàðíî âûñîêîé áèîëîãè÷åñêîé öåííîñòüþ è ýêñòðåìàëüíî ýôôåêòèâíî îòâå÷àåò âûñîêèì òðåáîâàíèÿì ñïîðòñìåíîâ â ïðîòåèíàõ, êîòîðûå íóæäàþòñÿ â ïðîòåèíàõ â äâà, â òðè ðàçà áîëüøå ÷åì îáû÷íûé ÷åëîâåê. Ïî ýòîé ïðè÷èíå ìîëî÷íî-ñûâîðîòî÷íûé ïðîòåèí øèðîêî èñïîëüçóåòñÿ â òðåíèðîâêàõ íà ïîâûøåíèå ìàññû òåëà. Çàìåíà æèðà ìûøöàìè ÿâëÿåòñÿ îñíîâíûì ôîêóñîì â òðåíèðîâêàõ, íàïðàâëåííûõ íà âåñ òåëà.
    Èññëåäóåìûå ñëó÷àè
    Ñüþçàí, 35-ëåòíÿÿ ïðîäàâùèöà ìîäíîé îäåæäû è ìàòü äâîèõ äåòåé, áûëà áîëüøèì ñòîðîííèêîì çäîðîâîãî îáðàçà æèçíè. Àýðîáèêà, ñòåï è äðóãèå êëàññû â òå÷åíèè 15 ëåò. Îíà áûëà ïîñòîÿííî íå óäîâëåòâîðåíà åå äåñÿòüþ ôóíòàìè æèðà, êîòîðûå íå äàâàëè åé äîñòè÷ü æåëàííîé ìûøå÷íîé ôîðìû. Çíàÿ ïðàâèëà ïèòàíèÿ îíà ïîíèìàëà, ÷òî îãðàíè÷åíèå êàëîðèé ñêîðåå âñåãî äàñò îùóùåíèå ïîëíîé èçìîòàííîñòè. Îíà íà÷àëà ïðèíèìàòü 40 ãðàììîâ ìîëî÷íî-ñûâîðîòî÷íîãî ïðîòåèíà â êîìáèíàöèè ñ ìèíèìàëüíûìè èçìåíåíèÿìè â ïîòðåáëåíèè æèðà è óãëåâîäîâ â åå ðàöèîíå. ×åðåç òðè íåäåëè îíà çàìåòèëà âîçðàñòàíèå âûíîñëèâîñòè âî âðåìÿ åå òðåíèðîâîê íà ñåðäå÷íî-îñóäèñòóþ ñèñòåìó è áûëà ñïîñîáíà ïîäíèìàòü áîëüøèå âåñà ñ áîëüøåé èíòåíñèâíîñòüþ. Óëó÷øèëàñü âîñòàíàâëèâàåìîñòü ìåæäó òðåíèðîâêàìè, ïîçâîëÿÿ åé ïðîäîëæàòü èõ áåç áîëåçíåííûõ îùóùåíèé. Åå âåñ îñòàâàëñÿ íåèçìåííûì. Íåñìîòðÿ íà òî, ÷òî îíà íå äåëàëà áîëüøèõ èçìåíåíèé â åå òðåíèðîâêàõ ïîñëå øåñòè íåäåëü ïðèåìà ïèùåâûõ äîáàâîê ëþäè â çàëå ñòàëè çàìå÷àòü êàê õîðîøî îíà ñëîæåíà.
    Äæîí ÷åìïèîí ñòðàíû ïî âåëîñèïåäíîìó ñïîðòó ïîíèìàë ôåíîìåí ïåðåòðåíèðîâîê è èõ âëèÿíèå íà èììóííóþ ñèñòåìó. Îí è åãî ïàðòíåðû ïî êîìàíäå õîðîøî îñîçíàâàëè òåíäåíöèþ çàáîëåâàòü ïåðåä áîëüøèìè ñîðåâíîâàíèÿìè åñëè îíè òðåíèðîâàëèñü ñëèøêîì óñåðäíî. Èìåÿ äâóõ äåòåé, êîòîðûå õîäèëè â äåòñêèé ñàä, îí ÿâíî èìåë îïàñíîñòü çàáîëåòü âèðóñíûìè èíôåêöèÿìè. Óñëûøàâ, ÷òî ïðîäóêò Immunocal èìååò ïîòåíöèàëüíî óñèëèâàþùèé ýôôåêò íà èììóííóþ ñèñòåìó îí âêëþ÷èë ýòîò ïðîäóêò â ñâîé åæåäíåâíûé ðàöèîí. ×àñòîòà çàáîëåâàíèÿ âèðóñíûìè èíôåêöèÿìè óìåíüøèëàñü è êîãäà îí çàáîëåâàë, ýòî äëèëîñü äåíü èëè äâà, à íå òðè èëè ÷åòûðå. Íà åãî óäèâëåíèå åãî ñïîðòèâíûå ðåçóëüòàòû óëó÷øèëèñü òàêæå êàê è åãî ñïîñîáíîñòü âîññòàíàâëèâàòüñÿ ïîñëå èçíóðèòåëüíûõ ñîðåâíîâàíèé. Ïîñëå ïåðâîíà÷àëüíûõ ñîìíåíèé îí ïîäåëèëñÿ ïðåèìóùåñòâîì ýòîãî ïðîäóêòà ñ ÷ëåíàìè åãî êîìàíäû.
    Çàêëþ÷åíèå
    Ïîëüçó îò ôèçè÷åñêèõ óïðàæíåíèé äëÿ çäîðîâüÿ íåâîçìîæíî ïåðåîöåíèòü. Ïðîñòî ãîâîðÿ, ëþäè ñ õîðîøåé ôèçè÷åñêîé ôîðìîé îáëàäàþò áîëüøåé ñîïðîòèâëÿåìîñòüþ áîëåçíÿì è æèâóò äîëüøå. Îäíàêî, óìåðåííîñòü èãðàåò âàæíóþ ðîëü. Ïåðåòðåíèðîâêè ìîãóò âåñòè ê îñëàáëåíèþ èììóíèòåòà, ïðîäîëæèòåëüíîìó ÷óâñòâó óñòàëîñòè è ïåðåðàñõîäó àíòèîêñèäàíòîâ, â îñîáåííîñòè ãëþòàòèîíà.
    Èññëåäîâàíèÿ â îáëàñòè ôèçè÷åñêîé àêòèâíîñòè ïîêàçûâàþò, ÷òî âîçðîñøèé óðîâåíü ãëþòàòèîíà óñèëèâàåò ôóíêöèè èììóíèòåòà, ïîìîãàåò îðãàíèçìó çàùèùàòüñÿ îò âèðóñíûõ èíôåêöèé, óìåíüøàåò ïîâðåæäåíèÿ ìûøö, ñîêðàùàåò âîññòàíîâèòåëüíûé ïåðèîä, óâåëè÷èâàåò ñèëó è âûíîñëèâîñòü è ñäâèãàåò ìåòàáîëèçì ñ ïðîèçâîäñòâà æèðà íà ðîñò ìûøö.
    Ìíîãî àòëåòîâ ìèðîâîãî óðîâíÿ îáíàðóæèâàþò, ÷òî õîðîøî ïîääåðæèâàåìûé óðîâåíü ãëþòàòèîíà äàåò èì ïðåèìóùåñòâî íàä ñîïåðíèêàìè, äàâàÿ áîëüøå ñèë è âûíîñëèâîñòè, ñîêðàùåííîå âðåìÿ âîññòàíîâèòåëüíîãî ïåðèîäà ïîñëå òðàâì, ìåíüøå áîëåé â ìûøöàõ è óñòàëîñòè, è ëó÷øåå óâåëè÷åíèå ìûøå÷íîé ìàññû.
    Îñîáåííîñòüþ ãëþòàòèîíà ÿâëÿåòñÿ òî, ÷òî îí äîëæåí áûòü âûðàáîòàí òîëüêî ñàìîé êëåòêîé. Ñàìûé íàäåæíûé ñïîñîá óâåëè÷èòü óðîâåíü ãëþòàòèîíà - äîñòàâèòü êëåòêàì ñòðîèòåëüíûå áëîêè èëè òàê íàçûâàåìûå ïðåêóðñîðû, èç êîòîðûõ ñîñòîèò ãëþòàòèîí. Çàïàòåíòîâàííàÿ, íå èìåþùàÿ àíàëîãîâ â ìèðå, áåçîïàñíàÿ íóòðèöåâòè÷åñêàÿ ïèùåâàÿ äîáàâêà Èììóíîêàë ñîäåðæèò òàêèå ñòðîèòåëüíûå áëîêè. Ïðîäóêò ñîäåðæèò 90% íåäåíàòóðèðîâàííîãî ïðîòåèíà, âûäåëåííîãî èç ìîëî÷íîé ñûâîðîòêè. Äëÿ òîãî, ÷òîáû ïîëó÷èòü ýêâèâàëåíò 10 ã ýòîãî ïðîäóêòà íàäî âûïèòü 1.5 ãàëëîíà (ïðèìåðíî 5.5 ëèòðîâ) ñûðîãî ìîëîêà (èç ïîä êîðîâû), ò.ê. ïàñòåðèçàöèÿ è ëþáàÿ äðóãàÿ îáðàáîòêà ìîëîêà ñðàçó æå íàðóøàåò õðóïêóþ ñòðóêòóðó ïðîòåèíîâ, íåîáõîäèìûõ äëÿ ïðîèçâîäñòâà ãëþòàòèîíà. Îäíèì ñëîâîì ýòè ïðîòåèíû (ñòðîèòåëüíûå áëîêè) äîëæíû áûòü íå äåíàòóðèðîâàííûå, ò.å. áèîëîãè÷åñêè àêòèâíûå. Áîëüøèíñòâî ïèùåâûõ äîáàâîê, ñîäåðæàùèõ ìîëî÷íîñûâîðîòî÷íûé ïðîòåèí, ñîäåðæàò åãî óæå â äåíàòóðèðâàííîì (ò.å. áèîëîãè÷åñêè íå àêòèâíîì) âèäå.
    Êëèíè÷åñêèå òåñòû ïîêàçàëè, ÷òî ïðè ïðèìåíåíèè ïðîäóêòà â òå÷åíèå òðåõ ìåñÿöåâ óðîâåíü ãëþòàòèîíà óâåëè÷èâàåòñÿ íà 30%. Áëàãîäàðÿ ýòîìó ñâîéñòâó îí ïðèðàâíåí ê ëåêàðñòâàì, ïîâûøàþùèì óðîâåíü ãëþòàòèîíà, è âíåñåí â ìåäèöèíñêèå ñïðàâî÷íèêè, òàêèå êàê Êðàñíàÿ ôàðìàöåâòè÷åñêàÿ êíèãà è Íàñòîëüíàÿ êíèãà âðà÷åé ÑØÀ. Íî â îòëè÷èå îò ëåêàðñòâ íå èìååò ïåðåäîçèðîâîê è ïîáî÷íûõ ýôôåêòîâ. Ïðîäóêò êëèíè÷åñêè èñïûòàí. Íà èõ îñíîâå ïîëó÷èë ïàòåíòû âî ìíîãèõ ñòðàíàõ. Îí èìååò 6 ïàòåíòîâ ÑØÀ (íîìåðà íà óïàêîâêå), 3 ïàòåíòà Êàíàäû, à òàêæå ïàòåíòû â Àâñòðàëèè, ßïîíèè, Åâðîïå è äðóãèõ ñòðàíàõ. Íàïðèìåð, ñðåäè íèõ òàêèå:
    Ïàòåíò ÑØÀ 5,888,552 Anti-cancer therapeutic compositions containing whey protein concentrate - Ïðîòèâîðàêîâûå òåðàïåâòè÷åñêèå êîìïîçèöèè ñîäåðæàùèå êîíöåíòðàò ìîëî÷íîñûâîðîòî÷íûõ ïðîòåèíîâ.
    Ïàòåíò ÑØÀ 5,456,924 Method of treatment of HIV-seropositive individuals with dietary whey proteins - Ìåòîä ëå÷åíèÿ ÂÈ×-ñåðîïîçèòèâíûõ ïàöèåíòîâ äèåòè÷åñêèìè ìîëî÷íîñûâîðîòî÷íûìè ïðîòåèíàìè.
    Òàêæå Ïàòåíòû ÑØÀ-

    5,290,571

    5,451,412

    5,230,902

    5,456,924

    5,888,552
    5,846,939


    Ïðåîáðåñòè Ïðîäóêò ìîæíî www.ImmunoSupporter.com
    Òàêæå ìîæíî ïðîñìîòðåòü Video english 8 min www.Immunocal.ws

    Ãëþòàòèîí


    Ãëþòàòèîí, òàê æå êàê è êàðíèòèí, íå ÿâëÿåòñÿ àìèíîêèñëîòîé.

    Ïî õèìè÷åñêîé ñòðóêòóðå ýòî òðèïåïòèä, ïîëó÷àåìûé â îðãàíèçìå èç öèñòåðíà, ãëþòàìèíîâîé êèñëîòû è ãëèöèíà.

    Ãëþòàòèîí ÿâëÿåòñÿ àíòèîêñèäàíòîì. Áîëüøå âñåãî ãëþòàòèîíà íàõîäèòñÿ â ïå÷åíè (íåêîòîðîå åãî êîëè÷åñòâî âûñâîáîæäàåòñÿ ïðÿìî â êðîâîòîê), à òàêæå â ëåãêèõ è æåëóäî÷íî-êèøå÷íîì òðàêòå.

    Îí íåîáõîäèì äëÿ óãëåâîäíîãî îáìåíà, à òàêæå çàìåäëÿåò ñòàðåíèå çà ñ÷åò âëèÿíèÿ íà ëèïèäíûé îáìåí è ïðåäîòâðàùåíèÿ âîçíèêíîâåíèÿ àòåðîñêëåðîçà.

    Äåôèöèò ãëþòàòèîíà ïðåæäå âñåãî ñêàçûâàåòñÿ íà íåðâíîé ñèñòåìå, âûçûâàÿ íàðóøåíèÿ êîîðäèíàöèè, ìûñëèòåëüíûõ ïðîöåññîâ, òðåìîð.

    Êîëè÷åñòâî ãëþòàòèîíà â îðãàíèçìå óìåíüøàåòñÿ ñ âîçðàñòîì.

     ñâÿçè ñ ýòèì ïîæèëûå ëþäè äîëæíû ïîëó÷àòü åãî äîïîëíèòåëüíî.

    Îäíàêî ïðåäïî÷òèòåëüíåå óïîòðåáëÿòü ïèùåâûå äîáàâêè, ñîäåðæàùèå öèñòåðí, ãëþòàìèíîâóþ êèñëîòó è ãëèöèí - òî åñòü âåùåñòâà, ñèíòåçèðóþùèå ãëþòàòèîí.

    Íàèáîëåå ýôôåêòèâíûì ñ÷èòàåòñÿ ïðèåì N-àöåòèëöèñòåèíà.

    Immunocal-Ýòî íåäåíàòóðèðîâàííûé ïðîòåèí, âûäåëåííûé èç ìîëî÷íîé ñûâîðîòêè. Èììóíîêàë êîðåííûì îáðàçîì îòëè÷àåòñÿ îò äðóãèõ ìîëî÷íî-ïðîòåèíîâûõ äîáàâîê ñâîèì óíèêàëüíûì áèîëîãè÷åñêèì äåéñòâèåì, êîòîðîå ñïîñîáñòâóåò ëó÷øåé ðàáîòå èììóííîé ñèñòåìû. Íå èìåþùèé àíàëîãîâ è î÷åíü ñëîæíûé ïðîöåññ ïðîèçâîäñòâà Èììóíîêàëà ñîõðàíÿåò äåëèêàòíóþ ñòðóêòóðó ìîëåêóë ïðîòåèíà, ÿâëÿþùåãîñÿ ñòðîèòåëüíûì áëîêîì äëÿ âíóòðèêëåòî÷íîãî ãëþòàòèîíà. Çà ñâîè óíèêàëüíûå ñâîéñòâà ïîääåðæèâàòü èììóííóþ ñèñòåìó è óâåëè÷èâàòü óðîâåíü ãëþòàòèîíà Èììóíîêàë ïîëó÷èë áîëüøîå ÷èñëî ïàòåíòîâ â ðàçíûõ ñòðàíàõ.  Ñåâåðíîé Àìåðèêå ýòîò ïîëíîñòüþ íàòóðàëüíûé ïðîäóêò ìîæíî ïðèîáðåñòè ÷åðåç ñåòåâîé ìàðêåòèíã, íî òàêæå îïðåäåëåííûå ãîñóäàðñòâåííûå àãåíòñòâà è ñòðàõîâûå êîìïàíèè (íàïðèìåð, Medicare and Medicaid â ÑØÀ) îïëà÷èâàþò åãî äëÿ òåõ ïàöèåíòîâ, êîìó Èììóíîêàë áûë âûïèñàí ïî ðåöåïòó âðà÷à. Ýòî ïåðâàÿ íàòóðàëüíàÿ äîáàâêà, ïîëó÷èâøàÿ òàêîå ïðèçíàíèå.
    Èììóíîêàë îòíîñèòñÿ ê êàòåãîðèè íóòðèöåâòè÷åñêèõ äîáàâîê. Ýòî åäèíñòâåííàÿ ïèùåâàÿ äîáàâêà, âíåñåííàÿ â ìåäèöèíñêèå ñïðàâî÷íèêè, òàêèå êàê Êðàñíàÿ ôàðìàöåâòè÷åñêàÿ êíèãà è Íàñòîëüíûé ñïðàâî÷íèê âðà÷åé ÑØÀ. Èììóíîêàë êëèíè÷åñêè èñïûòàí íà òåõ êòî áîëåí ðàêîì, ãåïàòèòîì,ÑÏÈÄîì, áîëåçíÿìè ñâÿçàííûìè ñ ëåãêèìè, ñèíäðîìîì õðîíè÷åñêîé óñòàëîñòè è ìíîãî äðóãèõ. Ýòè èñïûòàíèÿ ïîêàçàëè, ÷òî ïîâûøåííûé óðîâåíü ãëþòàòèîíà ÿâëÿåòñÿ ýôôåêòèâíîé çàùèòîé ïðîòèâ ðàêà, óâåëè÷èâàåò øàíñû íà âûæèâàíèå ó ÂÈ×-èíôèöèðîâàííûõ, âîññòàíàâëèâàåò ôóíêöèè ïå÷åíè ïîñëå ãåïàòèòà è ìíîãîå äðóãîå. Êëèíè÷åñêèå èñïûòàíèÿ è íàó÷íûå èññëåäîâàíèÿ ïðîäîëæàþòñÿ äî ñèõ ïîð, è ýòî ñîïðîâîæäàåòñÿ áîëüøèì ÷èñëîì ïóáëèêàöèé íîâûõ ðåçóëüòàòîâ â íàó÷íûõ è ìåäèöèíñêèõ æóðíàëàõ. Ïåðåäîçèðîâîê è ïîáî÷íûõ ýôôåêòîâ íå îáíàðóæåíî. Íà ïðîèçâîäñòâî 10 ã. Èììóíîêàëà òðåáóåòñÿ ïî÷òè 6 ëèòðîâ ÷èñòîãî ìîëîêà. Íåêà÷åñòâåííîå ìîëîêî íå ñîäåðæèò â äîñòàòî÷íîì êîëè÷åñòâå íåîáõîäèìûõ ïðîòåèíîâ.
    Ïðîäóêò íå ñîäåðæèò æèðà è ëàêòîçû. Êëèíè÷åñêèå òåñòû ïîêàçàëè, ÷òî ïðè ïðèìåíåíèè ïðîäóêòà â òå÷åíèå òðåõ ìåñÿöåâ óðîâåíü âíóòðèêëåòî÷íîãî ãëþòàòèîíà óâåëè÷èâàåòñÿ íà 30%. Ïðîäóêò çàùèùåí ìíîãî÷èñëåííûìè ïàòåíòàìè âî ìíîãèõ ñòðàíàõ ìèðà. Îí èìååò 6 ïàòåíòîâ ÑØÀ (íîìåðà íà óïàêîâêå), 3 ïàòåíòà Êàíàäû, à òàêæå ïàòåíòû â Àâñòðàëèè, ßïîíèè, Åâðîïå è äðóãèõ ñòðàíàõ. Íàïðèìåð, ñðåäè íèõ òàêèå:
    Ïàòåíò ÑØÀ 5,888,552 Anti-cancer therapeutic compositions containing whey protein concentrate - Ïðîòèâîðàêîâûå òåðàïåâòè÷åñêèå êîìïîçèöèè ñîäåðæàùèå êîíöåíòðàò ìîëî÷íîñûâîðîòî÷íûõ ïðîòåèíîâ.
    Ïàòåíò ÑØÀ 5,456,924 Method of treatment of HIV-seropositive individuals with dietary whey proteins - Ìåòîä ëå÷åíèÿ ÂÈ×-ñåðîïîçèòèâíûõ ïàöèåíòîâ äèåòè÷åñêèìè ìîëî÷íîñûâîðîòî÷íûìè ïðîòåèíàìè.
    Òàêæå Ïàòåíòû ÑØÀ-

    5,290,571


    5,451,412


    5,230,902


    5,456,924


    5,888,552


    5,846,939

    Ïðèìåíåíèå ïðîäóêòà ñäåëàåò ëþáîå ëå÷åíèå áîëåå ýôôåêòèâíûì, ñîêðàòèò âîññòàíîâèòåëüíûé ïåðèîä ïîñëå áîëåçíåé è ìèíèìèçèðóåò ïîáî÷íûå ýôôåêòû îò ëåêàðñòâ. Äëÿ òåõ, êòî íå ñòðàäàåò õðîíè÷åñêèìè çàáîëåâàíèÿìè, åæåäíåâíîå óïîòðåáëåíèå ïðîäóêòà óêðåïèò èììóííóþ ñèñòåìó, èçáàâèò îò ïðîñòóä, ãðèïïà, ïðîäëèò ìîëîäîñòü è äîëãîëåòèå, ïîâûñèò âûíîñëèâîñòü ó ñïîðòñìåíîâ. Ïðîäóêò ðåêîìåíäîâàí äëÿ âñåõ.
    Òàêæå ìîæíî ïðîñìîòðåòü Video english 8 min www.Immunocal.ws



    Thursday, January 3, 2008

    Diseases Related to Oxidative Stress

    Every moment we are alive, cells within our bodies are dying and being created. Oxidation within cells occurs as they "burn fuel and oxygen". Its our ability to deal with the oxidative stress that determines our overall health.

    If oxidative stress continually happens at a greater rate than we are capable of dealing with, it results in sickness and eventually disease. You may be surprised by the multitude of disease that are related to Oxidative Stress.

    The best strategy is to ensure adequate levels of antioxidants in your diet.
    • Neurodegenerative Diseases
    Parkinson disease, Alzheimer disease, Multiple Sclerosis, Schizophrenia, Dementia, Huntington’s disease
    • Aging Diseases
    Arthritis, Diabetes, Osteoarthritis, Cataract, Macular Degeneration, Prostate problems
    • Cancer
    Prostate cancer, Breast cancer, Lung cancer, Colorectal cancer, Bladder cancer, Uterine cancer, Ovarian cancer, Lymphoma, Skin cancer, Stomach cancer, Liver cancer & other Wasting Disease
    • Liver Diseases
    Toxic Hepatitis, Viral Hepatitis (A, B, C), Chronic Hepatitis, Cirrhosis
    • Lung Diseases
    Asthma, Emphysema, Pneumonia, Bronchitis (chronic and acute), Cystic fibroses, Pulmonary fibroses, Chronic obstructive pulmonary disease (COPD), Adult respiratory distress syndrome (ARDS)
    • Cardiovascular Diseases
    Arteriosclerosis & its consequences, Heart failure, Heart Attack, Kidney failure, High blood pressure, Stroke, Impaired circulation, Heart disease, Cholesterol and plaque formation, Reperfusion injury
    • Digestive Diseases
    Inflammatory bowel disease, Ulcerative colitis, Crohn’s disease, Gastritis, Stomach cancer, Pancreatitis, Peptic ulcer
    • Kidney Failure & Dialysis
    Kidney failure, Renal toxicity, Oxidative stress from dialysis
    • Infectious Diseases and Immunology
    Viral infection HIV and AIDS, Toxic Hepatitis & cirrhosis, Viral hepatitis (type A, B, & C), Herpes, Common Cold, Bacterial infection, Chronic fatigue syndrome, Certain autoimmune dysfunction
    • Skin Disorders
    Psoriases, Eczema, SLE (lupus), Vasculitis, Polymyositis, Mycosis fungoides, Scleroderma Pemhigoid, Atopic dermatitis, Contact dermatitis, Sebborrheic dermatitis, Dermatitis herpetiformis, Acne conglobata, Acne vularis, UV radiation skin damage
    • Eye, Ear, Nose, Throat & Teeth
    Cataract, Glaucoma, Macular degeneration, Hearing loss, Ear infection, Sinusitis, Periodontal (gum) disease, Nose, mouth & throat (upper respiratory tract) disease
    • Pregnancy, Lactation & Childbirth
    Pre-eclampsia, Eclampsia, Hypertension, Diabetes, GSH eliminates toxins and provides antioxidant defense system to the fetus during pregnancy. Mother’s milk (ideal precursor of GSH) has a very important role for the health and development of newborns, especially the long-term effects on the immune system.
    • Exercise & Athletic Performance
    Over-Training Syndrome & the related oxidative stress
    • Male Problems
    Prostate enlargement, Prostate cancer, Balding and hair loss, Male infertility.

    For more information go to Glutathione The Master Antioxidant.
    Labels: diseases related to oxidative stress, oxidative stress


    Âëîæåíèÿ Âëîæåíèÿ
    Ïîñëåäíèé ðàç ðåäàêòèðîâàëîñü gost_vash; 11.04.2008 â 03:41.

  9. êàòåãîðèÿ: ìåäèöèíñêèå ÝÊÑÏÅÐÒÛ, ìîäåðàòîðû, êîíñóëüòàíòû Nedug.Ru :::::
    ñîîáùåíèé
    1,998
    "ÂÑÅ Îñòàëüíûå ÀíòèÎêñèäàíòû íå ðîäíûå Íàì – îíè èçâíå – ÷óææåðîäíûå !"
    Ãëóïîñòè è åùå ðàç ãëóïîñòè íå çíàíèå áèîõèìèè âðåäèò âàøåìó "òðåçâîìó" âçãëÿäó íà î÷åðåäíîé ñåòåâîé áèçíåñ. (Ãëóòàòèîí, g-ãëóòàìèíèë-öèñòñèíèë-ãëèöèí, òðèïåïòèä, îáðàçîâàííûé îñòàòêàìè òð¸õ àìèíîêèñëîò - ãëóòàìèíîâîé êèñëîòû, öèñòåèíà è ãëèöèíà)-âû ÷òî ñ÷èòàåòå-îíè ó íàñ ðîæäàþòñÿ ÷òî ëè? òàê æå ïîñòóïàþò ÈÇÂÍÅ êàê è Vit C, ñåëåí è ïðî÷èå ïðî÷èå. À èç ðåàëüíûõ ÀÍÀËÎÃΠñîáñòâåííûõ àíòèîêñèäàíòîâ ýòî ÒÈÎÊÒÎÂÀß êèñëîòà (Áåðëèòèîí, Òèîãàììà, Òèîêòàöèä) ãîðàçäî ýôôåêòèâíåå è êñòàòè ÍÈÊÀÊÈÕ ïðîáëåì ñ ðåãèñòðàöèåé ÍÈÃÄÅ!!! À íàñ÷åò ïàòåíòîâ: ïðè èõ ðåãèñòðàöèÿ íèêàêèõ ïðîáëåì è íå ìîæåò áûòü:òàê êàê îíè ÍÅ ÐÀÑÑÌÀÒÐÈÂÀÞÒ êëèíè÷åñêóþ ñòîðîíó-òîëüêî þðèäè÷åñêóþ-ò.å. ÷åì ÁÎËÜØÅ âû ïðèäóìàåòå îò ×ÅÃÎ îíè ïîìîãàþò-òåì áîëüøå ïðîáëåì ó ñòîðîííèõ ëèö ïðè èõ ïðèìåíåíèè (ìîæåòå ëåãêî ïîïðîáûâàòü õîòü ïîìåò òèáåòñêèõ êîøåê â êà÷åñòâå ïðîòèâîîæîãîâîãî ñðåäñòâà îò âûñîêîãîðíîé èíñîëÿöèè)-2500 USD è òîëêàéòå ïî âñåìó ìèðó. À çàíèìàòüñÿ áàíêàìè Èììóíîêàëà îò 45 äîëëàðîâ çà øò. + êîìèññèÿ îò ïðîñòà÷êîâ -ìîæåò è íå çàçîðíî-íî õîòü íå îáâåøèâàéòå ýòî àòðèáóòàìè îêîëîìåäèöèíñêîé ôðàçåîëîãèè íà ÌÅÄÈÖÈÍÑÊÎÌ ñàéòå.
    Àíäðååâ Àíäðåé Âëàäèìèðîâè÷
    âðà÷-èíôåêöèîíèñò

  10. Àâàòàð äëÿ gost_vash Íîâè÷îê
    ñîîáùåíèé
    7
    Óâàæàåìûé Àíäðåé Âëàäèìèðîâè÷,

    Âèäàòü ÷åì òî çàäåë Âàñ ?

    Äåëî â òîì ÷òî ÿ íå ñïîðèòü ñþäà çàø¸ë, à ïðîñòî íàïèñàòü â çàùèòó ÍÅ òîãî Èììóíîêàë äèñòðèáüþòîðà,è åãî ìåòîäîâ ðàñïîñòðàíåííèÿ (ÿ åãî íåçíàþ,Immunotec Reashers òûñÿ÷è äèñòðèáþòîðîâ ïî ìèðó ),
    Íî äåëî â ïðîäóêòå , êòî-òî Âûøå íàïèñàë ,

    È íå ñòûäíî âàì? Îáîáðàòü äî íèòêè íóæäàþùåãîñÿ, à îòòîãî è ãîòîâîãî ïîâåðèòü â ëþáîå ÷óäîäåéñòâèå.

    Èììóíîêàë – ïîâåðòå íå “ ëþáîå ÷óäîäåéñòâèå “.
    Ñîòíè êëèíè÷åñêèõ èñïûòàíèé , â ðàçíûõ ñòðàíàõ ìèðà.


    Íà ìîèõ ãëàçàõ ïðèíèìàÿ ïðåïàðàò Ïîëíîñòüþ èçáàâëÿþòñÿ îò Àñòìû,Àëëåðãèè,Èíôåêöèé, Ãîíãðåíà , Ñàðêîìà,Ðàê ,

    Ïîýòîìó ðåøèë íàïèñàòü,÷òîáû íå áûë î÷åðí¸í ïðîäóêò,è çà íå òàêòè÷íîãî ïðåäëîæåíèÿ ïî áèçíåñó, õîòÿ êàæäûé ðåøàåò ñàì êàê ïðåäëàãàòü .

    Ñäåëàéòå èññëåäîâàíèÿ íà èíòåðíåòå èëè êàê òî åù¸…
    Ó Âàñ ïðåäóáåæäåíèå êî âñåì Áàä’àì è òï ?
    Ó ìåíÿ òîæå. Íî ýòî Óíèêàëüíûé ñëó÷àé !

    Ó ìåíÿ íåò öåëè ïðîäàòü Âàì Èììóíîêàë,ïîâåðòå áëàãîäàðíûõ êëèåíòîâ õâàòàåò.
    Ìîÿ Öåëü ÷òîáû è íà ìîåé Ðîäèíå óçíàëè îá ýòîì ïðîäóêòå.
    Êîòîðûé óïîòðåáëÿþò óæå âî ìíîãèõ ñòðàíàõ Àìåðèêè,Àçèè,Åâðîïû…
    Ïîñëå âèçèòà ê Âðà÷ó,÷åëîâåê åù¸ õî÷åò ÆÈÒÜ !

    Ïî ïîâîäó ðåçóëüòàòîâ,ýôôåêòèâíîñòè.
    Òûñÿ÷è çàäîêóìåíòèðîâàííûõ ñëó÷àåâ !

    À âåðèòü Íå âåðèòü Âàø âûáîð.
    Äëÿ ñðàâíåíèå î âåðèè – Õðèñòîñ ÷åäåñà âûòâîðÿë íà ãëàçàõ ó òåõ êòî ïîñëå îòêàçàëñÿ âåðèòü.À òå êòî Èññëåäîâàë Ïèñàíèÿ ïîíÿëè êòî Îí òàêîâ.
    ----------
    Êîíå÷íî ýòî ïðîñòî ñðàâíåíèå,íî ...

    Êàêîâ ÊÐÈÒÅÐÈÉ äëÿ âåðû ?

     Êàíàäå (ïðîèçâîäèòåëü IMMUNOCAL) , îãðîìíîå êîëè÷åñòâî ëþäåé ïðèíèìàþò Èììóíîêàë (åæåäíåâíî !), êàê äëÿ Ïðîôèëàêòèêè íå ðàçó íå áîëåÿ Ãðèïïîì èëè äð ÎÐÇ.
    Òàê ïüþò è äëÿ èçëå÷åíèÿ îò ñåðü¸çíûõ çàáîëåâàíèé.
    Íà ñåãîäíÿøíèé äåíü ëó÷øåãî / àíàëîãà íå ñóùåñòâóåò !

    3 Ñîñòàâëÿþùåå èç Ìîëî÷íîé Ñûâðîòêè â âèäå ïîðîøêà – Ïðîòåèíà , ìîæíî ïèòü ñ ëþáûì ñîêîì.  çàâèñèìîñòè îò äîçû ðåçóëüòàòû íàëèöî , â òå÷ íåñêîëüêèõ äíåé !  äàííûé ìîìåíò åñòü êëèåíò Ðàê ˸ãêèõ ñ ìåòàñòàçàìè , ïîñëå Áåçóñïåøíîé õèìèè è ðàäèî òåðàïèè.Ïü¸ò ìåñÿö.
    Âñå ïîêàçàòåëè óëó÷øåííû ! Âñòà¸ò è ÷óâñòâóåò ñåáÿ ïðåâîñõîäíî !
    Íèêàêîãî ×óäà ! – ÃËÓÒÀÒÈÎÍ – âîò è âñ¸ , íî íà óðîâíå êëåòêè.

    Íå Âåðèòå, Ìîãó ïî òåëåôîíó ñîåäåíèòü ñ íèì,ñ äðóãèìè ?
    Òîæå íå ïîâåðèòå ?
    Íó òîãäà ...
    Ìîæíî ñâÿçàòü Âàñ ñ Èññëåäîâàòåëüñêèì Îòäåëîì Óíèâåðñèòåò McGill Êàíàäà ?

    Õîòèòå ?

    Ìîæíî ñâÿçàòüñÿ ñ Âåäóùèìè Ïðîôåññîðàììè Immunocal,
    Dr. Gustavo Bounous

    Dr. Gustavo Bounous is a trained surgeon and the 1965 reciient of the distinguished Medal of the Canadian Royal College of Physicians and Surgeons. He was a career investigator for the Medical Research Council of Canada. He did experimental surgery and research at the Montreal General Hospital, a teaching hospital affiliated with McGill University.
    http://www.viddler.com/explore/life/videos/29/


    ÄÀÆÅ Ñ ÄÎÊÒÎÐÎÌ MD Jimmy Gutman ÑÂßÇÀÒÜÑß ÌÎÆÍÎ ?
    Êòî åòî ? Îäèí èç âåäóùèé Èììóíîëîã ìèðà.
    Èëè Âàì íå Àâòîðèòåò ?
    Íàáåðèòå íà ïîèñêå Èíòåðíåòå gooole.ru Jimmy Gutman, MD, FACEP


    Åñëè åñòü Æåëàíèå Óçíàòü – Ïîæàëóéñòà !


    Äóìàþ – “ ïîìåò îì òèáåòñêèõ êîøåê ” íå ñìîæåò çàâîåâàòü òàêîå ïðèçíàíèå, è âíèìàíèå ñî ñòîðîíûé Ìåäèöèíû è Ëå÷ÿùèõ ! òåì áîëåå îò ìåíÿ

    Ïî Ïîâîäó Áèîõèìèè…..
    Âëîæåíèÿ Âëîæåíèÿ
    Ïîñëåäíèé ðàç ðåäàêòèðîâàëîñü gost_vash; 12.04.2008 â 03:24.

  11. Àâàòàð äëÿ gost_vash Íîâè÷îê
    ñîîáùåíèé
    7
    Ïîëåçíàÿ Èíôîðìàöèÿ äëÿ Èíôeêöèàíèñòîâ è Âèðóñîëîãîâ ,îñîáåííî !

    Ñìîòðèòå Ïðèëîæåíèÿ
    Âëîæåíèÿ Âëîæåíèÿ
    Ïîñëåäíèé ðàç ðåäàêòèðîâàëîñü gost_vash; 12.04.2008 â 03:07.

  12. êàòåãîðèÿ: ìåäèöèíñêèå ÝÊÑÏÅÐÒÛ, ìîäåðàòîðû, êîíñóëüòàíòû Nedug.Ru :::::
    ñîîáùåíèé
    1,998
    Äà íå Âû çàäåëè ìåíÿ, à ýòîò ôàíàòè÷íûé áëåñê ñêâîçÿùèé èç êàæäîé ñòðî÷êè. Ëàäíî áû ýòî êàñàëîñü àâòî èëè HI-FI-à òóò çäîðîâüå âåäü êòî-òî æå â ýòèõ çàìóäðåííûõ òåêñòîâûõ êîëëèçèÿõ íå ïîéìåò ÃËÀÂÍÎÃÎ!!! Ýòî ÍÅ ËÅÊÀÐÑÒÂÎ è èì íå ÁÓÄÅÒ. Áûëè áû íà ñàìîì äåëå ïîäòâåðæäåííûå ñâåäåíèÿ î ÊËÈÍÈ×ÅÑÊÎÉ ýôôåêòèâíîñòè õîòÿ â ìàëåíüêîé òîëèêè òîãî ÷òî âàì äîáëåñòíî ñêîïèðîâàíî-íå áûëî áû ÍÈÊÀÊÈÕ ïðîáëåì ñ ðåãèñòðàöèåé. Ó Âàñ ïðîèçîøëî ëîãè÷åñêàÿ ïîäìåíà ïîíÿòèé:
    Åñëè À (îêñèäàòèâíûé ñòðåññ ) ïðèâîäèò ê  (ðÿäó çàáîëåâàíèé)-òî Ñ (àíòèîêñèäàíòû-ËÞÁÛÅ ïðè÷åì)-óìåíüøàþò à (êîëè÷åñòâî ñâîáîäíûõ ðàäèêàëîâ)-òî îòñþäà ñëåäóåò Ä (îíè èçëå÷èâàþò) òî âñåõ áîëåçíåé Â. Òàê âîò (âû òî ýòî íàâåðíÿêà çíàåòå), íî íå ïîñâÿùàåòå îêðóæàþùèõ â ñâîèõ, çàìåòüòå, ÊÎÐÛÑÒÍÛÕ èíòåðåñàõ. Ê ñîæàëåíèå âñå íàìíîãî ñëîæíåé: ýòî êàñàåòñÿ è âñàñûâàíèå "ãîòîâûõ" ôîðì, èõ äàëüíåéøåãî ìåòàáîëèçìà (ïåðåãðóçêà ïî îòäåëüíûì àìèíîêèñëîòàì), ðåàêöèè íà óðîâíå êëåòîê íà ïîâûøåíèå óðîâíÿ îòäåëüíûõ êîìïîíåíòîâ (ãëþòàòèîíà). Êàê ðàç ìíîãèå ðàáîòû íå ïîêàçûâàþò êîððåëÿöèè ìåæäó ïðèåìîì ãëþòàòèîíà è ïîâûøåíèå åãî óðîâíÿ â êðîâè-(ïî íåêîòîðûì åãî ïðåäøåñòâåííèêàì-ýòî ïîäòâåðæäàþò, íî ýòî íå ïðèâîäèò ê ÇÍÀ×ÈÌÎÌÓ ñíèæåíèþ â ñâîáîäíûõ ðàäèêàëîâ (hydroxyl radical ('OH), nitric oxide (NO') and peroxynitrite (ONOO-) â î÷àãå ïîðàæåíèÿ. Áîëüøèíñòâî òåîðèòè÷åñêèõ îáîñíîâàíèé ïîëó÷åííûõ in vitro è íà ìîäåëÿõ æèâîòíûõ íå ðàáîòàþò íà ÷åëîâåêå. È ê òîìó æå ãëþòàòèîí ÌÀËÀß ÷àñòü àíòèîêñèäàòèâíûõ ñèñòåì.  êëåòêè èõ äî 66000!!! ðàçíûõ ïðäóêòîâ ïðèñîåäèíåíèÿ. Ïî ÂÑÅÌ ãðóïïàì àíòèîêñèäàíîâ íà ñåãîäíÿøíèé ìîìåíò íåò äîêàçàòåëüíûõ äàííûõ ïî ÏÐÎÒÈÂÎÏÓÕÎËÅÂÎÌÓ ýôôåêòó. Ïðî èíôåêöèè äàæå âàì è íå ñòîèò íà÷èíàòü.
    Ïîñëåäíèé ðàç ðåäàêòèðîâàëîñü Chill; 12.04.2008 â 14:43.
    Àíäðååâ Àíäðåé Âëàäèìèðîâè÷
    âðà÷-èíôåêöèîíèñò

  13. Àâàòàð äëÿ gost_vash Íîâè÷îê
    ñîîáùåíèé
    7
    Ïðèâåòñòâóþ !
    Äàâíåíêî íå áûë...

    Õîòåë ïîäåëèòüñÿ ñâåæåé èíôîðìàöèåé î òîì ,÷òî ñîâåòóåò ôðàíöóçñêèé ó÷¸íûé Ëþê Ìîíòàíüå â îòíîøåíèè Èììóíîêàëà (Immunocal).

    Ñìîòðèòå ïðèëîæåíèå.

    Äà...
    ôðàíöóçñêèé ó÷¸íûé Ëþê Ìîíòàíüå - Íîáåëåâñêèé Ïðèç¸ð ïî ìåäèöèíå 2008 ãîäà !
    Ïðîôåññîð Ëþê Ìîíòàíüå, ïðåçèäåíò Âñåìèðíîãî ôîíäà ïî íàó÷íûì èññëåäîâàíèÿì è ïðåäóïðåæäåíèþ ÑÏÈÄà
    http://www.strf.ru/organization.aspx...221&d_no=15975

    Âñåõ áëàã!
    Âëîæåíèÿ Âëîæåíèÿ

  14. Àâàòàð äëÿ sergei20 Ìóäðåö
    ñîîáùåíèé
    911
    Ïî÷èòàë êëèíè÷åñêèå èññëåäîâàíèÿ â ìåäëàéí, à òàêæå, ïðèâåäåííûå àâòîðîì ïðåäûäóùåãî ïîñòà. Î÷åíü ñêðîìíûå ïî äèçàéíó èññëåäîâàíèÿ, ÿâíî íåäîñòàòî÷íûå äëÿ òîãî, ÷òîáû ðåêîìåíäîâàòü òàêîå ñðåäñòâî ê èñïîëüçîâàíèþ. Ñïåêóëÿöèè èìåíàìè Íîáåëåâñêèõ ëàóðÿòîâ â òàêîé ôîðìå íå óìåñòíû.

    î òîì ,÷òî ñîâåòóåò ôðàíöóçñêèé ó÷¸íûé Ëþê Ìîíòàíüå â îòíîøåíèè Èììóíîêàëà
    Ïðî÷èòàë - íè÷åãî íå ñîâåòóåò.

  15. Àâàòàð äëÿ gost_vash Íîâè÷îê
    ñîîáùåíèé
    7
    Öèòàòà Ñîîáùåíèå îò sergei20 Ïîñìîòðåòü ñîîáùåíèå
    Ïî÷èòàë êëèíè÷åñêèå èññëåäîâàíèÿ â ìåäëàéí, à òàêæå, ïðèâåäåííûå àâòîðîì ïðåäûäóùåãî ïîñòà. Î÷åíü ñêðîìíûå ïî äèçàéíó èññëåäîâàíèÿ, ÿâíî íåäîñòàòî÷íûå äëÿ òîãî, ÷òîáû ðåêîìåíäîâàòü òàêîå ñðåäñòâî ê èñïîëüçîâàíèþ. Ñïåêóëÿöèè èìåíàìè Íîáåëåâñêèõ ëàóðÿòîâ â òàêîé ôîðìå íå óìåñòíû.

    Ïðî÷èòàë - íè÷åãî íå ñîâåòóåò.

    Íó âîïåðâûõ - Íîáåëåâñêèõ ëàóðåàò à íå ëàóðÿò / íà çàìåòêó.

    Âû ïèøèòå Ïî÷èòàë êëèíè÷åñêèå èññëåäîâàíèÿ â ìåäëàéí,
    À Âû ïîíèìàíèå,÷òî òàêîå ìåäëàéí,è êàê òóäà ïîïàë íàòóð ïðîäóêò ?35 ëåò èññëåäîâàíèé íåäîñòà÷íî ??! øòî øóòêà ?!
    À ïðî ñïåêóëÿöèþ,ýò-çðÿ - Íîáåëüñêèé - íàâåðíîå ÿçûê âàì ïîäòÿíóòü íàäîáíî àíãåëüñêèé ...
    Âíèìàòåëüíî ññûëêè
    http://www.optimumimmunehealth.com/prominentdoctors/
    http://www.greathealthsupport.com/do...s/3doctors.pdf
    ÒÀÊÆÅ ÂËÎÆÅÍÈÅ ñìîòðèòåÓñïåõîâ â ïîèñêå !À ïàòåíòû òàêèå ÷òî ó ëåêàðñò òàêèõ íåò-òîÍàïðèìåð ïðîòèâî - ðàêîâîå ëå÷åíèåAnti-cancer therapeutic compositions containing whey protein concentrate

    Abstract This invention relates to a method of treatment of patients having lesions resulting from cancer cells and to an application as an anti-cancer composition of undenatured whey protein concentrate.

    Claims

    The embodiments of the invention in which an exclusive property or privilege is claimed are defined as follows:

    1. A method of prophylaxis of colon cancer of the type induced by dimethylhydrazine in mammals comprising the administration to a patient of an undenatured whey protein concentrate containing at least 9.5% serum albumin, at a daily dosage in the range 8 to 40 grams.

    2. A method for treating cancer, comprising administering to a patient having cancer an undenatured whey protein concentrate containing at least 9.5% serum albumin in amount sufficient to increase the lymphocyte number of the patient.

    3. A method for treating cancer, comprising administering to a patient having cancer an undenatured whey protein concentrate containing at least 9.5% serum albumin in an amount sufficient to decrease the G/L ratio of the patient.

    4. The method of any one of claims 2 or 3 in which the daily dosage level is in the range of 8 to 40 grams.

    5. The method of any one of claims 2 or 3 in which the undenatured whey protein concentrate is prepared from milk and contains substantially all the proteins present in the raw milk.

    6. The method of any one of claims 2 or 3 including administering, in addition, Vitamin B.sub.1 in the amount of about 1.5 to 2.0 mg per 60 grams of undenatured whey protein concentrate.

    7. The method of any one of claims 2 or 3 including administering, in addition, Vitamin B.sub.2 in the amount of about 1.7 to 2.2 mg per 60 grams of undenatured why protein concentrate.

    8. A method of treating cancer in a patient in need thereof comprising the administration to said patient of a substantially undenatured whey protein concentrate, which concentrate comprises substantially all thermolabile whey proteins of the source milk with glutamylcysteine groups and disulfide bonds, in an amount sufficient to replenish depleted intracellular glutathione, enhance immune response and exert anti-cancer effects.

    9. A method of treating cancer in a patient in need thereof comprising the administration to said patient of a substantially undenatured whey protein concentrate, which concentrate comprises substantially all thermolabile whey proteins of the source milk with glutamylcysteine groups and disulfide bonds, in an amount sufficient to increase the lymphocyte number.

    10. A method of treating cancer in a patient in need thereof comprising the administration to said patient of a substantially undenatured whey protein concentrate, which concentrate comprises substantially all thermolabile whey proteins of the source milk with glutamylcysteine groups and disulfide bonds, in an amount sufficient to decrease the G/L ratio of a patient having cancer.

    11. A method of treating cancer in a patient in need thereof comprising the administration to said patient of a substantially undenatured whey protein concentrate, which concentrate comprises at least about 2.4 grams cysteine per 100 grams protein, in an amount sufficient to replenish depleted intracellular glutathione, enhance immune response and exert anti-cancer effects.

    12. A method of claim 8, in which the serum albumin is at least 9.0%.

    13. A method as in any one of claims 8 to 12, in which the daily dosage level is in the range of 8 to 40 grams.

    14. A method as in claim 13, in which the daily dosage level is in the range of 20 to 40 grams.

    15. A method as in claim 14, in which the daily dosage level is in the range of 30 to 40 grams.

    16. A method of treating cancer in patients having lesions of the colon of the type induced by dimethylhydrazine and being in need of treatment comprising the administration to said patient of a substantially undenatured whey protein concentrate, which concentrate comprises substantially all thermolabile whey proteins of the source milk with glutamylcysteine groups and disulfide bonds, in an amount sufficient to replenish depleted intracellular glutathione, enhance immune response and exert anti-cancer effects.

    17. A method as in any of claims 8 to 11 or 16 above, in which selenium is administered in the amount of about 40-60 mcg (calculated as selenium methionine) per 60 grams of undenatured whey protein concentrate.

    18. A method as in any one of claims 8 to 11 or 16 above, in which Vitamin B.sub.1 is administered in the amount of about 1.5-2.0 mg per 60 grams of undenatured whey protein concentrate.

    19. A method as in any one of claims 8 to 11 or 16 above, in which Vitamin B2 is administered in the amount of about 1.7-2.2 mg per 60 grams of undenatured whey protein concentrate.

    20. A method as in any one of claims 2, 3, 8 to 11 or 16 above, in which the following are administered per 60 grams of undenatured whey protein concentrate:

    Vitamin B.sub.1 about 1.5-2.0 mg

    Vitamin B.sub.2 about 1.7-2.2 mg and

    Selenium 40-60 mcg (calculated as selenium methionine).

    21. A method of prophylaxis of colon cancer of the type induced by dimethylhydrazine in mammals comprising the administration to a patient of an undenatured whey protein concentrate, which concentrate comprises substantially all thermolabile whey proteins of the source milk with glutamylcysteine groups and disulfide bonds, at a daily dosage in the range of 8 to 40 grams.

    22. A method as in claim 20 in which the daily dosage level is in the range of 8 to 40 grams. Description

    SUMMARY OF THE INVENTION

    The present invention is based on the surprising discovery that undenatured whey protein concentrate has an enhanced immunological effect. More specifically, this invention relates to the effect of the oral administration of undenatured whey protein concentrate (WPC) on host resistance to the development of chemically induced cancer and also the effect of such oral administration on the inhibition of cancer.

    In U.S. application Ser. No. 298,971 and Ser. No. 417,246, and also in Bounous et al "Dietary Whey Protein Inhibits the Development of Dimethyl-hydrazine induced Malignancy" (1) we described experiments showing that continuous feeding of WPC in the diet inhibits the development (number and size of tumours) in the colon of a mouse over a period of 24 weeks of dimethylhydrazine (DMH) treatment. This anti-tumour effect could be caused by increased resistance of target cells to the carcinogen and/or a direct inhibitory effect of WPC on the cancer cells. A subsequent series of experiments (2) where animals were fed Purina diet for the first 20 weeks of DMH and then switched to WPC diet for the remaining 8 weeks of DMH treatment, suggested some inhibitory effect of WPC feeding on cancer cells.

    Most recently (3) a group of French scientists confirmed in vitro a direct inhibitory effect of WPC on human cancer cells. Indeed similar studies in vitro with human breast cancer cells have shown that bovine serum albumin (BSA) is the factor exerting inhibition of cancer cell replication (4).

    We have also shown that this activity of WPC is specifically dependent upon the glutamylcysteine groups (substrate for GSH synthesis) present in the BSA fraction of WPC (U.S. Ser. No. 563,794). Interestingly, the introduction of the cysteine delivery system ozothiazolidine-4-carboxylate (OTZ) (ozothiazolidine-4-carboxylate), while enhancing glutathione (GSH) levels in normal cells, was found to result in feedback inhibition of the GSH cycle in human tumour cells (5). This differential effect of OTZ was recently confirmed in vivo (6). The previously described direct inhibitory effect of WPC (3) and more specifically of BSA (4) could be explained therefore by the release during incubation of a potent cysteine delivery system such as glutamylcysteine.

    We have therefore reached the following conclusions:

    1) BSA is the protein fraction of WPC that we found to be primarily responsible for the GSH promoting activity of WPC. This activity which we believe to be the basis for the immuno enhancing and anticarcinogen effect of WPC, is specifically dependent upon the glutamylcysteine groups (substrate for GSH synthesis) present in the BSA fraction of WPC.

    2) The molecular weight of BSA is 66,267 hence quite different from the KW of the anti-cancer factor patented by Villadsen (MW 500-20,000). (7).

    3) Our earlier findings (1,2) could be explained as follows: During DMH treatment, WPC feeding, by increasing cellular GSH, protects the target cells against the effects of the carcinogen. In addition, increased availability of substrate for GSH synthesis could inhibit replication of formed cancer cells.

    4) We have now established the importance of a high level of serum albumin (BSA) in the WPC in providing a substrate for GSH synthesis. We can conclude that dietary whey protein concentrate in undenatured form and containing .gtoreq.10% BSA exerts an anti-tumour effect.

    BRIEF DESCRIPTION OF THE DRAWINGS

    FIG. 1 illustrates the liver glutathione content in male mice C57BL/6NIA fed undenatured whey protein (U-Lacp), denatured whey protein (D-Lacp), casein, egg white protein or Purina diet-fed counterparts at age 10 weeks, 27, 20 and 21 months.

    FIG. 2 illustrates the heart glutathione content of male mice C57BL/6NIA fed undenatured whey protein (U-Lacp), denatured whey protein (D-Lacp), casein, egg white protein or Purina diet-fed counterparts at age 10 weeks, 17, 20 and 21 months.

    FIG. 3 illustrates the effect of various sources of whey protein concentrate and casein (20 g/100 g. diet) on spleen PFC response to 5.times.10.sup.6 SRBC in mice.

    DETAILED DESCRIPTION

    Definitions

    (a) Whey Protein

    Whey proteins are the group of milk proteins that remain soluble in "milk serum" or whey after precipitation of caseins at pH 4.6 and 20.degree. C. The major whey proteins in cow's milk are beta-lactoglobulin (.beta. L), alpha-lactalbumin (.alpha. L), immunoglobulin and serum albumin (SA).

    The product of industrial separation of this protein mixture from whey is called "whey protein concentrate" (WPC) or isolate. The WPC that was used in most of our early experiments is from bovine milk (Lacprodan-80 from "Danmark Protein A.S."). Use in its undenatured state is indicated as U-Lacp, and in its denatured state is indicated as D-Lacp. Lactalbumin (L) is the term traditionally used to define WPC.

    (b) c=casein;

    (c) SRBC=Sheep red blood cells;

    (d) PFC=Plaque forming cells (spleen): enumeration of PFC in spleen is used to assess the humeral immune response to SRBC injection;

    (e) GSH=Glutathione (L-gamma-glutamyl-L-cysteinylglycine);

    (f) DMH=1,2-Dimethylhydrazine;

    (g) The defined formula diets tested varied only in the type of protein;

    (h) Whey of bovine milk contains approximately 6 g per liter protein, most of the lactose, mineral and water soluble vitamins.

    Diets Used in These Studies

    Referred to below in Table 3

    Diets are prepared in the following way: 20 g of selected pure protein, 56 g of product 80056 protein free diet powder containing corn syrup, corn oil, tapioca starch, vitamins and minerals (Mead-Johnson Co. Inc., U.S.A.), 18 g cornstarch, 2 g wheat bran; 0.05 g Nutramigen vit-iron premix (Bristol-Myers, Ontario, Canada), 2.65 g KCl; 0.84 g NaCl. The carbohydrate and lipid components of our formula diets were the same. The only variable in the various purified diets was the type of protein (20 g protein/100 g diet). At this concentration in diet all the different proteins tested provided the daily requirements of essential amino acids for the growing mouse (8).Vitamins and minerals were the same in each set of experiments and were added in the amount necessary to provide daily requirements for the growing mouse (9, 10). Table 1, below, indicates the variation in suggested vitamin requirements for mouse diets and their contents in some of our formulations. Therefore all the formula diets used in our experiments were designed to provide adequate nutrition as demonstrated by normal body growth, serum protein (9) and by the absence of hair loss, dermatitis, cataract, ataxia, fatty liver etc. The latter symptoms were of course present in very old mice and were related to the aging process.

    TABLE 1 __________________________________________________ ________________________ VITAMIN AND MINERAL CONTENT OF TEST DIETS (amount/100 g diet) JACKSON (9) (range of amount recommended in TEST Jackson labora- DIETS torics diets) __________________________________________________ ________________________ VITAMINS: AIN 76(10) Vitamin A, IU 1295 ............ 1800 24-550 400 Vitamin D, IU 260 ............ 360 14-506 100 Vitamin E, IU 11.6 ............ 18 1-2.7 5.0 Vitamin K, mg 0.06 ............ 0.09 -- 0.005 Thiamine (Vitamin B1), .... ............ 0.34 0.63 0.22-.99 0.60 mg Riboflavin (Vitamin B2), .... ............ 0.38 0.69 0.24-1.1 0.60 mg Vitamin B6, mg 0.26 ............ 0.36 0.1-0.55 0.70 Vitamin B12, mg 0.0012 ............ 0.054 .0039-.0055 0.001 Niacin, mg .... ............ 5.1 9.2 26-143 3.0 Foilc add, mg 0.063 ............ 0.12 0.05-0.27 0.2 Pantothenic acid, mg 1.93 ............ 3.38 1-5.5 1.6 Biotin, mg .... ............ 0.031 0.058 0.019-0.165 0.02 Vitamin C, mg 53.3 ............ 65 -- -- Choline, mg .... ............ 44 76 49-145 100 Inositol, mg .... ............ 19.8 19.8 -- -- MINERALS: AIN 76 Calcium, mg .... ............ 430 # 520 Phosphorus, mg 260 ..........# 400 Magnesium, mg 63.2 ..........# 50 Iron, mg .... ............ 7.9 3.5 Zinc, mg .... ............ 3.57 # 3.0 Copper, mg .... ............ 0.47 # 0.60 Iodine, mg .... ............ 0.023 0.02 Sodium, mg .... ............ 232 100 Potassium, mg 997 360 __________________________________________________ ________________________ # After Minerals Analysis (9) Hoag W. G., Dickie M. M. "Nutrition: in Green E. L. (Ed) Biology of the Laboratory Mouse McGrawHill NY 1966 pp 39-43. (Jackson was our supplier). (10) The Mouse in Biomedical Research, vol III Eds FosterH. L., Seall J. D., Fox J. B., Academic press 1983, NY pp 57-58

    Immunization for Plaque Assays

    The diet-fed mice were immunized by an intravenous injection of 5.times.10.sup.6 washed sheep red blood cells obtained weekly from Institut Armand-Frappier, Laval des Rapides, Quebec, Canada.

    Plaque Forming Cell (PFC) Assay

    The method used for assaying IgM plaque forming cells was essentially the one described by Cunningham and Szenberg (11), with certain minor modifications. Spleen cell suspensions were prepared by gently tamping the spleen through a 50-mesh stainless steel screen, and collecting the cells in balanced salt solution (BSS) supplemented with 10% heat-inactivated calf serum (Grand Island Biological Company, Montreal, Quebec, Canada). The spleen cells were washed and made up to 15 ml with BSS. Sheep red blood cells were washed twice and made up to a 20% concentration. Guinea pig serum (Grand Island Biological Company, Montreal, Quebec, Canada) as a source of complement was diluted 1/15 with BSS. All stock solutions were kept on ice water until used. The test consisted of mixing 0.05 ml of spleen cells, 0.15 ml of sheep red blood cells and 0.75 ml of the complement solution in a test tube at 37.degree. C. The whole mixture was immediately withdrawn and put into slide chambers, sealed with warm paraffin wax, and incubated at 37.degree. C. for 45 to 60 min. The number of plaque forming cells was counted and their total number per spleen estimated by multiplying the number of plaque forming cells in each sample (0.05 ml spleen cells) by 300. The values are expressed per total organ rather than per 10.sup.6 spleen cells, since this appears to reflect more accurately the functional status of the spleen per se.

    Mice were assayed for the plaque forming cell response to sheep red blood cells normally on the fifth day after immunization when the response was shown to peak or, in the kinetic study, on days 3, 4, 5 and 6 post-immunization.

    Statistics

    The mean plaque forming cell values were compared among the dietary groups using either Student's test, when two groups were being compared, or the analysis of variances (ANOVA) for more than two groups. Because of the heterogeneity of variances among groups, the adjustment given by Brown and Forsythe was used.

    Spleen Glutathione Content

    Ninety milligrams of mouse spleen were weighed using a Mettler PM-300 balance and samples varied from 90 mg by less than 5 mg (5%). The samples were then homogenized in 5-sulfosalicylic acid (5% w/v). Homogenates were centrifuged for 5 min in a microfuge at 10,000 x g. The assay was carried out using the supernatants on the same day according to the methods of Anderson (12). Values are expressed as .mu.mol per g/wet tissue.

    Tissue Glutathione Assay

    Ninety milligrams of mouse heart or liver were homogenized in 5-sulfosalicylic acid (5% w/w). Homogenates are centrifuged for 5 minutes in a microfuge at 10,000 x g. The assay is carried out using the supernatants on the same day according to the method of Anderson (12), Values are expressed as .mu.mol/g wet tissue.

    After three months on either diet initiated at age 17 months, GSH content was found to be higher in the liver and heart of U-Lacp (undenatured whey protein Lacprodan-80) fed mice compared to the D-Lacp (denatured whey protein Lacprodan-80), casein, egg white protein or Purina diet-fed counterparts (FIGS. 1 & 2). The GSH values in heart and liver of mice fed Purina laboratory chow was similar at age 10 weeks, 17, 20, 21 months. The U-Lacp diet appears to enhance the GSH content of heart and liver above "normal" values after 3 and 4 months of continuous feeding (FIGS. 1 & 2).

    In addition, after three weeks on the U-Lacp diet, spleen GSH content is increased during the antigen driven clonal expansion of the lymphocytes in young adult C3H/HeN mice as compared to a decline in controls fed D-Lacp, casein or egg white protein diets. In old C57BL/6NlA mice, long term feeding of U-Lacp diet results in a moderate but sustained increase in liver and heart GSH levels (FIGS. 1 and 2). The GSH enhancing activity of WPC is restricted to its undenatured form (U-Lacp).

    TABLE 2 ______________________________________ AMINO ACID COMPOSITION (g/100 g protein) Whey Protein Egg White Amino Acid Concentrate* Protein** ______________________________________ Aspartic acid 11.3 7.9 Threonine 7.2 4.4 Serine 6.1 7.9 Glutamic acid 20.1 14.1 Proline 6.6 3.8 Glycine 2.0 3.7 Alanine 5.4 7.6 Valine 6.5 7.8 Isoleucine 6.7 6.5 Leucine 11.2 8.8 Tyrosine 2.9 4.2 Phenylalanine 3.1 6.4 Lysine 9.5 6.0 Histidine 1.9 2.2 Arginine 2.7 5.9 Methionine 2.2 3.9 Cysteine 2.4 2.4 Tryptophan 1.7 1.5 ______________________________________ *Lacprodan-80 from Danmark Protein A/S, Copenhagen,. Denmark, 1986; used in these experiments. **Values calculated from "Amino Acid Content of Foods", U.S.D.A., 1957. Values from cysteine analyzed by Sigma on samples used = 2.38 g/100 g protein and in our laboratory = 2.4 g/100 g protein.

    This property is not solely due to the high cysteine content of WPC because another protein source with similar cysteine content (egg white) (see Table 2) does rot exhibit this biological activity. This property of U-Lacp does not depend specifically on its nutritional efficiency as evaluated by body weight, serum proteins, and food consumption, but appears to depend on the primary, secondary and tertiary structure of the protein in its native form.

    Some of the previously discussed methods of increasing intracellular levels of glutathione concentration are either toxic (13) or dangerous owing to the risks related to the initial phase of glutathione depletion (14, 15). The methods involving the use of gamma-glutamylcysteine (16), athiazolidine (17) or glutathione esters (18) (U.S. Pat. No. 4,784,685) offer an interesting possibility for short term intervention. However, their long term effectiveness in producing sustained elevation of cellular glutathione has not been shown, nor has the possible toxicity of their long term use been disproved. Indeed, glutathione and glutathione disulfide were found to be positive in the most commonly used short term tests for carcinogenicity and mutagenicity (13). Relevant to our invention are recent data indicating specifically that a lack of the GSH precursor, cysteine, rather than a decrease in biosynthetic enzyme activities is responsible for the deficiency of GSH noted in aging animals (19). Similarly, the fall in cytosolic GSH in the liver of chronic ethanol fed rats does not appear to be caused by a limitation in the capacity of gamma-glutamylcysteine synthetase activity (20).

    Data in FIGS. 1 and 2 show that the concentration of liver and heart glutathione in control Purina fed mice remains very constant over time. On the other hand a moderate but sustained elevation of tissue GSH was noted in mice fed the nutritionally equivalent whey protein (U-Lacp) diet. Only minuscule quantities of glutathione and no breakdown products that can be readily attributed to glutathione are excreted in urine (21). The magnitude of change in cellular glutathione concentration that can be achieved may be quite limited, perhaps reflecting the critical importance of this molecule and the attendant tight regulatory control. Glutathione itself serves as a negative feedback on the GSH synthetic enzymes, which obviously limits cellular capacity to increase GSH concentration (22). Glutathione reductase maintains GSH in its predominant reduced form (.gtoreq.90%). This serves both to maintain this functional state and also to control cellular concentration since reduced glutathione (GSH) cannot cross the membrane, whereas the oxidized form (GSSG) can and does afflux, resulting in decreased total glutathione. Besides these enzymes, gamma glutamyltranspeptidase (GGT) is important in GSH metabolism. GGT serves as a salvage pathway for glutamyl moieties at the cell membrane level, passing them back into the cytosol to be used in GSH synthesis. Increased activity of this enzyme has been associated with elevated GSH concentration in a number of cell lines and malignant tissues (23, 24).

    It is advantageous to include Vitamin B.sub.1 (thiamine) in a diet that results in elevated GSH. Thiamine is involved in the transketolase reaction of the pentose phosphate shunt yielding NADPH (GSSG is reduced back to GSH by NAPPH; GSH reductase).

    Vitamin B.sub.2 (riboflavin) is also an advantageous addition. Flavin mononucleotide (FMN) and flavin adenin dinucleotide (FAD) are synthetized sequentially from riboflavin and are involved in GSH reductase.

    Some milks, especially those from New Zealand, are low in selenium. Selenium is contained in GSH peroxidase. Mammals deficient in selenium have markedly decreased peroxidase activity. Therefore glutathione formation which is advantageous for its anticancer effect requires an adequate level of selenium.

    If we assume a dosage level of 60 grams undenatured whey protein as a daily intake, the recommended levels of Vitamin B.sub.1, Vitamin B.sub.2 and selenium are as follows:

    Vitamin B.sub.1 1.5-2.0 mg

    Vitamin B.sub.2 1.7-2.2 mg

    Selenium Methionine 40 mcg.-60 mcg.

    The effects of a small increment in cellular GSH are greater than expected. For example, there are many reports of human and murine tumour cell lines selected in vitro for resistance to a variety of chemotherapeutic agents. In a number of these cell lines cellular GSH is increased consistently by 2-fold compared to the drug sensitive parental cell line, despite the fact that the level of drug resistance is often much greater, e.g. as much as 30-fold (24, 25, 26). In these cell lines, depletion of cellular GSH by selective inhibition of synthesis restores drug sensitivity to the resistant cells. This is effective only if the GSH depletion is maintained throughout the drug-treatment period.

    Given the fact that cellular GSH is very tightly regulated, that a 2-fold increase may be maximal, and that the effect of small increments in GSH may be amplified by a variety of GSH-utilizing enzymes (e.g. glutathione peroxidase, glutathione-S-transferase), the reproducible change in GSH concentration observed in animals fed the whey-rich diet is likely to have biological importance. The chronic nature of this augmentation may contribute significantly to this effect.

    Our findings show that in mice fed a casein diet the number and size of DMH induced colon carcinoma were reduced by a factor of 0.3 and 0.4 respectively in comparison to Purina fed controls (Table 3, below). However, in mice fed the whey protein diet with similar nutritional efficiency the number and size of DMH-induced colon carcinoma were reduced four fold in comparison to the Purina fed controls (Table 3, below). DMH-induced colon tumours appear to be similar to those found in humans as far as type of lesions and chemotherapeutic response characteristics are concerned (27, 28).

    The superiority of the anti-cancer effect of whey protein in comparison to casein has been reported in our previous study (1). About 80% of the proteins in bovine milk are caseins and the remaining 20% are whey proteins (29, 30). In addition, using the traditional process of preparing casein, the amount of whey protein co-precipitated along with the casein varies from about 40 to 60% of the total amount of whey protein present in the milk (31). Therefore it is conceivable that the minor anti-cancer effect seen with casein could be due to the relatively (to caseins) small amount of whey protein coprecipitated with it. It is apparent from the above described studies that the antitumour activity of the dairy products is in the protein fraction and more specifically, as our invention demonstrates, in the whey protein component of milk.

    The beneficial effect of this dietary WPC supplement is enhanced to the extent that it is a replacement for some or all of the patient's protein intake from other sources.

    SURVIVAL STUDIES

    The Biological Activity is Dependent on the Undenatured Conformation of WPC

    (a) Survival of Old Mice During a Limited Time Period:

    Our study shows that the mean survival time, over a limited observation period of 6-7 months ending when 55% of male C57BL/6NlA mice were dead, is increased by about 30% in mice commenced on the undenatured whey protein (U-Lacp) diet at the onset of senescence (age 21 months) in comparison with "controls" fed the nutritionally equivalent Purina mouse chow. The survival curve of Purina fed mice was very similar to that of casein diet-fed mice. However, in the subsequent four months, mice on undenatured whey protein diet were switched to a denatured whey protein concentrate (D-Lacp) diet. During this period, the time of death of the remaining whey protein diet-fed mice became similar to that of their casein diet or Purina-fed counterparts. Throughout the study repeat bioassays of PFC formation confirmed the correlation between host immunoenhancement and undenatured state of WPC in diet as indicated in FIG. 3. In the second part of the study, when the difference between survival curves began to narrow, the immunoenhancing property of WPC was absent although its nutritional quality was preserved (D-Lacp). Throughout the entire study no significant intergroup difference was seen in calorie intake, and body weight. Since longevity is dependent primarily upon the genome of the individual it is unlikely that delayed mortality over a limited period of time would have influenced overall longevity.

    TABLE 3 __________________________________________________ ________________________ Effect of dietary milk protein on animal growth and tumour development in A/J mice treated with the carcinogen 1,2-Dimethylhydrazine. Whey Prot. Casein Purina Pur/Whey Pur/Cas 28 Weeks.sup.a 28 Weeks.sup.a 28 Week.sup.a 20/8 Weeks.sup.b 20/8 Weeks.sup.b __________________________________________________ ________________________ Initial 21.7 .+-. 0.5 21.5 .+-. 0.7 21.9 .+-. 0.8 21.9 .+-. 0.4 22.0 .+-. 0.7 Weight.sup.c (g) Final 21.5 .+-. 0.3 21.8 .+-. 0.4 19.7 .+-. 0.7 21.3 .+-. 1.0 21.0 .+-. 0.6 Weight.sup.c (g) Number of 8.4 .+-. 1.5 24.7 .+-. 3.0 35.9 .+-. 2.6 15.1 .+-. 3.2 21.7 .+-. 4.3 Tumours.sup.c Tumour Area.sup.c 38.8 .+-. 6.4 90.9 .+-. 10.6 160.0 .+-. 11.4 47.9 .+-. 10.4 77.7 .+-. 10.9 __________________________________________________ ________________________ .sup.a) Mice treated with DMH for 24 weeks, and then sacrificed 4 weeks later. .sup.b) Mice treated with DMH for 24 weeks, and then sacrificed 4 weeks later. They were maintained on Purina Mouse Chow for 20 weeks and then switched to either Whey Protein or Casein diet for the remaining 8 weeks. .sup.c) Mean .+-. SEM. ANOVA: solid line(s) connect those means not significantly different (p < 0.05).

    Group Whey Pur/Whey Pur/Casein Casein Number of Tumours Tumour Area

    However, at least in terms of the immunoenhancing effect of the diet, this study could be regarded as a single direction cross-over from test (ULacp) to control (D-Lacp) diets, showing that the biological activity of WPC on survival of old mice is dependent upon its undenatured state and correlating directly with the PFC assay used in our study (as illustrated in FIG. 3).

    (b) Short and Long Term Survival of Mice with DMH-Induced Colon Cancer:

    In DMH treated mice we noticed a difference between mortality by the 28 weeks end point and the survival time to the end of the experiment in relation to dietary protein type. During the first seven months of study, the mice fed undenatured whey protein (U-Lacp) had no death as compared to a 33% mortality observed towards the end of this period in the casein and Purina groups. In the subsequent four months mice on whey protein were fed denatured whey protein (D-Lacp). During this latter period the D-Lacp diet appeared to have no favourable effect on survival in comparison to the casein diet (Table 4, below).

    Throughout the study repeat bioassays of spleen PFC were done to document the physiologic effects of the diets on immune function as reported previously and the stability of these effects. The immunoenhancing effect of the U-Lacp diet was consistently confirmed for the first 7 months of the study; however, in the following four months-(D-Lacp), the immunoenhancing effect previously observed in mice fed the U-Lacp diet was absent. The values of PFC response in relation to either the U-Lacp diet or the D-Lacp diet were consistent with those presented in FIG. 3. This study therefore confirms the hypothesis that the biological activity of WPC on survival of tumour bearing mice is dependent upon its undenatured state correlating directly with the PFC assay used in our study.

    TABLE 4 ______________________________________ Effect of dietary milk protein on short and long term survival in A/J mice treated with the carcinogen 1,2- Dimethylhydrazine for 24 weeks. DIETARY GROUP.sup.b Whey Protein.sup.d Casein Purina ______________________________________ Mortality.sup.a at 28 weeks 0% 33% 33% Survival time.sup.c in weeks 40 41 30 ______________________________________ .sup.a significant by Chi Square analysis: Whey Protein vs. Purina vs. Casein p<0.05. .sup.b Originally 12 mice per group. .sup.c Survival time in weeks from the first dose of carcinogen. Whey protein and Casein differ significantly from Purina, MantelCox test p<0.01. .sup.d Undenatured Whey Protein used from weeks 3 to 28. Denatured Whey Protein used from weeks 28 until end.

    The experiment referred to above which are summarized in Tables 3 and 4 used Lacprodan 80 as a source of undenatured WPC:

    We now prefer to use a whey protein concentrate (WPC) in undenatured form prepared from milk treated in the most lenient way compatible with accepted standards of safety with regard to bacterial contamination. The extremely high solubility index indicated that the proteins present are essentially undenatured, hence demonstrating the leniency of the ultrafiltration process [31]. Although the proteins contained in the concentrates from the other commercially available sources examined were mostly in undenatured form, as indicated by the relatively high solubility of the concentrates, the content of serum albumin and immunoglobulins in these mixtures is below the level activity [31]. These very thermolabile proteins are denatured, hence precipitated and partially lost from whey when high pasteurization temperatures are utilized.

    Our studies also showed that administration of S(n-butyl) homocysteine sulfoximine, which reduces splenic glutathione in half, significantly reduced the humoral immune response of whey protein-fed mice. This was taken as further evidence for the important role of glutathione in the immunoenhancing effect of dietary whey protein (32).

    Tissue glutathione concentration may be increased by administration of gamma-glutamyl-cysteine. Intracellular glutathione increased in the kidney by about 50%, 40-60 minutes after subcutaneous (s.c.) injection in mice, returning to control values 2 hours later (33). The administered gamma-glutamylcysteine is transported intact into the cells, and serves as a substrate for glutathione synthetase (33).

    Advances in amino acid sequencing of food proteins allowed us to investigate the occurrence of glutamylcysteine groups in whey protein and the possible relation to glutathione promotion. Indeed, whey protein concentrate from bovine milk contains substantial amounts of glutamylcysteine groups, unlike casein, which does not increase tissue glutathione when fed to mice (35). The glutamylcysteine groups are located primarily in the serum albumin fraction (six groups/molecule). Glutamylcysteine groups are extremely rare in animal and plant edible proteins. Extensive search of all available data on amino acid sequencing of edible proteins reveals that the Glu-Cys group with a disulfide link is indeed limited to some of the whey protein, and to the ovomucoid fraction of egg white which contains 2 of these groups in a 30,000 mol.wt.molecule (31).

    Our recent (31) data further indicate that the humoral immune response is highest in mice fed a dietary whey protein concentrate exhibiting the highest solubility (undenatured conformation) and, more importantly, a greater relative concentration of the thermolabile bovine serum albumin (.gtoreq.10%) and immunoglobulins. In addition, the mice fed this type of whey protein concentrate exhibit higher levels of tissue GSH. The glutamylcysteine groups (rare in food protein) and the specific intramolecular bond as related to the undenatured conformation of the molecule are considered to be key factors in the glutathione-promoting activity of the protein mixture.

    Recent experiments in Japan [36] showed that spleen cells of BALB/c male mice fed 25 g of our undenatured whey protein concentrate (WPC) (for which the Trademark name "Immunocal" has been applied) per 100 g diet for 4 weeks had an increased immune response to SRBC in vitro and a high content of L3T4+ cells (12.58.times.10.sup.6 .+-.1.36) than mice fed an isocaloric diet with 25 g. pure casein/100 g. diet (3.69.times.10.sup.6 .+-.0.50). Similarly, the speen L3T4+/LYt-2+ ratio was 1.36.+-.0.07 in undenatured WPC fed mice and 0.55.+-.0.07 in casein-fed controls (P<0.001). Conversely, the relatively high concentrations of the thermosensitive serum albumin and immunoglobulins resulting from the low degree of pasteurization of milk in our WPC, may reflect more closely the pattern of raw milk. These data lend support to the hypothesis that the thermolabile Glu-Cys containing proteins such as serum albumin in undenatured conformation are crucial elements for the biological activity of whey protein concentrate.

    Suitable bovine whey protein concentrate (WPC) has been prepared by the "Service de recherche sur les aliments du Ministere de l'agriculture du Quebec" in St-Hyacinthe, Quebec, Canada, with the following characteristics: pure protein content 75% (the rest mostly lactose, some fat and moisture); solubility index: (pH 4.6); 99.5%. Protein composition as of total whey protein measured by polyacrylamide gel electrophoresis (31) was: beta-lactoglobulin 59.1.+-.4.0; alpha-lactalbumin: 6.6.+-.0.7; serum albumin: 9.7.+-.1.0; immunoglobulin 24.6.+-.2.6 (mean.+-.SD). The solubility index should preferably be above 99%.

    The serum albumin of about 10% of the total whey protein was almost twice the corresponding value found in other commercially available whey protein concentrates that have been examined. It is believed that a serum albumin level .gtoreq.10% is highly advantageous to improving the immune system.

    Serum albumin includes a substantial amount of glutamyl cysteine which is a substrate for glutathione synthesis in the body. The role of glutathione is discussed in detail in or article "The Biological Activity of Undenatured Dietary Whey Proteins: Role of Glutathione", Clin. Invest Med 14: 296-309, 1991 (31), which is incorporated by reference in its entirety.

    Immunoglobulin in the range of about 25 to 30% of total whey protein is also important. Pasteurization at 72.degree. C. for 13 seconds resulted in an immunoglobulin level of 28.+-.2%. We have found it possible to achieve a serum albumin level as high as 14.+-.1% with milk pasteurized at 72.degree. C. for 13 seconds.

    Upon bacteriological analysis no staph, salmonella, B cereus, or E coli were isolated in either the WPC prepared by the "Service de recherche sur les aliments du Ministere de l'agriculture du Quebec" or in the sample pasteurized at 72.degree. C. for 13 seconds. Other samples were prepared by heating the milk to 63.degree. C. for 30 minutes, with good results.

    30 ml of heparinized blood may be used to determine the glutathione content of blood mononucleated phosphate buffered saline adjusted so that there are 10.sup.7 cells per tube. After centrifugation 900 ml of water is added to the pellet to lyse all the cells. To each aliquot is added 30% sulfosalicylic acid for a final concentration of 3% in 1 ml. After 15 minutes incubation, the samples are centrifuged, and the clear supernatant is used for the biochemical assay according to the method of Anderson [37]. Values are expressed as nanomol (nMol) per GSH/10.sup.7 cells. Blood lymphocyte subsets may be determined by flow-cytometry.

    The total serum protein, including the albumins and the immunoglobulins may be determined by the Biuret method. The level of Immunoglobulin A (IgA), Immunoglobulin G (IgG) and Immunoglobulin M (lgM) may be measured by immunonephlometry.

    The presence of glutamylcysteine groups in the serum albumin component of the whey protein concentrate is considered to be a key factor in the glutathione-promoting and immunoenhancing activity of the protein mixture of the undenatured WPC. Our laboratory studies indicate that whey protein concentrates from other sources did not produce significant biological activities even though they exhibited similar nutritional efficiency. The percent serum albumin concentration in these products is (as mean.+-.SD) respectively: 4.+-.1 in Promod (Ross laboratories), 4.+-.1 in Alacen 855 (New Zealand Dairy), 4.8.+-.1 in Lacprodan-80 (produced from 1989 by Danmark Protein), 4.+-.0.1 in Sapro (Sapro, Montreal), 4.+-.1 in Savorpro-75 (Golden Cheese, Calif., USA), 5.+-.1 in Bioisolate (Lesueur, Isolates, Minn.) [8] and 4.3.+-.1 in Promix (Dumex, Quebec). Similarly, the content of the other thermolabile protein, immunoglobulin, was about half the value of the undenatured WPC used in this study.

    The results indicate that undenatured whey proteins by providing specific fuel for glutathione replenishment in the immunocytes could represent an adjuvant to other forms of therapy.

    Historically, and up until now, bacteria and spores in milk were reduced by thermal treatment (pasteurization). In order to be effective, that method inevitably produced denaturation, and hence subsequent precipitation and loss in the curd of a substantial amount of the most thermolabile and presumed biologically active fractions of serum albumin and immunoglobulin.

    Our objective is to obtain a whey protein concentrate (w.p.c) containing the proteins in proportion and conformation as close as possible to that of raw milk, compatible with accepted safety standards of bacterial content. Up until now we have utilized the lowest acceptable level of heat treatment of milk in order to preserve thermolabile whey protein.

    An alternative to heat treatment is a method based on membrane microfiltration. Utilizing Bactocatch (Alfa-Laval Ltd. Scarborough, Ontario) we can obtain a permeate by special membrane microfiltration of the skimmed milk whose bacteria content has been reduced to less than 0.5% of original input levels.

    This permeate is then treated with rennet and the proteins in the whey supernatant concentrated by a lenient procedure to obtain the desired undenatured whey protein concentrate. The membrane microfiltration concept is an alternative to the heat treatment of milk as an appropriate way to preserve heat labile whey proteins, although techniques and equipment may be improved in time.

    Tables 5 and 6 illustrate schematically a process to produce an improved undenatured WPC which we have referred to under the trademark Immunocal. Table 7 is a comparative chart showing the characteristics of Immunocal in comparison with the sources of WPC and showing also the consequences of 3 weeks dietary treatment.

    We have concluded as a result of our work that undenatured whey protein concentrate (WPC) is of value in the prophylaxis of cancers, such as chemically induced cancer, typically such as colon cancer which is promoted by carcinogens such as dimethylhydrazine. It also is useful for the treatment of patients having cancer cells such as chemically induced cancer cells, to inhibit the replication of such cells. An approximate dosage for humans is in the range of about 8 to 40 grams daily and preferably 20 to 40 grams daily. It is particulary beneficial to administer 30 to 40 grams daily. It has been established that it is particularly advantageous to use WPC having a serum albumin in concentration of at least 10%.+-.1. The serum albumin should be at least 9% and most preferably at least 9.5%.

    As the published literature shows, tumors of the colon induced by dimethylhydrazine in experiments with mice are similar to cancer of the colon in humans in terms of the type of lesion and response to chemotherapy. (27,28).

    The discovery that the granulocytes/lymphocytes (G/L) ratio is increased in terminal cancer cases and correlates with the patient's condition (38) has prompted an interest in the factors that might influence this important parameter.

    TABLE 5 ______________________________________ A SCHEMATIC REPRESENTATION OF THE PROCESS TO PRODUCE THE WPC WHICH WE PREFER TO AS IMMUNOCAL ______________________________________ Raw milk .dwnarw. Skimmed at 35.degree. C. = .fwdarw. cream .dwnarw. Skimmed milk pasteurized at 63.degree. C. for 30 minutes. .dwnarw. At 38.degree. C.: Addition of rennet (20 ml/100 kilos), allowing the agitation to resolve at low speed. .dwnarw. = .fwdarw. curd Whey .dwnarw. Filtered with cheese cotton to remove debris (45 minutes): At 40.degree. C.: Ultrafiltration (Romecon UFSI, polysulphone membrane, cut off 50,000, pore diameter 0.06 of an inch, surface 2-3 m.sup.2). : Diafiltration to wash out salts and lactose. Whey Protein Concentrate .dwnarw. Pasteurized at 63.degree. C. for 30 minutes. .dwnarw. At 40.degree. C.: Lyophylization (16 hours). .dwnarw. Whey Protein Concentrate, Powder: ______________________________________

    TABLE 6 ______________________________________ ASSAY OF PRODUCT OF TABLE 5 ______________________________________ Polyacrylamide Serum Albumin .beta.-Lactoglobulin gel electrophoresis 10 .+-. 1% 57.8 .+-. 0.9% .alpha.-Lactalbumin Immunoglubin 11.4 .+-. 0.6% 22 .+-. 0.7% ______________________________________

    For example granulocyte depletion using extracorporeal circulation was found to significantly reduce the size of a transplanted tumor in rabbit (39). Recent experimental studies in mice suggested the possibility that the second parameter of the G/L equation could be influenced by dietary means. Mice fed whey protein concentrate prepared so as to preserve the most thermosensitive molecule of whey, such as serum albumins in their native undenatured form, exhibited an enhanced immune response (35) manifested, in part, by an increased resistance to pneumococcal infection (40,1) and carcinogen induction of cancer (1)

    This is the product which we referred to as undenatured WPC. Increased immune reactivity of mice fed with undenatured WPC was found to persist in naive cells transferred in vitro (36). The serum albumin contains six glutamylcysteine groups (31) hence provides the specific substrate for the synthesis of glutathione (33, 34) (GSH). These groups are extremely rare in food proteins (31).

    TABLE 7 __________________________________________________ ________________________ PHYSICAL-CHEMICAL CHARACTERISITCS AND BIOLOGICAL ACTIVITY OF DIFFERENT TYPES OF WHEY PROTEIN CONCENTRATES Undenatured conformation Protein composition (% of Effect of 3 weeks dietary treatment Solubility total whey proteins) Immuno- PFC.sup.4 Glutathione (.mu.mol/g).sup.5 index (pH 4.6) .beta.-LG.sup.a .alpha.-La.sup.2 SA.sup.3 globulins .times. 10.sup.-3 Liver Heart __________________________________________________ ________________________ Immunocal 99.5% 57.8 .+-. 0.9 11.4 .+-. 0.6 10 .+-. 1 22 .+-. 0.7 148 .+-. 16 7.95 .+-. 0.40 1.15 .+-. 0.7 Promod 97% 61 .+-. 3 20 .+-. 1 4 .+-. 1 15 .+-. 3 65 .+-. 14 6.64 .+-. 0.41 1.0 .+-. 0.7 Alacen 855 97.1% 62 .+-. 8 22 .+-. 3 4 .+-. 1 12 .+-. 6 66 .+-. 17 6.04 .+-. 0.36 -- Lacprodan-80 96% 62 .+-. 4 18 .+-. 2 4.8 .+-. 2 15 .+-. 4 44 .+-. 15 6.70 .+-. 0.20 -- Sapro 95% 60 .+-. 3 21 .+-. 2 4 .+-. 1 14 .+-. 3 31 .+-. 8 -- -- Savorpro-75 98% 63 .+-. 3 20 .+-. 1 4 .+-. 1 13 .+-. 3 31 .+-. 8 -- -- Biolosolate 90.1% 66 .+-. 4 15 .+-. 1 5 .+-. 1 12 .+-. 3 65 .+-. 20 -- -- Casein -- -- -- -- -- 35 .+-. 9 -- 1.0 .+-. 0.8 __________________________________________________ ________________________ Values are expressed as mean .+-. S.D.; 20 g protein/100 g diet. .sup.1 LG, Lactoglobulin .sup.2 La, AlphaLactalbumin .sup.3 S.A., Serum Albumin2 .sup.4 Number of plaqueforming cells/spleen 5 days following immunization with a 5 .times. 10.sup.6 sheep red blood cells -- Signifies not done *Please see test for statistical reference.

    The favourable effect of undenatured WPC in animal experiments were associated with a sustained elevation of tissue glutathione levels (41). However, nowhere this effect was more evident than in the spleen cells during the antigen driven clonal expansion of the lymphocyte pool (32): these experiments clearly indicate that the immune enhancing activity i.e. increased lymphocyte proliferation of dietary undenatured WPC is related to the observed greater production of GSH in the lymphocytes in comparison to an actual GSH decrease noted in casein fed controls during a similar antigenic challenge (32). GSH, a tripeptide thiol found in virtually all cells, is the major free radical oxygen scavenger (42). More specifically, the GSH content of the lymphocytes appears to be correlated with the ability of oxidants and thiols to modulate their proliferation (43). In this sense modulation of intracellular GSH may affect immune responsiveness (44, 45).

    These experiments further indicate that the enhancing effect of dietary whey proteins on the lymphocytes is particularly evident when the antigenic stimulus for active proliferation is present.

    However, this unique relation between dietary undenatured WPC and lymphocytes production is also manifest in normal unimmunized mice. After three weeks of dietary regimen, the spleen weights, as well as the spleen weight: body weight ratio of mice fed 20 g or 30 g undenatured WPC/100 g diet were moderately higher than the corresponding values of mice fed nutritionally equivalent diets containing 20 g or 30 g of either casein, soy protein or fish protein/100 g diet (46). More specifically, the number of cells per spleen were higher in undenatured WPC fed mice than the corresponding values in mice fed equivalent amounts of casein, wheat, soy and fish protein (35).

    A more detailed study revealed that the number of nucleated cells in the spleen of mice fed a 25% undenatured WPC diet was significantly higher than the corresponding values in mice fed a control 25% casein diet. Interestingly, the observed changes were specifically related to doubling of the T cell population: particularly the L3T4.sup.+ subpopulation increased four fold, whereas the number of B-cells was unchanged (36). This later finding is consistent with other studies showing that the effects of undenatured WPC are not exerted centrally on the rate of primary B-lymphoctye production in the bone marrow and that the immune enhancing effect is specifically seen in response to T-cell dependent antigens (47).

    The above described effect of undenatured WPC on the lymphocytes may well explain the observed inhibitory effect of this form of dietary regimen on experimental tumors. Recent experiments showed that continuous feeding of undenatured WPC in the diet inhibits the development (number and size) of tumors in the colon of mice over a period of 24 weeks of dimethylhydrazine (DMH) treatment (1). This antitumor effect could be caused by increased resistance of target cells to the carcinogen and/or a direct inhibitory effect of dietary undenatured WPC on tumor growth. A subsequent series of experiments (2) where animals were fed standard laboratory diet for the first 20 weeks of DMH and then switched to the undenatured WPC diet for the remaining 8 weeks of DMH treatment, clearly indicate an inhibitory effect of undenatured WPC feeding on cancer cells.

    It is noteworthy that the enhancing effect of undenatured WPC on the peripheral lymphoid tissues of normal animals is not associated with significant changes in the total number of blood lymphocytes (36,46). The absence of variation in total number of circulating lymphocytes was also noted in healthy humans (Otsuka Pharmaceutical Co. Ltd.).

    The induction of cellular GSH synthesis by the glutamylcysteine groups of undenatured WPC may constitute another interesting effect of this product in cancer patients. Indeed, the introduction of the cysteine delivery system OTZ (ozothiazolidine -4-carboxylate), while enhancing GSH levels in normal cells was found to result in feedback inhibition of the GSH cycle in human tumor cells (5).

    A clinical trial was arranged in Japan by Otsuka Pharmaceutical Co. Ltd. The clinical team was directed by Dr. Masakazu Adachi. The clinical trial involved five patients who had an advanced stage terminal cancer. A summary report is reproduced below as Table 8 and laboratory data of hematocytes and glutathione levels are given in Table 9 for four of the patients. The dosage level for each patient was 30 grams per day.

    As shown in Table 8 the lymphocyte number in all patients increased during the adminstration of the undenatured whey protein concentrate. Two other patients with an advanced stage had withdrawn from the trial because of digestive problems. Previous investigation had reported that once the lymphocyte number had dropped in cancer patients, the recovery of the lymphocyte number to a normal level may not be possible. The increase of the lymphocyte number is of importance because of its potentiality for improving the G/L ratio.

    The results shown in Tables 8 and 9 may be contrasted with healthy individuals who (based on tests of 14 individuals) will usually have an glutathione PMN level of 0.34.+-.0.02, a glutathione RBC level of 0.066.+-.0.006, a WBC of 6640.+-.1700, a lymphocyte number of 2200.+-.460 a G/L ratio of 1.85.+-.0.45 and Plt 25.4.+-.3.3.

    Table 10 shows the bacteriological analysis and also the protein distribution and solubility of the undenatured WPC used in the trials described in Tables 8 and 9.

    In conclusion, it appears that the administration of WPC to cancer patients increases the number of blood lymphocytes and decreases the G/L ratio. The lymphocyte concentration, very low at the outset, tends to return towards normal values. On the basis of previously described experimental evidence (38,39), the observed effect of WPC suggests inhibition of cancer cell growth.

    In tests of undenatured WPC subsequent to those described in Tables 8 and 9, the following observations were made:

    (1) Patient F had solid tumors in her abdomen that could be identified by physical examination and she had received chemotherapy. She had difficulty in consuming the undenatured WPC and was about to withdraw from treatment. However it was found that as long as she was taking the undenatured WPC her lymphocyte number increased, and the increasing number of tumor markers even showed signs of decreasing.

    TABLE 8 __________________________________________________ ________________________ improvement or terminal stage during undenatured WPC administration: Patient Cancer Recurrence exacerbation G/L lymphocytes GSH/lymphocytes period __________________________________________________ ________________________ A Gastric peritonitis tumor .uparw. (+) n.c. 980 .fwdarw. 1400 n.t. 54 days carcinomatosa ascites .uparw. ileus drop out B Uterus primary scc. 26 .fwdarw. 100 liver n.c. 960 .fwdarw. 1300 0.36 .fwdarw. 0.47 .fwdarw. 0.34 143 days lung meta. tumor p.s.: 0 metastasis .uparw. unfavourable C Breast bone meta. improveoment 4.4 .fwdarw. 2.2 480 .fwdarw. 1250 0.33 .fwdarw. 0.43 133 days bone meta (radiation therapy) p.s.: 0 favourable D Lung LN meta. tumor .uparw. (+) 11.6 .fwdarw. 4.0 340 .fwdarw. 930 0.85 .fwdarw. 0.53 79 days brain meta bone meta disturbance of consiousness died 50 days later after drop out E Esophag. -- lung metastasis (+) n.c. 600 .fwdarw. 1000 0.26 .fwdarw. 0.46 .fwdarw. 0.27 56 days LN meta. unfavourable __________________________________________________ ________________________

    TABLE 9 __________________________________________________ ________________________ Lab Data of Hematocytes and Glutathione Level: Cancer Pre Immu After Patient Cancer Compli. GSH/PMN GSH/RBC WBC Lymp. Gran. G/L RBC Plt. Mono. __________________________________________________ ________________________ 0 day C Breast L.C. 0.33 0.075 26.9 4.8 20.9 4.4 356 9.5 1.2 8 days C Breast 0.47 25.1 35 days C Breast 0.40 0.083 34.3 8.3 23.4 2.8 352 11.5 2.6 77 days C Breast 0.43 0.095 32.6 8.1 22.l 2.7 357 10.0 2.4 91 days C Breast 0.37 0.074 40.4 11.6 25.7 2.2 362 12.0 3.1 119 days C Breast 0.088 38.6 16.1 19.2 1.2 367 11.4 3.3 133 days C Breast 0.31 0.090 40.0 12.5 24.5 2.0 359 10.7 3.0 26 days E Esophag. 0.26 0.067 38.5 5.9 29.4 5.0 416 23.6 3.2 0 days E Esophag. 0.46 0.078 48.2 6.8 38.6 5.7 401 24.8 2.8 14 days E Esophag. 0.39 0.061 45.5 7.4 34.6 4.7 405 26.0 3.5 42 days E Esophag. 0.066 53.6 8.7 40.6 4.7 393 25.1 4.3 56 days E Esophag. 0.27 0.066 57.8 0.5 43.0 4.1 408 25.1 4.3 5 days D Lung 0.85 0.073 44.7 3.4 39.3 11.6 345 32.9 2.0 15 days D Lung 0.46 0.072 51.3 6.2 39.5 6.4 292 28.2 5.6 42 days D Lung 0.53 0.071 50.6 9.3 37.3 4.0 325 32.9 4.0 3 days B Uterus 0.38 0.083 45.8 9.6 33.6 3.5 319 19.1 2.6 10 days B Uterus 0.34 0.083 42.8 7.7 32.9 4.3 306 17.9 2.2 18 day B Uterus 0.50 0.087 57.5 12.1 42.4 3.5 575 21.7 3.0 45 days B Uterus 0.55 0.090 51.0 13.1 35.5 2.7 315 19.8 2.4 87 days B Uterus 0.43 0.099 52.2 10.1 37.1 3.7 324 19.2 5.0 101 days B Uterus 0.47 0.076 66.5 12.9 49.5 3.8 296 28.8 4.1 129 days B Uterus 0.086 72.0 13.7 53.0 3.9 258 28.6 5.3 143 days B Uterus 0.34 0.092 77.3 13.3 58.7 4.4 267 30.9 5.3 __________________________________________________ ________________________

    TABLE 10 __________________________________________________ ________________________ Undenatured WPC powder preserved at 4.degree. C. in dry environment with 3 exposures at room temperature (22-25.degree. C.) for about 4 days. __________________________________________________ ________________________ BACTERIOLOGICAL ANALYSIS Time after production Staph. Salmonella B cereus E coli Coliforms __________________________________________________ ________________________ 4 days 0 0 0 0 <100/100 g 14 months 0 0 0 0 <100/100 g __________________________________________________ ________________________ Protein distribution (1) and solubility (2) Time after production Solubility Beta-Lactoglubulla Alpha Lactalbumin Serum albumin Others (3) __________________________________________________ ________________________ 4 days 98.9 59.1 .+-. 4.0 (4) 6.6 .+-. 0.7 9.7 .+-. 1.0 24.6 .+-. 2.6 14 months 99.0 58.9 .+-. 3.9 9.6 .+-. 1.1 9.6 .+-. 1.1 22 .+-. 2.9 __________________________________________________ ________________________ (1) Months by polyacrylamide gel electrophoresis (2) Solubility index (ph 4.6) (3) Mostly immunoglobulin (4) Mean .+-. SD

    (2) Patient G was treated for a local recurrence of cancer after radiation. She received radiation treatment in November, 1992. Administration of undenatured WPC commenced December 4. Her lymphocytes improved between December 3 and Jan. 20, 1993 from 960 to 1310. As of February 3 there was no recurrence and her lymphocytes were 1370 and G/L 3.1.

    (3) Patient H had received radiation therapy for a local tumor. Administration of undenatured WPC was commenced Dec. 16, 1992. At that time, test results were as follows:

    ______________________________________ WBC 2700 Lym. 480 G/L 4.6 P/t 9.5 ______________________________________

    Results on December 24 were:

    ______________________________________ CEA 11.0 WBC 4320 Lym. 910 G/L 3.7 P/t 10.7 ______________________________________

    On January 20 results were:

    ______________________________________ CEA 7.1 WBC 3420 Lym. 830 P/t 11.5 ______________________________________

    On February 3 the results were:

    ______________________________________ CEA 5.2 WBC 3,300 Lym. 860 G/L 2.5 P/t 11.5 ______________________________________

    It was noted that progress of the patient was good.

    (4) Patient "I" had received radiation therapy on mediastinum, on cervical and total brain. Administration of undenatured WPC was started on Dec. 1, 1992. His lymphocytes increased from 340 on November 26 to 930 on January 13. His G/L ratio decreased from 12.1 to 4.4 and WBC increased from 4500 to 5100.

    REFERENCES

    Which Are Incorporated by Reference in Their Entirety

    1. Bounous, G., Papenburg R, Kongshavn, P. A. L., Gold, P, Fleiszer, D. (1988) "Dietary whey protein inhibits the development of dimethylhydrazine induced malignancy." Clin. Invest. Med. 11:213-217.

    2. Papenburg R., Bounous, G., Fleiszer, D., Gold, P. (1990) "Dietary milk proteins inhibit the development of dimethylhydrazine-induced malignancy." Tumor Biology 11:129-136.

    3. Bourtourault, M., Buleon, R., Samperez, S., Jovan, P., (1991) "Effet des proteines du lactoserum bovin sur la multiplication de cellules cancereuses humaines." C.R. Soc. Biol. 185:319-323.

    4. Laursen, I., Briand, P., Lykkesfeldt, A. E., (1990) "Serum albumin as a modulator of growth of the human breast cancer cell line MCF-7." Anti-cancer Res. 10:343-51.

    5. Russo, A., De Graff, W., Friedman, N., Mitchell, I., (1985) "Selective modulation of glutathione levels in human normal versus tumour cells and subsequent differential response to chemotherapy drugs." Cancer Res. 46:2865-48.

    6. Baruchel, S., Wang, T., Farah, R., Batist, G., (1992) "Different effects of OTZ on organ GSH levels in rats bearing tumours".

    7. Villadsen, British Patent 1,495,940 published Dec. 21, 1977 and entitled "Anti-Cancer Active Whey Fractions".

    8. JOHN, A. M., BELL, J. M. Amino acid requirements of the growing mouse. J. Nutr. 106: 1361-1367, 1976

    9. The mouse in biochemical research, Volume III, H. L. Foster, J. D. Small, J. D. Fox, editors, Academic Press, p.58, 1983.

    10. HOAG, W. G., DICKIE, M. M. Nutrition in; Biology of the laboratory mouse, E. L. Green, editor, McGraw-Hill, New York, pp. 39-43, 1966.

    11. CUNNINGHAM, A., and SZENBERG, A. Further improvements in the plaque technique for detecting single antibody forming cells. J. Immun. Vol 14, pg. 559-600,(1968)

    12. ANDERSON, M. E. Tissue glutathione: In; Handbook of methods for oxygen radical research. C.R.C. Press, 317-329, 1985.

    13. GLATT, H., PROTIC-SABLGIC, M., OESCH, F. Mutagenicity of glutathione and cysteine in the Ames Test. Science 220: 961-962, 1983.

    14. TAYLOR, Y. C., BROWN, J. M. Elevation of intracellular glutathione levels following depletion and its relationship to protection against radiation and alkylating agents. Pharmacol. Ther. 39: 293-299, 1988.

    15. WHITE, C. W., JACKSON, J. H., McMURTRY, I. F., REPINE, J. E. Hypoxia increases glutathione redox cycle and protects rat lungs against oxidants. J. Appl. Physiol. 65: 2607-2616, 1988.

    16. ANDERSON, M. E., MEISTER, A. Transport and direct utilization of gamma-glutamylcyst(e)ine for glutathione synthesis. Proc. Natl. Acad. Sci. U.S.A. 80: 707-711, 1983.

    17. WILLIAMSON, J. M., BOETTCHER, B., MEISTER, A. Intracellular cysteine delivery system that protects against toxicity by promoting GSH synthesis. Proc. Natl. Acad. Sci. U.S.A. 79: 6246-6249, 1982.

    18. PURI, R. N., MEISTER, A. Transport of glutathione as gamma-glutamylcysteinyl-glycylester, into liver and kidney. Proc. Natl. Acad. Sci. U.S.A. 80: 5258-5260, 1987.

    19. RICHIE, J. P., MILLS, B. J., LANG, C. A. Correction of a glutathione defiency in the aging mosquito increases its longevity. Proc. Soc. Exp. Biol. Med. 184: 113-117, 1987.

    20. FERNANDEZ-CHECA, J. C., OOKHTENS, M., KAPLOWITZ. Effects of chronic ethanol feeding on rat hepatocyte glutathione. J. Clin. Invest. 83: 1247-1252, 1989.

    21. LAUTERBURG, B. H., MITCHELL, J. R. Therapeutic doses of acetaminophen stimulate the turnover of cysteine and glutathione in man. J. Hepatol. 4: 206-211, 1987.

    22. MEISTER, A., ANDERSON, M. E. Glutathione. Ann. Rev. Bloch. 52: 711-760, 1983.

    23. MEKHAIL-ISHAK, K., HUDSON, N., TSAO, M. S., BATIST, G. Drug metabolizing enzymes in human colon cancer: Implications for therapy. Cancer Res. (In press), 1989.

    24. LEWIS, A. D., HICKSON, I. D., ROBSON, C. N., HARRIS, A. L., ET AL. P.N.A.S. 85: 8511-8515, 1988.

    25. HAMILTON, T. C., WINKLER, M. A., LOUIE K. G., BATIST, G., ET AL. Augmentation of adriamycin, melphalan and cisplastin cytoxicity in drug resistant and sensitive human ovarian cancer cell lines by BSO mediated GSH depletion. Biochem. Pharm. 34: 2583-2586, 1985.

    26. SUZUKAKE, K., VISTICA, B. P., VISTICA, D. T. Dechlorination of L-phenylalanine mustard by sensitive and resistant tumor cells and its relationship to intracellular glutathione content. Biochem. Pharm. 32: 165-171, 1983.

    27. ENKER, W. E., JACOBITZ, J. L. Experimental carcinogenesis of the colon induced by 1,2-dimethylhydrazine-di HCl: Value as a model of human disease. J. Surg. Res. 21: 291-299, 1976.

    28. CORBETT, T. H., GRISWOLD, D. P., ROBERTS, G. J. ET AL. Evaluation of a single agent and combination of chemotherapeutic agents in mouse colon carcinogenesis. Cancer 40: 2650-2680, 1977.

    29. WALSTRA; P. JENNEP. Dairy chemistry and physics. Wiley J. Nitork, (ed.), p. 106, 1984.

    30. SWAISGOOD, M. E. Characteristics of edible fluids of animal origin: Milk, in; Food Chemistry, O. R. Fennema, (ed.)., Marcel Dekker, p. 796, 1985.

    31. Bounous G,, Gold P: The biological activity of undenatured dietary whey proteins: role of glutathione. Clin Invest Med 14:296-309, 1991.

    32. Bounous G,, Batist G,, Gold P: Immunoenhancing property of dietary whey protein in mice: Role of glutathione. Clin Invest Med 12:154-61, 1989.

    33. Anderson M E, Meester A: Transport and direct utilization of gamma-glutazylcyst(e)ine for glutathione synthesis. Proc Natl Acad Sci 80:707-11,, 1983.

    34. Meister A: 5-Oxoprolinuria and other disorders of glutathione biosynthesis. In: Stranbury J B, Wymgaarden J B, Frederikson D S, eds. Metabolic basis of inherited diseases 4th edn. McGraw Hill, 1978:328-35

    35. Bounous G. Kongshavn P A L, Gold. P: The immunoenhancing property of dietary whey protein concentrate. Clin Invest Med 11:271-8, 1988.

    36. Hirai Y,, Nakay S. Kikuishi H,, Kawai K; Report: Evaluation of the immunological enhancement activities of Immunocal. Otsuka Pharmaceutical Co. Ltd: Cellular Technology Institute: Dec. 13, 1990, Osaka, Japan.

    37. Anderson M E: Tissue glutathione: In: C.R.C. Handbook of methods for oxygen radical research. Boca Raton, Fla.: CRC Press, Inc., 1985:317-29

    38. IETOMI K. A study on the role of granylocytes in carcinoma-bearing hosts.

    G/L ratio a new host indicator-J. Jpn Soc. Cancer ther. 25/662-671/1990

    39. TABUCHI T., SOMA T., TONEKAWA M., KOMAI T., HASHIMOTO T., ADACHI M. "Reduction of V X 2 transplanted tumor by granulocyte depletion using extracorporeal circulation on rabbit models". Anticancer Res.

    40. BOUNOUS G, KONGSHAVN P A L, GOLD P: Influence of protein type in nutritionally adequate diets on the development of immunity. In: Friedman M, ed. Adsorption and utilization of amino acids. Vol. II. Boca Raton, Fla.: C.R.C. Press, Inc., 1989: 212-33

    41. BOUNOUS, G., GERVAIS R., AMER V., BATIST G., GOLD P., "The influence of dietary whey protein on tissue glutathione and the diseases of aging". Clin. Invest. Med. 12: 343-349, 1989.

    42. RICHIE J. P. The role of glutathione in aging and cancer. Exper. Gerontology 27: 615-626, 1992

    43. NOELLE R J, LAWRENCE D A: Determination of glutathione in lymphocytes and possible association of redox state and proliferative capacity of lymphocytes. Biochem J: 198: 571-9, 1981

    44. FIDELUS R K, TSAN M F: Enhancement on intracellular glutathione promotes lymphocyte activation by mitogen. Cell Immunol 97: 155-63, 1986.

    45. GOUGEROT-POCIDALO M A, PAY M, ROCHE S: Mechanisms by which oxidative injury inhibits the proliferative response of human lymphocytes to PHA, Effect of the thiol compound 2-mercapto-ethanol. Immunology 64: 281-8, 1988.

    46. BOUNOUS G., LETOURNEAU L., KONGSHAVN P. A. L., "Influence of dietary protein type on the immune system of mice". J. Nutr. 113: 1415-1421, 1983

    47. BOUNOUS G., SHENOUDA N., KONGSHAVN P. A. L., OSMOND D. G., "Mechanism of altered B-cell response induced by changes in dietary protein type in mice". J. Nutr. 115: 1409-1417, 1985

    http://cnw.ca/en/releases/archive/Au.../01/c2216.html
    Âëîæåíèÿ Âëîæåíèÿ

Êëèíèêà ñòîìàòîëîãèè è êîñìåòîëîãèè â Ìîñêâå

Ìåòêè ýòîé òåìû

Âàøè ïðàâà

  • Âû ìîæåòå ñîçäàâàòü íîâûå òåìû
  • Âû ìîæåòå îòâå÷àòü â òåìàõ
  • Âû íå ìîæåòå ïðèêðåïëÿòü âëîæåíèÿ
  • Âû íå ìîæåòå ðåäàêòèðîâàòü ñâîè ñîîáùåíèÿ
  •